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ABSTRACT
Chest pain is a non-specific complaint and is the most frequent reason for patients to
seek urgent medical attention. A small group of these patients will have acute
coronary syndromes (ACS). Acute coronary syndromes carry high morbidity and
mortality and require rapid early identification and treatment. The current diagnostic
and triage systems based on the clinical history and ECG lack both sensitivity and
specificity. It may result in some of these patients being misdiagnosed and therefore
admitted to the wrong units or receive inappropriate care, treatment, and
investigations. In some patients the diagnosis is delayed resulting in the late
administration (or no administration) of essential early treatment. A few patients with
ACS may be inadvertently discharged from the accident and emergency department
[A&E department] with serious health and legal consequences. These systems also
result in an inappropriate admission of a large number of patients without ACS, with
substantial costs. The diagnosis, triage, and management of patients with ACS can be
considerably improved by implementations of serial cardiac markers testing that can
identify ACS in the very early stages of presentation. The work of this thesis
involves a series of studies that evaluate the role of the novel cardiac marker heart
fatty acid-binding protein (H-FABP) for the early diagnosis of ACS and its
comparison with standard cardiac markers creatine kinase muscle brain mass (CK-
MB mass), cardiac troponin I (cTnl), cardiac troponin T (cTnT) and myoglobin.
1. The value of serial cardiac markers testing for the early diagnosis of acute
myocardial infarction (AMI) was studied in 45 patients with AMI admitted to
Coronary Care Unit within 6 hours after symptom onset. Heart-FABP peak
concentration occurred at 8 hours and was the most sensitive early marker with
75.5% and 100% of patients with AMI identified at presentation and 2 hours after
presentation respectively. The sensitivity of cardiac markers [CK-MB mass, cTnl,
cTnT, and myoglobin] at presentation was < 62%. The sensitivity and negative
predictive value of H-FABP was also superior to other markers within the first 2
hours of presentation. Myoglobin was the second best sensitive early marker at
presentation. Peak sensitivity of cTnl, CK-MB mass, and cTnT were present at 4, 8,
and 8 hours respectively. The combination of H-FABP and cTnl improves
specificity. Measurement of H-FABP and cTnl at two intervals during the first 8
hours after presentation is sufficiently sensitive and specific for the early diagnosis of
most patients with AMI. This serial combination testing may also be useful in;
timing the onset ofAMI; clarification of non-diagnostic ECG; detection of successful
reperfusion and detection of re-infarction and infarct extension if it occurs early.
2. The value of serial cardiac markers testing for the diagnosis and management of
patients with non-Q wave myocardial infarction [non-Q wave MI] and unstable
angina [UA]) was assessed in 55 consecutive patients seen in the A&E department
with acute chest pain within 7 hours after symptom onset. Heart-FABP was the most
sensitive early marker with 79% of patients with non-Q wave MI showing evidence
of myocardial damage at presentation [Less than 71% were detected using other
markers]. Myoglobin and H-FABP had equal sensitivity (93%) at 2 hours for the
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diagnosis of non-Q wave MI. Creatine kinase-MB mass and cTnl were sensitive in
93% within 4 hours of presentation. Cardiac-TnT was a late marker (> 16 hours).
These serial testing also diagnosed a substantial numbers of patients with subtle
ischaemic ECG changes at admission [e.g. minimal ST elevation < 1 mm, and left
bundle branch block] that may qualify for early reperfusion therapy. Heart-FABP
also showed high positive values in patients with UA [40%], and was low in normal
coronary patients with chest pain [10%]. Cardiac-Tnl, cTnT, CK-MB mass, and
myoglobin were elevated in 55%, 40%, 30%, and 25% respectively of patients with
UA. Implementations of serial testing policy may result in reduced costs of in-
hospital care by approximately 34%. In addition, early serial testing identifies high-
risk patients and can help with their management such as; prevent discharge; triage
from A&E; admission to Coronary Care Unit; antiplatelet therapy; invasive
investigations; and identify low-risk patients for early discharge.
3. The release characteristics, the diagnostic and prognostic value of cardiac markers
were assessed in 80 consecutive patients who had elective angioplasty. Elevated
concentrations of cardiac markers were correlated with demographic, angiographic
and procedural variable. Patients were followed up for 20 - 26 months. Heart-FABP
peaked early at 2 hours after angioplasty, and was the most useful test for the early
detection of evolving AMI within 1-3 hours after angioplasty. Cardiac-Tnl,
myoglobin, H-FABP, CK-MB mass, and cTnT concentrations were elevated in
46.25%, 17.5%, 13.3%, 11.25%, and 7.5% respectively. Cardiac-Tnl was the most
sensitive marker for detecting all complications and was superior to all other
markers. Elevated cTnl had positive predictive accuracy for major complications of
81%, and for all types of complications of 62%. Elevated cardiac markers were
correlated with old age [p < 0.02], occurrence of chest pain ± ECG changes of
ischaemia [p < 0.003], increased use of stents [p < 0.019] and major complications
(major dissection [p < 0.004], transient vessel closure [p < 0.022] and bail out stent
[p < 0.003], and AMI [p < 0.042]). Elevated cardiac markers were associated with a
reduction of event-free survival [16.92 vs 20.67 months, p < 0.03], However, the
complications rate between patients with and without elevated cTnl was not
statistically different (angina [46% vs 28%, p = NS], non-target vessel
revascularisation [14% vs 9%, p = NS] and increased clinical events [73% vs 48%, p
= NS]) respectively.
Conclusions: Heart-FABP was the most sensitive early marker for the detection of
myocardial injury in patients with ACS. Measurement of H-FABP and cTnl at two
intervals during the first 8 hours after presentation is sufficiently sensitive and
specific for the early diagnosis of most patients with ACS. This serial combination
testing may be cost effective, provides additional valuable diagnostic and prognostic
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1.1 SCALE OF THE PROBLEM
In the United Kingdom, chest pain is the most frequent reason for patients receiving
emergency medical attention, and coronary heart disease (CHD) is the commonest
cause of death. Although official statistics are lacking, from the data that are
available it can be estimated that approximately 2.1 million people suffer from
angina, 300,000 have myocardial infarction, and approximately 125,000 die from a
heart attack each year.1
In general, the ratio of unstable angina (UA) and acute myocardial infarction (AMI)
2 • ....is 1.2:1 across Europe. The economic burden of caring for patients with CHD is
approximately £1.6 billion per year.1 In the United States, each year 5 million
patients with chest pain are admitted to hospital from accident and emergency (A&E)
■y
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departments. Patients presenting with chest pain form 5% of the total workload of
the A&E department. It is estimated that 90% of patients presenting with chest pain
do not have AMI and internationally less than 30% of patients admitted to Coronary
Care Unit (CCU) or Intensive Care Unit (ICU) with suspected AMI are subsequently
found to have AMI (Figure l).3'4"7'8
The cost of caring for such patients in whom AMI has been ruled out is
approximately $ 4 billion per year.3'9 It is also estimated that up to 3 million patients
present with silent ischaemia and between 20,000 - 40,000 patients are
inappropriately discharged from A&E department with 'missed AMI' (Figure 2).3,10
Missed AMI is the leading cause of malpractice lawsuits and settlements in A&E
. 1 1 ■ 19
departments in the United States. '
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Figure 1. The schematic diagram below shows the relative percentages of
patients who present to the A&E department with AMI, non-cardiac chest pain
and other cardiac chest pain. Abbreviations: CP, chest pain; A&E, accident and
emergency department; AMI, acute myocardial infarction; UA, unstable











Figure 2. Shows schematic diagram of the proportions of patients with
cardiovascular disease who present with chest pain and silent myocardial
ischaemia, and their outcome.10
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1.2 RECENT TRENDS OF CHEST PAIN PRESENTATION
A series of interacting developments have given rise to a marked increase in the
frequency of patients presenting to A&E departments with chest pain. These include;
(1) Revolutionary success with reperfusion treatment (thrombolytic treatment and
PCI for AMI;13 (2) The improved community and ambulance services; (3)
Awareness of the need for early presentation of patients with AMI to hospital to
achieve the maximum benefits of treatment;14,15 and (4) The potential advantage of
monitoring patients with AMI in the CCU or ICU.16
These factors have lead to educational programmes for the public to raise their
awareness of symptoms of AMI and encourage early presentation to hospital. As a
result, increasing numbers of patients present to A&E departments, and the time of
presentation after symptom onset is substantially shortened. It is estimated that
patients present within a mean duration of 6 hours compared to 10 - 12 hours
previously.8,16 This has increased the pressure on the A&E department physicians to
make rapid but accurate diagnoses of acute coronary syndromes (ACS) and avoid
inappropriate admissions and discharges.
1.3 THE DILEMMA OF ACUTE CORONARY SYNDROMES DIAGNOSIS
The accurate diagnosis ofAMI and UA in the early stages ofmyocardial damage still
represents a major challenge in clinical cardiology. Accurate early diagnosis of such
patients is essential to determine whether a patient needs hospitalisation and if so,
whether ischaemia and evolving infarction are present. Diagnosis of AMI relies on
clinical history, the ECG, and measurement of cardiac marker proteins. The clinical
4
history may not be reliable as the differential diagnosis of chest pain includes many
cardiac, pulmonary, gastrointestinal, and muskeloskeletal conditions that have to be
• •• 17.10 ..
differentiated from cardiac pain (Table 1). ' There is insufficient time for an
exhaustive history in the emergency setting. The ECG is helpful for the diagnosis of
ACS when there are positive changes of ischaemia, but the early ECG can be normal
or non-diagnostic in up to 50% of patients with AMI.7'19"21 Also old ECG changes
may persist in patients with new presentation of cardiac pain obscuring further
interpretation. When confronted with a patient with chest pain at rest and
accompanying ECG abnormalities of ischaemia, the treating physician cannot
sometimes distinguish between unstable angina, non-Q wave MI and ST elevation
MI in evolution until the full ECG pattern evolves or the cardiac enzymes become
available.
Since the clinical history may not necessarily be reliable or specific and the early
ECGs often do not show diagnostic changes, increasing reliance has been placed on
biochemical cardiac markers. However, the available tests have limited ability to
influence decision-making in the very early hours since they are either not detectable
quickly enough or they are not sufficiently specific.
1.4 TRIAGE OF PATIENTS FROM ACCIDENT AND EMERGENCY
DEPARTMENT
Due to the lack of distinguishing features of chest pain in some patients and the lack
of diagnostic sensitivity of the ECG, the treating physicians tend to admit patients
with uncertain diagnosis for further diagnostic work up rather than risk inappropriate
5
discharge with all its health and legal consequences. This strategy achieves a low rate
of missed AMI but also results in the admission ofmany patients without AMI. As a
result, increased economic pressures arise from patients consuming expensive
resources and this also results in patients being subjected to investigations to rule in
or rule out AMI.22 Furthermore, the use of more invasive investigations has specific
hazards. Current triage policy also results in some patients without ACS occupying
intensive care beds and prevents other patients with appropriate needs gaining access
to these units.

























Table 1. This table illustrates the most frequent causes of chest pain that must
be differentiated in patients who present to the A&E department.
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In this era of minimisation of health costs, and the pressures for effective use of
resources, there are also important legal implications ofmalpractice. Thus, there is a
demand for a strategy to improve efficiency in managing patients presenting with
ACS and to reduce unnecessary admissions and discharges and to make proper use of
expensive beds, without compromising the safety of the patients. Clinical history and
ECG interpretation have limited scope for further improvement. However, a potential
area for improvement is in the use of cardiac markers with improved predictive
accuracy to help with the early diagnosis ofACS.
A cardiac marker that is released early and is reliable would offer a simple and
effective method for the identification of ACS patients and would help ensure that
appropriate patients are admitted thus improving health economic efficiency. In
choosing markers for this purpose some considerations need to be met. First, markers
must have a high sensitivity and specificity for the early diagnosis of AMI within 6
hours after symptom onset. Second, they must have a high negative predictive value
since 90% of patients will not have AMI. Third, they should have a short turn around
time so that decisions regarding patients' management can be made within the time
course relevant to guide early therapy.
1.5 CARDIAC MARKERS AND THE EARLY DIAGNOSIS OF ACUTE
CORONARY SYNDROMES
Cardiac markers differ with respect to the time required after symptom onset in order
to exceed the upper limit of normal. Current cardiac marker proteins, creatine kinase
(CK), creatine kinase muscle brain (CK-MB), cardiac troponin T (cTnT), and cardiac
7
troponin I (cTnl) are not elevated within 6 hours of symptom onset and myoglobin
lacks specificity. Creatine kinase-MB is used in many laboratories but plasma
concentration of this marker are not consistently elevated until 8-12 hours after
symptom onset, and in patients with UA and minor myocardial injury the
concentration may remain normal.9
Cardiac-Tnl and cTnT are more specific markers of myocardial damage than CK-
MB, but the maximum or peak plasma concentration of these proteins can be reliably
9T • •
detected 12-16 hours after symptom onset. Myoglobin is released more rapidly
but it lacks cardiac specificity.24'25 Creatine kinase-MB isoforms have recently
undergone evaluation as early markers ofAMI within the first 6 hours after symptom
onset.8'9'26 However, some investigators have claimed these isoforms to have similar
sensitivity to CK-MB mass and myoglobin and do not offer considerable advantages
over them.27
The low molecular weight cytosolic protein, heart fatty acid binding protein (H-
FABP) is a marker of myocardial damage and has the advantage that it is released
more rapidly than CK, CK-MB, cTnT, and cTnl and is more cardiac specific than
98 TO •
myoglobin. " Recent studies using H-FABP for the diagnosis of AMI have shown
promising results. The sensitivity ofH-FABP for the early diagnosis ofAMI within 3
hours after symptom onset was reported to be 91.4%. The myoglobin and H-FABP
ratio in skeletal and cardiac muscle is noticeably different. The utilisation of this
ratio for the differentiation of cardiac and non-cardiac injury has also been reported
to be useful.25
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1.6 ACUTE CORONARY SYNDROMES
Acute coronary syndromes describe a clinical spectrum of conditions including AMI
and UA, which occur following rupture or erosion of an atheromatous plaque with
subsequent platelet aggregation and thrombus formation. These events lead to some
degree of coronary artery occlusion, and thus reduce blood flow. This produces
myocardial ischaemia, which leads to UA and may progress to myocardial infarction,
depending on the severity and duration of occlusion. Proteins are released from the
infarcted myocardium and these can be measured in plasma.
Heart-FABP is a recently characterised protein, which appears to be an early and
• • 98 • •
sensitive marker of myocardial injury. Measurement of this protein would enable
rapid assessment of patients with chest pain, allowing physicians to institute early
treatment of patients with ACS, and to differentiate cardiac from non-cardiac chest
pain, and may prevent unnecessary or prolonged admissions.
In this thesis studies are described to examine the use of this biochemical marker
protein in patients with ACS in comparison with other currently available markers of
myocardial injury like CK-MB mass, cTnl, cTnT, and myoglobin. The aim is to
determine whether H-FABP is a reliable, early and sensitive marker ofACS.
1.7 ORIGINAL HYPOTHESES
Pilot phase findings were obtained prior to the work of this thesis using serum H-
FABP in patients with ACS and suggested that further and more detailed studies
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should be carried out in order to evaluate the role of this marker protein, thus the
hypotheses are:
1. Serum/plasma H-FABP is the most useful (optimal sensitivity and specificity)
early marker for AMI, whilst the cardiac specific markers cTnl (or cTnT), and CK-
MB mass are more useful indicators ofmyocardial damage at later time points.
2. Serum/plasma H-FABP can identify myocardial injury in unstable angina and
non-Q wave MI prior to the release of cTnl (or cTnT), or CK-MB mass.
3. Serum/plasma H-FABP is a sensitive and specific marker of injury induced by
brief episodes ofmyocardial ischaemia during coronary angioplasty.
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CHAPTER 2





Acute myocardial infarction is the leading cause of death in the United Kingdom and
other developed countries.1 The in-hospital mortality from this cause has been
declining over the last three decades.2"3 This reduction in mortality coincides with
improvement in health and living standards and with new treatments like
thrombolysis and the introduction of new interventions like percutaneous coronary
intervention and coronary artery bypass grafting (CABG). Secondary and primary
prevention strategies have contributed significantly and the age-adjusted mortality is
expected to continue to decline with further improvements in treatments, better
uptake of primary and secondary prevention strategies and also with further
improvement in our ability to recognise this challenging disease very early in its
course. The success of treatment rests on two elements; (1) The identification of
patients in the very early stages of AMI and implementation of treatment to
recanalise the occluded artery; (2) Access to early defibrillation and admission to
properly monitored units (CCU or ICU) for the detection and treatment of
complications.
The diagnosis of AMI is based on the criteria set by the World Health Organisation
(WHO) and must include two of the following; (1) Typical history of prolonged
ischaemic chest pain; (2) The presence of typical acute ischaemic changes on the
admission ECG; (3) Typical rise and fall of cardiac enzymes in blood.4 This old
definition is likely to change with the recent publication of a new definition of
myocardial infarction by The Joint European Society of Cardiology/American
College of Cardiology (ESC/ACC) Committee, which redefines myocardial
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infarction according to cardiac markers as; (1) An increase in cardiac markers cTnl,
cTnT exceeding the decision limit (99th percentile of the value for a reference control
group) on at least one occasions; (2) an increase in CK-MB (preferably CK-MB
mass) exceeding the decision limit (99th percentile of the value for a reference control
group) on at least two occasions with a rise and fall pattern, or greater than twice the
upper limit of normal on one occasion.20 Within this definition ACS are also
classified into ST elevation and non-ST elevation (Figure 1).
Acute coronary syndromes
No enzyme elevation Enzyme elevation (troponins, CK-MB, or ck)
Figure 1. The new ESC/ACC clinical classification of ACS. Acute coronary
syndromes are classified into ST and Non-ST elevation. ST elevation ACS is
further classified into Q-wave and non Q-wave MI. Non-ST elevation MI (with
cardiac markers elevation) is also classified into Q-wave and non Q-wave MI.
Non-ST elevation ACS without cardiac markers elevations is called unstable
20
angina. Abbreviations: ST, Q, are ST segment and Q wave of the ECG;
NSTEMI, non-ST elevation myocardial infarction; MI, myocardial infarction.
The very early diagnosis ofAMI can be a challenging task to many physicians in the
A&E department. When typical history is present it helps to orientate the clinician to
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the diagnosis, but its absence by no means rules it out. This is often the case in a
significant proportion of patients in whom history is either atypical or absent.
Diabetic, hypertensive, and elderly patients often have silent AMI. In these cases
AMI may go unnoticed or may produce atypical symptoms such as hypotension,
breathlessness, or arrhythmias.5 The ECG is an important tool to rule in AMI, but it
lacks sensitivity and as many as 30 - 50% of patients may initially present with
normal or non-diagnostic ECG.6'27 The ECG has an overall diagnostic sensitivity for
AMI of 70 - 81%.7'8 However, when changes of AMI are present on the admission
ECG (ST elevation and new Q wave) they are highly specific and have a very high
positive predictive value for the diagnosis of AMI. Cardiac markers are formidable
tools for the diagnosis of AMI.9'10 The number of cardiac markers in use is growing
rapidly. This is an important area of cardiology and researches in this field are
expanding rapidly.
2.2 HISTORICAL DEVELOPMENT OF CARDIAC MARKERS OF ACUTE
MYOCARDIAL INFARCTION
The utilisation of cardiac markers for the diagnosis of AMI has developed over the
years from the use of non-specific and non-sensitive late markers to the use of highly
sensitive and specific cardiac markers. The first biochemical cardiac marker used in
the identification of AMI was aspertate aminotransferase in 1954. This was joined
and gradually taken over by creatine kinase in 1965. Together with Lactate
dehydrogenase (LDH), these three markers became the cornerstone for biochemical
diagnosis of AMI in the early days. The development of electrophoresis lead to the
identification of LDH and CK isoenzymes (LDH1, CK-MB activity), as cardiac
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markers with higher specificity. Myoglobin measurement became available in 1976.
The first mass assay for CK-MB to be evaluated in AMI patients was in 1985.
Cardiac-TnT as a marker for AMI was first evaluated in 1989, three years later
(1992), cTnl came into use. Creatine kinase-MB isoforms underwent evaluation in
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Figure 2. Illustrates the historical development of biochemical cardiac markers
over the past five decades. Earlier non-specific and non-sensitive cardiac
markers are gradually replaced by more specific and sensitive markers.
2.3 CHARACTERISTIC FEATURES OF BIOCHEMICAL MARKERS OF
MYOCARDIAL INJURY
The ideal characteristics of a marker of myocardial injury are; (1) It should be
abundant in myocardium and not present in other tissues. This gives it a high
specificity for the myocardium and reduces the rate of false positive results; (2) It
should have a high concentration in myocardium and low or undetectable
concentration in the blood in the absence of disease. This gives it a high sensitivity
so that the release of only a small amount can be readily detected thereby reducing
the rate of false negatives; (3) It should be released completely and quickly when
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myocardial damage occurs. This will allow its utilisation for the early detection and
quantification of injury; (4) It should persist in the circulation to give a convenient
diagnostic window, but not too long to prevent the detection of complications such as
early re-infarction; and (5) The assay must have a high analytical sensitivity and
specificity and a short turn around time, so that results could be obtained fast to
influence decision-making process regarding patients' triage and management.
2.4 BIOCHEMICAL MARKERS AND EARLY DETECTION OF ACUTE
MYOCARDIAL INFARCTION
Cardiac markers play an important role in the detection of AMI when the patient's
history and ECG are non-diagnostic or equivocal." Diagnosing AMI early i.e. within
6 hours after symptom onset is difficult, because some time must elapse after
symptom onset for markers to exceed values above the normal level. The diagnosis
of AMI based only on one single value at presentation or soon after admission is
unreliable, and serial sampling is the most effective method. The sensitivity and
specificity of the cardiac markers for the early diagnosis of AMI is influenced by
several factors such as:
1. Time of presentation. Early presentation after symptom onset is likely to
show a relatively increased sensitivity for markers like myoglobin, which are
released very early in the course ofAMI, and less sensitivity for markers like
CK-MB or cTnl, which are released slightly later. A delayed presentation is
likely to have the opposite effect. Therefore, the onset of symptoms should be
used as the reference point when commenting on the sensitivity and
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specificity of the markers for the early diagnosis of AMI rather than, for
• •12
example, issues like time of presentation, and time of admission.
2. Size of infarct. Cardiac markers are released in proportion to the volume of
myocardium in jeopardy, the bigger the infarct the greater the quantity of
cardiac markers released. This will lead to improved sensitivity compared to
small infarcts where limited release of markers may be close to the threshold
• 1 ^
for detection.
3. Selection criteria and prior probability of acute myocardial infarction.
Selecting certain group (s) of patients for the study with a high possibility of
AMI, such as those admitted to the CCU, can also influence sensitivity of a
marker.
4. Treatment. Treatment can have an influence on the sensitivity of the marker.
For example, patients who have been successfully thrombolysed show a
greater and earlier peak of some of the markers compared to those who were
not successfully reperfused.
5. Diagnostic threshold. The selection of an appropriate diagnostic threshold
requires careful consideration of concentrations seen in the normal and
disease free population and those seen in diseased populations. There is
always a continuous balance between sensitivity and specificity of any
marker. If the cut-off concentration used is low, the sensitivity is improved at
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the expense of specificity unless the marker is 100% cardiac specific, and
only present in diseased populations.
6. Kinetic factors. Kinetic factors like the molecular size of the marker, the
biological compartment of the marker (i.e. whether it exchanges freely in the
cytoplasm or is attached to structural elements within the cell), the volume of
distribution, and whether the marker is released directly into the blood or
cleared by the lymphatic system can all influence plasma concentration.
Markers that have small molecular weight, lie free in the cytoplasm, and
released directly into the circulation, show better early sensitivity compared
with larger molecules that are attached to structural elements and/or cleared
slowly by the lymphatic system.
It is not surprising therefore that different studies report differing results for
sensitivity and specificity for the various cardiac markers for the early diagnosis of
AMI. The variations in the reported results will predominantly be influenced by the
above factors.
This chapter of the thesis will discuss the currently available markers of myocardial
damage like CK, CK-MB mass, CK-MB activity, cTnT, cTnl, myoglobin, LDH, and
LDH1. The discussion will focus on the suitability of these markers as tools for the
diagnosis of ACS. In particular; (1) Their suitability for early diagnosis of AMI
(within 6 hours); (2) Their ability to detect myocardial damage during ischaemic
episode in patients presenting with UA or in patients undergoing cardiac intervention
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like percutaneous coronary intervention (PTCA); (3) Their ability to detect
reperfusion and re-infarction; (4) Their specificity and limitations and (5) Future
directions with these markers. The discussion will also focus on some of the recent
markers that have undergone evaluation as very early makers of AMI like CK-MB
isoforms.
2.5 CREATINE KINASE
Creatine kinase is an enzyme composed of two subunits, M and/or B. Three different
pairs of these units combine to give rise to three different isoenzymes, each with
molecular weight of about 80 Kilodalton (KDa); CK-BB, CK-MB and CK-MM.
Creatine kinase-BB is the brain isoenzyme and is present in large quantity in the
brain. Creatine kinase-MB is the heart specific isoenzymes and has been the gold
standard method for the diagnosis of AMI in many laboratories around the world. It
exists in large quantity in heart muscle but is not totally cardiac specific and exists
also in skeletal muscles and other tissues. About 15-40% of the total CK activity of
heart muscle is due to CK-MB, the rest is largely due to CK-MM isoenzyme.
Creatine kinase-MM is the skeletal muscle isoenzyme. It has the highest distribution
in skeletal muscles. The three isoenzymes are present in varying concentrations in
the smooth muscle of the colon, ileum, stomach, and urinary bladder.14
Fractionation of CK isoenzymes by electrophoresis results in two more additional
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isoenzymes, called mitochondrial CK (mit CK) and macro CK (type 1 and 2). Mit
CK is the mitochondrial form of the enzyme. Macro CK type 1 is believed to be the
fab' fragment of the immunoglobulin IgA or IgG bound to two molecules ofCK-BB.
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Macro CK type 2 is a polymer of mit CK. The presence of mit CK and macro CK in
serum does not have much diagnostic significance but when they are present in large
concentrations they could interfere with the analysis of total CK or its isoenzymes.15"
16 The normal range for CK is approximately 80 - 200 IU/L for men and 60 - 140
IU/L for women. This is the result of the normal turnover of this enzyme in skeletal
muscles. The normal range is influenced by factors like muscle mass and physical
work.
2.5.1 Creatine kinase and acute myocardial infarction
Creatine kinase was introduced in 1965 as a biochemical marker for myocardial
damage and it is one of the oldest markers in this field.17 It has a clinical sensitivity
for the diagnosis of AMI of 90%. Unfortunately, this is not matched by high
specificity. It is released within 12 hours after symptom onset of AMI, peaks in
serum at 24 - 36 hours, and returns to normal in 48 - 72 hours. As a result of these
release kinetics, measurement of total CK is not suitable for the early diagnosis
(within 6 hours) of AMI. Creatine kinase as a marker is also unsuitable for the
detection ofmyocardial damage that may occur in patients presenting with UA, or in
patients undergoing PCI.
A marker that is suitable for the early diagnosis of AMI, and the detection of small
injuries to the heart should have; high cytoplasmic (cell) to vascular (plasma) ratio;
very low or undetectable normal plasma concentration; and total cardiac specificity.
Creatine kinase does not fulfil these criteria since it has a moderate cytoplasmic to
vascular ratio of 60,000:1, high resting normal range values up to 200 IU/L, and is
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widely distributed in the body. To improve on the cardiac specificity of CK for the
diagnosis of AMI, it was combined with CK-MB (the cardiac specific isoenzyme of
CK) in a ratio. A CK-MB to CK ratio > 6% is reported to be specific for myocardial
injury, whereas a ratio < 6% is consistent with skeletal muscle damage or non-
cardiac cause.
In some clinical settings a CK-MB test is not requested unless the total CK activity is
elevated. The use of total CK as a screening test before ordering CK-MB could miss
some patients with AMI and should be used with caution. As there are cases ofAMI
without total elevation of CK concentration but the total CK-MB fraction and the
CK-MB to CK ratio in these patients is diagnostic for AMI. This is likely to happen
in situations when there is a small MI in a small sized person with a low muscle bulk,
and a low base line value of total CK. The normal reference range of CK is very
broad and these patients could release small amounts of the enzyme, insufficient to
raise the concentration above the normal reference range. If this possibility is not
bome in mind the diagnosis could be missed when CK is used. Unless the base line
total CK is known in a patient presenting with highly suspicious diagnosis of
ischaemia, a low total CK should not exclude the diagnosis nor it should preclude
requests for CK-MB.12
2.5.2 Limitations of creatine kinase measurement
Creatine kinase enzyme is widely distributed and there are various causes of elevated
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total CK in the absence of myocardial injury. Haemolysis leads to the release of
adenylate kinase enzyme, which interferes with the assay and causes false elevation
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of total CK activity. Various forms of skeletal muscle injury can lead to increased
CK activity including strenuous exercise, intramuscular injection, rhabdomyolysis,
burns, and trauma. Chronic muscle disease like Duchenne muscular dystrophy,
polymyositis, dermatomyositis, and myopathy can all lead to increased
concentrations of CK. Total CK activity is a very sensitive indicator of injury to
skeletal muscles. Drugs like cocaine and alcohol can also raise CK concentrations to
abnormal values, presumably due to the associated myopathy that can occur with the
use of these drugs. Neurological conditions like myasthenia gravis also elevates total
CK activity. Other miscellaneous conditions including pregnancy, hypothermia, and
sepsis can increase total CK concentrations. In many of these situations the activity
of CK-MB is also increased, giving a ratio of CK-MB to CK that remains below the
6% cut-off point required to differentiate between skeletal muscle injury and cardiac
muscle injury.49
2.5.3 Future direction with creatine kinase assays
Creatine kinase measurement is a relatively cheap assay that is widely available. For
this reason total CK measurement will probably continue to be used as a marker for
myocardial injury especially in situations such as; (1) In the absence of cTnl, cTnT,
and CK-MB assays; (2) In patients with unequivocal ECG diagnosis of myocardial
infarction where non-specific marker such as CK can be used to monitor the progress
of the patient in hospital and to gauge infarct size.
2.6 CREATINE KINASE MUSCLE BRAIN ISOENZYMES
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Creatine kinase-MB isoenzyme has been considered the gold standard for the
diagnosis ofAMI. It is the isoenzyme of CK specific for heart muscle. It is measured
in serum or plasma by one of two methods; (1) CK-MB activity measurements:
This measures the total activity of the enzyme in serum/plasma by methods like
electrophoresis, column chromatography, immunoinhibition or immunoprecipitation.
The results are reported as international units per litre (IU/L). These methods are
non-specific, measure only active enzymes, and have a low analytical sensitivity (5
IU/L); (2) CK-MB mass measurement: This measures the protein mass in serum/
plasma using specific antibodies against the M, B or MB subunits. The results are
reported in nanogram per millilitre (ng/ml) or microgram per litre (p.g/1). These
assays are highly specific and have a high analytical sensitivity (0.3 ng/ml) and can
measure both active and inactive enzymes. The normal range for CK-MB activity
using various methods has been reported to be 8 - 16 IU/L. The normal relative index
of CK-MB activity to total CK activity is < 6%. The normal range for CK-MB mass
measurement is 5 - 10 ng/ml. The normal relative index of CK-MB mass to total CK
activity is < 4%.
2.6.1 Creatine kinase-mb activity versus creatine kinase-mb mass
Different groups have reported that measurement of CK-MB using mass is better
than that measuring CK-MB activity.19 The recent guidelines for the redefinition of
AMI mentioned at the beginning of this chapter recommend the use ofCK-MB mass
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as opposed to CK-MB activity. The problems inherent in measuring activity are:
(1) The enzyme may become deactivated by experimental manipulations leading
to a low value or underestimation. This is likely to happen in the low range of
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CK-MB activity such as in patients with small AMI or with minor myocardial
damage. In the extreme situation a false negative result could result in the
missed diagnosis of AMI. Unlike CK-MB activity assays, CK-MB mass
assays measure both active and inactive enzyme.
(2) In haemolysed blood samples interference from adenylate kinase, an enzyme
released from red blood cells and catalyses the same reaction as CK-MB,
could result in false positive results. This problem is irrelevant with mass
assays because the antibodies are specific for the CK-MB and the presence of
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adenylate kinase will have no effect on the results of the assay.
(3) Creatine kinase-MB measurement using mass have better early sensitivity for
the diagnosis of ST elevation AMI. They have also been reported to be more
sensitive in detecting small injuries to the myocardium that occur in patients
with non-ST elevation ACS.21
(4) The presence of CK-BB, macro CK type 1, or macro CK type 2 in high
concentrations could interfere with the result and lead to false elevation of
CK-MB when activity measurement is used. These interferences have no such
effects when mass assays are used because the antibodies are specific for CK-
99 *9T
MB and do not cross react with these compounds. '
(5) Creatine kinase-MB activity measurement is non-specific, whereas CK-MB
mass measurement is specific. This higher specificity allows a lower cut-off
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concentration to be used giving it higher sensitivity.
(6) Creatine kinase-MB activity measurement requires technical expertise and
the turn around time is prolonged. With CK-MB mass measurement the
results could be available in as little as 13 minutes, using new point of care
instruments, and can be used to influence decisions regarding patients'
management.24
2.6.2 Creatine kinase-mb and st elevation acutemyocardial
infarction
Creatine kinase-MB follows the same release kinetics as CK and has a sensitivity and
specificity for the diagnosis of AMI of more than 90%. This sensitivity and
specificity changes with the time of presentation after symptom onset. Creatine
kinase-MB activity measurement is most reliable in the 12-24 hours period after
symptom onset. A negative result for CK-MB activity before 12 hours from the
start of symptoms is too early to rule out AMI, and a negative result after 24 hours is
too late. Studies comparing the utilisation of these assays for the early diagnosis of
AMI have shown that CK-MB using mass measurement reaches the cut-off point in
serum several hours before CK-MB activity measurement and have claimed its
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superiority within 4-8 hours after symptom onset. ' The CK-MB mass assay have
been shown to be sensitive for the diagnosis ofAMI even in situations were the ECG
is equivocal and can increase the number of diagnosis made within the time scale
2708
required for the administration of thrombolytic treatment. '
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2.6.3 Creatine kinase-mb and unstable angina
Creatine kinase-MB activity tends to be normal in patients with UA, whereas CK-
MB mass is increased in a proportion of these patients. This observation has been
substantiated by different research groups.38'39'40 A study by Seo et al (1993)
compared CK-MB mass vs CK-MB activity and concluded that CK-MB mass is
more sensitive when CK-MB concentration is in the low range.41 This is important
especially in cases of myocardial injury in UA and following complicated PCI, and
in radiofrequency ablation of arrhythmias, when the amount of CK-MB released can
be small.
Sensitive CK-MB mass assays can detect prolonged ischaemia in UA and have been
used for risk stratification in these patients.38 One small study has shown very high
death rate (64%) during a four years follow-up in patients who were admitted to the
CCU with chest pain, positive CK-MB mass, and non-diagnostic ECG changes for
AMI.42 Several investigators have also studied the release ofCK-MB mass following
PCI.43'44"46 They demonstrated that CK-MB mass is a sensitive indicator of
myocardial injury following PCI. One study reported that 40% of patients showed
evidence ofmyocardial damage following PCI using both CK-MB mass and cTnT 47
2.6.4 Limitations and future direction of creatine kinase-mb assays
Creatine kinase-MB measurement is not totally specific for myocardial infarction
# 1 O AO
and there are various causes for elevated CK-MB concentration other than AMI. '
Cardiac pathologies like congestive cardiac failure and arrhythmia lead to elevated
CK-MB concentration. Severe skeletal muscle damage e.g. acute muscle trauma,
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skeletal muscle disorders like myositis, polymyositis, chronic inflammatory and
degenerative muscle disorders can lead to CK-MB elevation. In these situations the
CK-MB to CK ratio or cardiac troponins can be used to differentiate cardiac and
non-cardiac pathologies.49 Creatine kinase-MB measurement is a widely accepted
assay that is both sensitive and relatively specific for the detection ofAMI. However,
CK-MB (activity or mass) is not sensitive in the first 6 hours after symptom onset for
the early diagnosis of AMI. Measurement using CK-MB mass is the preferred
method and is likely to be the dominant method in the future.20
2.7 CREATINE KINASE MUSCLE BRAIN ISOFORMS (SUBFORMS)
Creatine kinase-MB isoforms are variants of CK-MB isoenzyme, which result from
post-synthetic modification of the M subunit.50 They were discovered by Weavers in
1972 m They have recently been evaluated as markers of myocardial damage in
52 • •1994. After ischaemic damage to the heart, CK-MB isoenzyme is released from the
damaged heart muscle into the blood.50 This isoenzyme is converted into other forms
by the action of the plasma enzyme carboxypeptidase N (CPN) according to the
following reaction:53'54'55'56
CPN
CK-MB2 (tissue form) ^ CK-MB1 (plasma form)
-Lysine
In this reaction CPN enzyme removes one lysine amino acid from the M subunit of
the released CK-MB2 to produce CK-MB1. It is suggested that this post-synthetic
change prepare the molecule for clearance from the body.57 Creatine kinase-MB2
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and CK-MB1 exist in equilibrium [1:1 ratio] in the serum of normal healthy people.
Therefore, measurement of total CK-MB at any point in time is equivalent to 50%
CK-MB2 and 50% CK-MB1.58;61
Most assays that measure CK-MB use a relatively high upper limit of normal (10
ng/ml, 14 IU/L). Humans differ in their background level of CK-MB and some
people may express normal concentrations as low as 1 - 2 IU/L (or ng/ml).
Therefore, in the event of myocardial injury, it will require several-fold increases in
the marker before it exceeds the upper limit of normal of the assays. Creatine kinase-
MB being a relatively large molecule means it will take even longer time to reach the
circulation and becomes important diagnostically. When myocardial injury occurs
there is a sudden release and rise of the tissue isoforms i.e. CK-MB2 compared to the
plasma form CK-MB 1 leading to a rise in the ratio of CK-MB2 to CK-MB1. By
using CK-MB isoforms effectively each patient acts as their own control, and only a
release of a small amounts of the marker is required to raise the ratio to significant
level much earlier. The requirement for the diagnosis of AMI is two-fold; (1)
Increase ofCK-MB2 > 2.6 IU/L; (2) Increase of CK-MB2 to CK-MB 1 ratio > 1.7.
2.7.1 Creatine kinase-mb isoforms and acutemyocardial infarction
Creatine kinase-MB isoforms are reported to be released within 1 hour after
symptom onset and peak at 4 hours. Evidence ofAMI can be detected as early as 1 -
2 hours post-infarction, several hours before total CK-MB reaches diagnostic
level.52'59 These release kinetics make CK-MB isoforms potential markers for the
early diagnosis ofAMI. The sensitivity and specificity of CK-MB2 to CK-MB 1 ratio
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for the diagnosis of AMI is reported to be 92% and 95% respectively within 6 hours
of infarction.60 During this time interval total CK-MB mass or activity would just be
approaching the upper limit of normal. One study reported a sensitivity and
specificity of 95.7% and 93.9% respectively with a high positive predictive value and
a high negative predictive value within 6 hours of infarction.
One hundred and fourteen out of 118 patients with AMI were identified using CK-
MB isoforms within 6 hours. The sensitivity and specificity of conventional CK-MB
during this time interval was 48% and 94% respectively.61 Seventeen patients who
were discharged from the emergency department fulfilled the criteria for the
diagnosis of AMI using CK-MB isoforms (missed diagnosis). The assays also
identified a substantial number of patients with UA (26 out of 133) with abnormal
CK-MB isoforms results but no evidence of AMI on the basis of conventional CK-
MB activity results. The test was also positive in patients with hypothyroidism and
rhabdomyolysis.61 These findings were also substantiated by other studies.62
Some investigators however, have questioned the value of CK-MB isoforms for the
early diagnosis of AMI.26 A study by Laurino et al (1996) showed no difference
between CK-MB isoforms and conventional CK-MB isoenzyme at 6 hours after
63 •
symptom onset. Another study by Bhayana et al (1993) using comparison between
CK-MB mass, CK-MM3 to CK-MM1 ratio, and CK-MB2 to CK-MB 1 ratio found
no significant advantage of isoforms over CK-MB mass for the diagnosis of AMI
within 6 hours.64
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2.7.2 Limitations of cratine kinase-mb isoforms assays
There are still some unresolved issues surrounding the use of CK-MB isoforms for
the early diagnosis of myocardial infarction. There is still some concern regarding
the stability of these isoforms in serum/plasma after their release from damaged
tissues.65 There are also some reports of possible variations in the activity of the CPN
enzyme among humans.66'67 This may have profound effect for the use of the
isoforms as markers for the early diagnosis ofAMI and could lead to false positive or
false negative results.52'65'68 The other drawback is that the use of isoforms does not
obviate the need to analyse total CK and the relative index of CK-MB to total CK to
exclude false positive results.69 Future work should be directed towards the
resolution of the above concerns and to the development of more sensitive and
reliable assays that can offer rapid results to aid in the early diagnosis and triage of
patients.
2.8 MYOGLOBIN
Myoglobin is a small heme protein (17 K Da) that functions in oxygen binding and
transport. It stores oxygen in red muscles (skeletal and cardiac) and under conditions
of severe oxygen deprivation, it releases the oxygen to be used by muscle
mitochondria for synthesis of Adenosine triphosphate (ATP). The myoglobin content
of heart muscle is reported to be 2.5 mg/g wet weight of tissue and the skeletal
muscle content is twice this value 4.0 mg/g wet weight of tissue.70 Myoglobin
constitutes 2% of the total cytosolic protein content of cardiac muscle. The normal
range of serum myoglobin is about 20 - 80 ng/ml. Males have higher levels than
females because they have bigger body size and muscle bulk.
33
2.8.1 Myoglobin and acute myocardial infarction
Myoglobin is one of the best available early markers of AMI within 3 hours after
symptom onset. The relationship between AMI and high myoglobin level was first
reported in 1975.71 Myoglobin becomes abnormal within 2 hours after symptom
onset of AMI, peaks at 6 - 9 hours, and return to normal within 24 hours. This early
release feature ofmyoglobin is attributed to its small size and localisation within the
cytosol of the cell. Several investigators have confirmed a significant role for
myoglobin in the early diagnosis of AMI, the most promising role being in the early
• • • • • 72'73-80rule out of AMI in patients presenting within 6 hours after symptoms onset. '
Within this period the overall diagnostic sensitivity and specificity ranged from 77 -
97% and 90 - 97.9% respectively.
The variation in sensitivity is most dependent on the time of presentation after
symptom onset and drops considerably with very early (< 2 hours) or late
. , n # ...
presentation (>15 hours) to the hospital. A consistently negative result within this
time interval has such a high negative predictive value for ruling out AMI, that
confident decisions regarding patients' management can be based on it. However, a
positive result should be used with caution, as there are many situations that could
give rise to myoglobin elevation in the absence ofAMI.
2.8.2 limitations of myoglobin measurement
Myoglobin is a non-specific marker protein for myocardial injury. The serum
concentration of myoglobin is raised in skeletal muscle damage including
intramuscular injection, exhaustive exercise, muscle trauma, direct current shock
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cardioversion, and also in patients and carriers of genetic muscle disease. Severe
renal disease leads to failure of clearance of myoglobin from the circulation. The
concentration tends to rise and the circulation time is prolonged in these patients.
Although these factors interfere with the specificity of the test, in clinical practice
most of them could be ruled out by careful attention to history taking and simple
blood tests like urea and creatinine to exclude renal failure. In situations where clear
ambiguity exists, myoglobin could be combined with more specific investigations.
The specificity is increased when myoglobin measurement is combined with other
diagnostic methods like ECG or more specific cardiac markers like CK-MB, cTnT,
or cTnl.
2.8.3 Myoglobin and the detection of reperfusion
Ideally all AMI patients should be treated with intravenous thrombolytic treatment or
r1 • • • •
PCI. The success of thrombolytic treatment in establishing reperfusion is reported
• • 82 • •
to be 50 - 80% (depending on the thrombolytic agent). Establishment of reperfusion
after the initiation of thrombolytic treatment is of important interest to the clinicians
in terms of treatment and prognostic implications. Coronary angiography is the most
definitive method to assess the success of thrombolytic treatment, but this procedure
is invasive, carries morbidity and mortality risks, requires catheterisation laboratory
team, and is not widely available.
Biochemical markers like myoglobin (among others) offer an alternative non¬
invasive, safe and potentially sensitive method for the detection of reperfusion. This
can be done by monitoring the changes in serum concentration immediately before
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and 60 or 90 minutes after initiation of thrombolysis. Patients who successfully
reperfuse their occluded artery show a higher and early concentration peak of the
83 • *i
biochemical marker compared to those who fail to reperfuse. In patients with
uncomplicated myocardial infarction who reperfuse, achieve peak value of
myoglobin at 1 hour, whereas those who fail to reperfuse reach peak value about 5
hours later.84 A two-fold increase in myoglobin concentrations within 60 minutes
compared to base line pre-thrombolysis value is associated with 95% predictive
accuracy for the detection of reperfusion.85'86 The existence of "no-reflow" is an
important indicator of impaired reperfusion and functional recovery. Thus a patent
artery does not invariably indicate tissue reperfusion. Accurate markers of tissue
reperfusion are required. The combination of serial 12-lead ECG, clinical features,
and serial cardiac markers testing offer a practical alternative to coronary
angiography for assessment of reperfusion status.
2.9 LACTATE DEHYDROGENASE AND ISOENZYMES
Lactate dehydrogenase is a vital enzyme of approximately 135 kilodalton and is
present in the cytoplasm of almost all cells of the body. There are five isoenzymes of
LDH [LDH1 to LDH5]. Lactate dehydrogenase 1 and LDH2 are the predominant
isoenzymes in the heart muscle, red blood cell, and kidney. The level of LDH in
normal healthy people is about 95 - 200 IU/L. Under normal circumstances LDH2 is
the predominant isoenzyme in the circulation with LDH1 concentration less than
LDH2. When myocardial damage occurs there is more release of LDH 1 than LDH2
leading to the reversal of the ratio. This is called LDH1 to LDH2 flip, and is used as
an index of AMI. Lactate dehydrogenase 1 starts to appear in serum 8-12 hours
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after symptom onset and peaks at 24 - 72 hours.87 The half-life of LDH activity in
blood is prolonged, and it does not return to pre-infarction levels until 5-10 days
post-infarction. Confirmation of AMI using LDH can be based on one or
combinations of the following methods of measurements; (1) Increased total LDH
concentration; (2) Increased LDH1 concentration; (3) Flipped LDH1 to LDH2 ratio;
(4) Increased LDH1 to total LDH ratio.
The LDH1 to LDH2 flip has been reported to have a sensitivity and specificity that
varies between 70 - 100% and 80 - 99% respectively. That depends on the time of
presentation, methods used and the selected ratio. However, the presence of a flipped
ratio in the absence of total increase of LDH is of equivocal significance. The clinical
sensitivity of LDH1 is 89%, with specificity of 95%.88 Reliance on a single value of
LDH1 is useless and serial samples that show a rise and fall are the most sensitive. A
combination of absolute LDH1 value and as a ratio with LDH (LDH1 to total LDH
ratio), or with LDH2 (LDH1 to LDH2 ratio), or LDH4 (LDH1 to LDH4 ratio) has
been reported to be the most sensitive method for this marker.87'89
Various types of anaemia with associated haemolysis show elevated concentrations
of LDH 1, and LDH1 to LDH2 ratio that could mimic AMI.90 Other conditions such
as liver disease, cancer, and congestive cardiac failure also lead to LDH elevation in
the absence of AMI.91 Some patients with skeletal muscle damage like muscular
dystrophy, myositis or following severe physical exercise, and cardioversion also
show elevated concentration of LDH activity.92"94 Other conditions that lead to
elevated concentrations of LDH activity include pregnancy and alcohol overdose.95'96
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The LDH and isoenzymes are less specific than CK-MB, cTnl, and cTnT. The use of
one single marker like cTnT or cTnl is more sensitive, specific, convenient, cost
effective, and obviates the need to perform several other less specific tests like serial
LDH, LDH1, or LDH1 to LDH ratio.
2.10 CARDIAC TROPONINS
The troponin complex is found on the thin filament (actin) of all types of striated
muscle (fast, slow, and cardiac). Its function is to regulate calcium dependent
contraction of muscles. There are three types of troponins; troponin T (TnT);
troponin I (Tnl); and troponin C (TnC). They are designated with a letter that refers
to the function of the troponin protein; TnC, binds Calcium; Tnl, Inhibits the action
* • • 98of the enzyme actomyosin Adenosine triphosphatase; TnT, binds to Tropomyosin.
They are called isoforms and have a pre-fix to indicate the muscle type they are in
e.g. cTnT, sTnT, ITnT stands for cardiac muscle, slow twitch skeletal muscle, and
fast twitch skeletal muscle TnT respectively. Each troponin protein within these
muscles has different molecular weight, amino acids, and amino acid sequence
unique to that muscle type. The different isoforms of TnT and Tnl share between 40
- 55% amino acid sequence homology."
2.10.1 Cardiac troponin t and acute myocardial infarction
Cardiac-TnT (34 KDa) was first introduced in 1989 as a marker for AMI.100 The
upper limit for cTnT has been reported as < 0.1 pg/1, but concentration between 0.03
- 0.1 pg/1 may also have significance as markers of adverse outcome.101 Cardiac-TnT
appears in the serum within 12 hours after symptom onset in patients with AMI. It
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shows similar release kinetics to CK-MB and cTnl, and thus does not provide an
earlier detection for AMI than CK-MB or cTnl within the first 6 hours after symptom
onset.102'103'104 Once in the circulation it persists for a long time (2-3 weeks) after
symptom onset. The half-life of cTnT in circulation is 120 minutes and this long
diagnostic window is thought to be due to the continuous release of the marker from
myocardial cells after necrosis, and not due to slow clearance from the
circulation.103'105 The clinical sensitivity of cTnT for the diagnosis of AMI
approaches 100% at about 12 hours after symptom onset and remains elevated at
100% for at least 4 days.105'106
2.10.2 Cardiac troponin t and unstable angina
Unstable angina carries significant morbidity and mortality risks and early detection
and treatment are essential to minimise complications.29"33 Cardiac-TnT has been
shown to be elevated in some patients with UA (non-ST elevation ACS) and the
magnitude of elevation can be used for diagnostic purposes, risk stratification, and
for selection of appropriate patient groups for treatment. Elevated cTnT in patients
i r\n. 1 no
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with UA is associated with poor prognosis. ' The increase correlates well with
the severity of coronary artery lesions determined by angiography.109 In one
important study, the prognostic value of cTnT was assessed in 967 patients with UA.
It was found that the group that had elevated concentration of cTnT had an increased
risk for cardiac events and the higher the cTnT the more frequent the complications.
Patients were followed-up for 6 months for cardiac complications. The risk of AMI
and death was 4.3% in patients with cTnT less than 0.06 p.g/1 and 16.1% for those
with cTnT equal or greater than 0.18 pg/1.110 In another study by Stubbs et al (1996),
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62 UA patients were followed-up for about three years after their admission with
cTnT concentration greater or equal to 0.2 ng/ml. The incidence of complications in
this group was very high, cardiac death (12 patients), coronary revascularisation (22
patients), death and non-fatal AMI (18 patients).111
Cardiac-TnT measurement can help select the appropriate patients for treatment with
antithrombotic treatment. Treatment of UA patients with thrombolytic therapy had
not been found to be useful.34 35 However, treatment of UA with antiplatelet and
antithrombotic drugs like aspirin, low molecular weight heparin (LMWH),
glycoprotein Ilb/IIIa (GP Ilb/IIIa ) receptor antagonist, and clopidogrel is associated
with 30% reduction in the incidence of mortality and AMI. ' Those patients with
cTnT < 0.1 ng/ml fared equally well whether they were treated by the LMWH
deltaparin or placebo [4.7 vs 5.7% - 40 day mortality respectively]. However,
patients with cTnT greater than or equal to 0.1 ng/ml had reduced AMI and mortality
• • • *112if they received deltaparin rather than placebo [7.4 vs 14.2% respectively].
2.10.3 Specificity of cardiac troponin t assays
Elevated cTnT concentration has been reported in a significant numbers of patients
with chronic renal failure. These levels do not seem to be affected by haemodialysis,
with elevations persisting after treatment.113"116 Vigorous exercise [like marathon
runners], rhabdomyolysis, inflammatory muscle disease [like polymyositis and
dermatomyositis], and degenerative muscle disease [like Duchenne/Becker muscular
117*
dystrophy] have been reported to show elevated concentrations of cTnT. High
cTnT and cTnl concentrations have been reported in critically ill patients who had
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not been diagnosed with comorbid AMI. Blunt trauma to the chest, closed heart
massage, external defibrillation is also reported to result in elevation of cTnT.119'120
Elevations have also been reported in cases ofmyocarditis and drug induced cardiac
toxicity.121'122
The increase in cTnT concentrations in the above conditions can be due to; (1)
Genuine elevation due to the release of cTnT from the heart; (2) False elevation due
to cross reactivity with sTnT using the first generation cTnT assays which have 3.6%
cross reactivity with sTnT;123 (3) Elevation due to the re-expression and release of
113foetal isoforms of cTnT during muscle regeneration. Indeed, some of these
elevation in cTnT have been shown to be due to cross reactivity with sTnT using the
second generation assays which is more specific and have < 0.005% cross reactivity
with sTnT.101 The advantage of the cTnT immunoassay is that it is marketed by one
source only hence there are well-established standards in terms of normal range,
detection limits, and clinical cut-off concentrations. There is however, a slightly
higher rate of positive results with cTnT assays in some patients with chronic renal
failure and acute or chronic muscle disease.113"117'124
2.10.4 Cardiac troponin i and acute myocardial infarction
Cardiac-Tnl (24 KDa) is reported to have a unique segment containing 31 amino
acids that makes it different to either sTnl or fTnl (19 KDa). During foetal
development both sTnl and cTnl are expressed in the myocardium. At birth however,
only the cTnl remains as the only isoform present in the human myocardium.125'126
Cardiac-Tnl has not been shown to be expressed in any type of skeletal muscle
41
during either development or disease stimuli.127 This makes cTnl 100% specific for
the myocardial tissue, and an excellent marker for the detection ofmyocardial injury
in serum.
Cardiac-Tnl was first reported as a biochemical marker ofmyocardial injury in 1992,
and has since been shown to be a very sensitive and specific marker for the diagnosis
of AMI. It has similar release kinetics to CK-MB and to cTnT and does not provide
128 •
an earlier detection for AMI within the first 6 hours after symptom onset. Cardiac-
Tnl peaks between 12-36 hours after onset of AMI and remains elevated for 3 - 7
days after AMI. The half-life of cTnl is < 2 hours and the prolonged diagnostic
window is due to the continuous release of this marker from the myofibril. Cardiac-
Tnl is more sensitive and specific than LDH1 to LDH2 ratio for the detection of
• • 17q
myocardial injury up to 5 days after admission.
2.10.5 Cardiac troponin i and unstable angina
Cardiac-Tnl is cardiac specific and its concentration in normal and disease free
populations is undetectable or very low. This makes it a suitable marker for the
detection of myocardial injury in UA patients as well as other situations where
myocardial injury is expected but the amount released could be small e.g. following
1 to • ...
PCI. Many studies have also shown cTnl to have prognostic value in patients with
UA similar to that of cTnT. Those patients showing higher levels at admission have
ni.i -j-j
more complications [increased mortality and AMI] on subsequent follow-up. '
The prognostic risk in these patients is significantly altered if early intervention
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[pharmacological and invasive] was undertaken in these patients compared to
conservative treatment.
2.10.6 Specificity of cardiac troponin i assays
• • • 133Cardiac-Tnl was not found in patients who underwent uncomplicated angioplasty.
Cardiac-Tnl was not elevated in patients who undergo non-cardiac surgery, but was
raised in patients undergoing CABG due to surgical injury of the myocardium.
Cardiac-Tnl or cTnT may be the preferred markers of choice to detect myocardial
injury in patients who undergo surgery. In the situation of surgery, cTnl (or cTnT)
being specific to the myocardium will also help to distinguish elevation of CK-MB
due to skeletal muscle damage alone from elevation due to myocardial injury.134 In
patients with chest trauma, cocaine associated chest pain, and hypothyroidism where
CK, CK-MB are elevated; cTnl is able to show true myocardial injury from those
with false elevation. In marathon runners, more than 80% of samples were positive
for CK-MB and in all of these samples cTnl was negative. The main problem with
cTnl is that there are several commercial assays available, and each assay differs
with respect to normal range, detection limit, and medical decision cut-off limits.
Thus there is a lack of standardisation of methodology for cTnl assays. However,
cTnl has been reported to show slightly better specificity in situations where there is
severe skeletal muscle injury and renal failure.
2.11 CONCLUSIONS AND REMARKS
Based on the aforementioned discussion the markers that are well suited for the early
diagnosis of AMI within the time interval 0-6 hours after symptom onset are
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myoglobin, and CK-MB isoforms. Creatine kinase-MB mass measurement is suitable
in the 6-24 hours interval, CK-MB based on activity measurement is more sensitive
in the 12 - 24 hours interval,25 and the other cardiac markers like total CK, LDH and
isoenzymes, cTnT, and cTnl are most reliable after 12 hours from symptom onset.
Decision-making regarding triage and treatment of patients should not be based on a
single measurement of cardiac markers alone because of the time delay required for
the marker to exceed the upper limit of normal (false negatives).135 Based on the
recent recommendations by the ESC/ACC, cTnl and cTnT are the best markers for
the confirmation of AMI. Creatine kinase-MB (preferably mass) is the second best
• 90
marker in the absence of troponins assays.
The management of patients who present with chest pain suspicious of ACS is best
dealt with in specifically designated units that have rapid access to specific
equipment (ECG, echocardiogram) and facilities (to measure cardiac markers), and
with appropriate staffing. Acute chest pain units attached to A&E departments can
accommodate patients for 12 hours, so that appropriate investigations can be carried
out quickly to identify patients with evolving infarction and unstable angina who are
at increased risk early after presentation.
A serial combination testing of a sensitive early marker (e.g. myoglobin) and one of
the cardiac specific troponins offers the best approach. ' Two serial testing at
least within 12 hours after symptom onset provide reliable sensitivity and specificity
for detecting ischaemia and evolving infarction within the time interval required for
the implementation of reperfusion therapy. This 12 hours strategy also identifies
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patients at low-risk for acute ischaemic events.137'138 These serial testing should not
be viewed as an expensive strategy for the following reasons; (1) It is cost effective
because within 12 hours after admission, decisions can be made regarding triage,
implementation of treatment and discharge with great confidence and without
compromising the safety of the patient. This strategy will optimise treatment and
result in a reduction of inappropriate admissions and discharges; (2) This protocol
will not be applicable to patients with unequivocal diagnosis of AMI i.e. significant
ST segment elevation, but will be used in selected groups of patients with chest pain
and either atypical clinical history or non-diagnostic ECG on admission. Early rule in
of AMI (or UA) patients based on serial cardiac marker results or evolving ECG
changes will optimise the early implementation of appropriate care.
Figure 3 shows flow chart with a suggested protocol for triage and management of
patients who present to the A&E department with acute chest pain. High clinical
probability of AMI means typical prolonged ischaemic symptoms in patients of the
appropriate age and sex with evidence of risk factors or documented evidence of
CAD or previous history of ACS. Low clinical probability of AMI means atypical
chest pain in a young male or female without risk factors or documented evidence of
CAD or previous history ofACS. Positive ECG changes ofAMI means the presence
of significant ST segment elevation ± new Q-waves or new left bundle branch block
(LBBB). Atypical or equivocal ECG changes of AMI mean ST segment depression,
T-wave inversion, ST elevation in one lead only, and Q-waves in patients with
known cardiomyopathy or left ventricular hypertrophy. Confounding ECG means the
presence of old LBBB, or paced rhythm, or any other conditions that may preclude
the correct interpretation of the ischaemic changes present on the ECG.
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Patients with high clinical probability of AMI but no definite ECG changes of AMI
are admitted to chest pain units for rapid monitoring of evolving ischaemic changes.
Serial blood sampling at least twice during the first 12 hours after symptom onset
with serial ECG recordings will allow appropriate management of most patients.
Positive ECG changes of AMI at any time interval during this first 12 hours ±
cardiac marker rise consistent with AMI result in the rapid implementation of
reperfusion therapy and transfer to CCU. Patients with elevated cardiac markers +
ECG changes of ischaemia e.g. ST segment depression, T wave inversion (no
definite ischaemic ECG changes of AMI) are treated as non-ST elevation MI with
newer antiplatelet and antithrombotic medications and admitted to CCU. These
patients may be considered for early investigations by means of coronary
angiography ± angioplasty.
Patients with no increases in cardiac markers and without conclusive evidence of
ischaemia on ECG can either be discharged or admitted and considered for further
investigations of CAD, or investigated for alternative diagnoses other than ischaemic
chest pain e.g. pulmonary embolism or peptic ulcer disease. Borderline cases with no
clear cut ECG or cardiac markers changes are admitted to regular unit for further
investigation by means of exercise tolerance test (ETT), stress thallium, or
angiography. Patients with chest pain and low clinical probability of AMI, no
significant ECG changes of ischaemia, are screened for cardiac ischaemia using
specific cardiac marker between 0 hour and 12 hours. Negative screening results in
the discharge of patients, whereas positive screening results in their admission and
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Serial blood sampling twice during the
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antithrombotic treatment
consider angiography
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further investigations
e.g. ETT, stress thallium,
or angiography
Figure 3, Shows flow chart with a suggested protocol for triage and
management of patients who present to the A&E department with acute chest
pain. Abbreviations; A&E, accident and emergency department; AMI, acute
myocardial infarction; ECG, electrocardiogram; +, positive.
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CHAPTER 3
DO WE NEED NEW EARLY MARKERS OF MYOCARDIAL DAMAGE:
THE POTENTIAL VALUE OF HEART FATTY ACID BINDING PROTEIN
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3.1 INTRODUCTION
The fatty acid binding proteins (FABP) describe a family of cytosolic proteins that
show a large extent of structural homology and many important differences. They
were discovered by Ockner in 1972 in studies on the intestinal absorption of fatty
acids.1 They are called FABP because they exhibit a high affinity for the non-
covalent binding of fatty acids. These proteins are widely distributed and are present
in the fatty acids metabolising tissues of many mammals. Their presence has also
been reported in some species like birds, insects and fish. There are several types
and they all have low molecular weight (12 - 15 KDa), but they differ markedly in
tissue distribution, concentration within tissue, isoelectric point (PI), binding
capacity, and binding specificity. These proteins have been extensively reviewed
elsewhere.3"10 The FABP are relatively tissue specific and are designated by a letter,
which refers to their tissue of origin e.g. L-FABP, H-FABP, I-FABP refers to liver,
heart and intestine fatty acid binding protein respectively.11 Tissue specific FABP
have also been reported in muscle, adipose tissue, kidney, brain and nerve cells.
Tissue specific FABP such as liver (L-FABP) and intestinal (I-FABP) have been
used to detect pathologies in these tissues using specific antibodies raised against
these proteins.1 ' Different FABP share between 30 - 80% amino acid sequence
homology. Heart and liver contain the highest concentrations of these proteins.9
3.1.1 Function
Fatty acids are the major energy source of the heart.14 They are also important
molecules for the synthesis of membrane lipids and lipid mediators such as
prostaglandins, leukotriens, and thromboxanes.15 In general, 50 - 80% of the heart
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energy is provided by lipid oxidation. In extreme cases (sustained exercise), this may
rise to 100%. The heart is a poor fatty acid synthesiser and contributes only 0.1% of
the total body fatty acid synthesis,16 yet 10% of the total body turnover of fatty acids
is by the heart.17 Fatty acids are insoluble in the intravascular and extravascular
space, and also in the intracellular space. In plasma they are transported bound to
albumin, or as part of the lipoproteins complex.1 '18 Heart-FABP is believed to be the
intracellular equivalent of albumin for the intracellular transport of the insoluble fatty
acids within the cells. Sixty per cent of fatty acids are bound to H-FABP and 50 -
70% of bound fatty acids are of the unsaturated type. These proteins are truly
cytoplasmic in the sense that they do not exist anywhere else e.g. plasma or
extracellular space under normal conditions.19'20 Recent work has suggested more
9 1 ■99-97
complex regulatory functions for these proteins other than just lipid transport.
The precise physiological functions of these abundant proteins are not fully
understood at the present time.
3.2 1SCHAEMIA AND ITS EFFECT ON THE HEART
Under normal circumstances the oxygen supply to and the demand of the heart are in
balance. During myocardial ischaemia there is a reduction of blood flow through the
coronary arteries resulting in the decline of the oxygen supply to the heart tissue, thus
causing imbalance between oxygen supply and oxygen demand. Initially this is
compensated for by an increase in heart rate and vasodilatation of the coronary
arteries. When the oxygen shortage becomes severe and prolonged multiple enzymes
in the mitochondria oxidation pathways become inhibited leading to disturbance of
fatty acids oxidation and ATP production.28 Fatty acids and their derivatives fatty
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acyle coenzyme A, and fatty acyle carnitine accumulates in the ischaemic cells. '
In the absence of oxygen the cell produces ATP through anaerobic metabolism with
accumulation of lactic acid, causing cellular acidosis.
Ischaemia is also associated with increased catecholamine hormone production due
to increased sympathetic activation. ' ' The metabolic effects of this hormonal
change is further increase in plasma and intracellular fatty acids due to
catecholamine induced lipolysis.31'56 Phospholipases are activated in the ischaemic
myocardium and lead to break down of membranous phospholipids, with the
formation of lysophosphatides, which are thought to play a role in the pathogenesis
• • • • • ^9
of some of the cardiac abnormalities seen in ischaemic heart disease.
The combinations of the following pathological processes; (1) Accumulation of fatty
acids; (2) Reduction of ATP; (3) Activation of enzymes that hydrolyse phospholipids
; (4) Increased cellular acidosis; (5) Accumulation of lipid degradation products and
their integration with the cell membrane; and (6) The prevention of the wash out of
these degradation products during the ischaemic phase, interferes with many cardiac
functions. Many ion channels become inhibited leading to failure of ion
homeostasis.33 This leads to cell swelling and the integrity of membranes is
disturbed.34 If reperfusion is not restored quickly during this reversible phase, the
ischaemic cells reach the point beyond which the damage becomes irreversible and
restoration of reperfusion at that stage has little effect because cell rupture and death
occurs. Early reperfusion supplies oxygen and nutrients, washes out degradation and
waste products, and helps the cell reverse the damage.
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3.2.1 Factors that affect the release of cardiac markers from the
myocardial cell after damage
When the ischaemia is prolonged, cell death occurs. The cell enzymes and proteins
are released into the intercellular space. The release of these proteins is thought to be
influenced by several factors like their size, location within the cell, their behaviour
after release, and route of elimination from the intercellular space. Small proteins
like H-FABP (15 KDa), and myoglobin (17 KDa) are released faster than larger
molecules like CK-MB (80 KDa) or LDH (130 KDa). Cardiac markers that lie free in
the cytosol of the cell like myoglobin, H-FABP, and CK-MB are released faster than
compounds that are attached to the structural elements of the cell like cTnT, cTnl, or
myosin light chain, which require prior degradation before release.
After their release from the cell some proteins like CK-MB may partially bind to
structural elements. Further delay may also result from the route of elimination
from the interstitial space. Compounds that reach the circulation by traversing
through the endothelium (trans-endothelium) are faster than those compounds that
are drained by the lymphatic system. Once in the circulation the marker protein
requires to build up concentration to sufficient quantities to exceed the upper limit of
normal range for that particular assay. This is influenced by degradation and the rate
of elimination from circulation.
3.3 EARLY DIAGNOSIS OF ACUTE CORONARY SYNDROME AND ITS
IMPACT ON PATIENTS' CARE
Early diagnosis of ACS based on multiple samples would contribute to patients' care
in the following ways.
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Triage ofpatientsfrom accident and emergency department
Biochemical markers of early damage can help with the triage of patients from the
A&E department. Those patients with positive results for ischaemia need to be
admitted to the CCU or to one of the monitored beds. Those with "true negative"
results i.e. after sufficient time for liberation of marker into the circulation can be
considered for early discharge if there is a low probability of ischaemia and the
patient remain free of recurrence. These strategies will optimise the effective use of
expensive resources in the CCU and other acute units for the appropriate groups of
high and moderate risk patients.
Acute myocardial infarction and non-diagnostic electrocardiogram
Early cardiac markers can be helpful in the diagnosis of AMI in the following
situations when there is a high clinical suspicion of infarct, but the diagnostic value
of the admission ECG is limited; (1) When the ECG cannot be interpreted or has
reduced diagnostic accuracy e.g. the presence of conduction disorders including left
bundle branch block (LBBB) or paced rhythm; (2) If Q waves and ST-T changes are
already present e.g. old infarcts and digoxin toxicity respectively; (3) With ST-T
changes of marked left ventricular hypertrophy (LVH); (4) In posterior infarct or
right ventricular infarct which may produce no clear-cut diagnostic ECG changes on
the standard 12-lead ECG; (5) When diagnostic changes of AMI are present in one
lead only; and (6) In the 30% of patients who have no diagnostic changes on their
admission ECG.36"38'39'40 In clinical practice today reperfusion therapy, thrombolysis
or PCI, is only given to patients with clinical evidence of ischaemia and ST segment
elevation.
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Unstable angina and non-Q wave myocardial infarction
Clinical trials have shown most benefit of treatment in the UA and non-Q wave MI
groups with positive biochemical marker evidence of ischaemia. Those patients with
UA but no biochemical marker evidence of ischaemia show least benefit (or no
benefit) from treatment compared to placebo.43 Cardiac markers can help with risk
stratification of patients early in the course of ischaemia.43'44 In those patients with
UA and non-Q wave MI, early diagnosis results in the admission of these patients to
the CCU or to a monitored bed in a higher dependency area. Administration of
antithrombotic agents (aspirin, clopidogrel, LMWH, and GPIIb/IIIa receptor
antagonists) is associated with a significant reduction of subsequent complications
(AMI and death).45'46 In addition to early identification and implementation of
treatment, these patients can have further risk stratification assessments e.g. exercise
tolerance test, perfusion scans or angiography and where appropriate PCI or CABG.
Most of the trials evaluating early benefits of antithrombotic treatment in UA and
non-Q wave MI patients were based on patients recruited to these trials within 24 -
48 hours of their admission. There have been few studies evaluating these treatments
very early in the course ofUA and non-Q wave MI i.e. within the first 6-12 hours in
patients with biochemical marker evidence of ischaemia. This is partly because this
group is very difficult to identity with certainty in the early stages. It is not known
whether antithrombotic treatment in UA and non-Q wave MI is time-dependent just
like thrombolytic treatment in AMI patients. Both conditions share a common
pathophysiology although differing in severity. Theoretically, it is possible to assume
that early treatment in UA and non-Q wave MI might have better outcome compared
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to patients receiving no or delayed antithrombotic treatment. The precise answer to
this question is not possible unless a biochemical marker that can identity UA and
non-Q wave MI patients in the first 6-12 hours is available. Only then may the full
benefits of very early antithrombotic treatment in UA and non-Q wave MI patients
be realised. Thus biochemical markers could have a potential role in identifying such
patients early adding to risk stratification and prognostic accuracy and optimising
treatment.
Prevention ofinappropriate discharge ofpatients
In the very early stages of AMI some patients may present with atypical chest pain
and non-diagnostic ECG changes. Without an appropriately timed biochemical
marker to rule out AMI, these patients could be misdiagnosed and inappropriately
discharged. It is estimated that between 2 - 10% of patients with AMI are discharged
from A&E departments.47,48'49 This is more likely to happen in high volume medical
institutions where the turn over of patients is high and there is limited availability of
beds. Common features of cases of missed AMI include factors like age [young
patients], sex [females], ethnic factors, atypical history of chest pain, absence of
previous cardiac history, and being reviewed by inexperienced physicians.47'48
Financial implications
It is estimated that less than 30% of patients admitted to the CCU with suspected
AMI are eventually diagnosed with AMI 49 Conservative policies that opt for the safe
admission of patients without clear-cut diagnosis of ischaemia rather than risk
inappropriate discharge, result in the admission of a large number of patients without
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ACS. The cost of caring for such patients is very substantial.49 It has been shown that
decisions based on cardiac markers for the triage of patients result in a considerable
reduction of this financial burden without compromising the safety of patients. '0
3.4 HEART FATTY ACID BINDING PROTEIN
Heart-FABP is a small (15 Kda) soluble non-enzyme protein. It is composed of 132
amino acids. It is one of the most abundant proteins in the heart and comprises 5 -
15% of the total cytosolic protein pool in the aqueous cytoplasm. This is equal to 0.5
mg/g wet weight of tissue.51'53'60'6' Heart-FABP specific to the mitochondria has also
been reported.54 The gene is located on chromosome l.55 Heart-FABP binds two
molecules of fatty acids and is involved with the delivery of fatty acyle coenzyme A
for oxidation with the generation of heart energy in the mitochondria.'3
Myocardial ischaemia results in a significantly higher level of fatty acids in the
plasma and the myocardial tissue, which can be harmful to the heart.'6'57"59 The
presence of H-FABP is believed to serve a protective function for the myocardial
cells against the oxidation of these fatty acids while still having these substances
readily available for the cells metabolic needs. During ischaemia (e.g. AMI), H-
FABP leaks out of myocardial tissue and their concentration increase in plasma.60
The leakage of H-FABP from the myocardium may make the myocardium more
vulnerable to the harmful effects of fatty acids during reperfusion and may account
for some of the complications seen during reperfusion e.g. arrhythmias. Some reports
have suggested another protective role for H-FABP as scavengers of free radicals
that are present in the heart during ischaemia.61'62
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Heart-FABP exists in high concentrations in the heart only. However, this protein is
not totally cardiac specific and occurs in other tissue although in a much lesser
concentrations.63'64 It occurs in skeletal muscles in concentrations varying between
0.05 - 0.2 mg/g wet weight of tissue, depending on muscle fibre type studied.65 It has
also been reported in very low concentrations in tissues like the kidney, aorta, testes,
mammary glands, placenta, brain, adrenal glands, adipose tissue, and stomach.63'64
It must be noticed however that, the presence of H-FABP in these tissues does not
necessarily means its presence in all cells of that tissue. Also the evidence was
obtained in some of these studies by immunohistochemical methods using antibodies
to H-FABP. The different FABP from heart, liver and intestine share between 20 -
35% amino acid sequences homology. Heart, nerve, and adipose tissue FABP share
60 - 80% amino acid sequence homology.9 Antibodies raised against heart, liver, or
intestine in the earlier studies may have up to 5% cross reactivity with each other and
have a detection limit of around 1 ng/ml. In addition, antibodies raised against H-
FABP have 80% cross reactivity with skeletal muscle FABP.7'
It is therefore possible that cross reactivity with other FABP or other as yet
unidentified protein in these tissues is an alternative explanation for the reported
presence of H-FABP in these tissues.66"70 The newer assays have a much improved
sensitivity and can detect H-FABP in concentrations as low as 0.25 ng/ml and the
cross reactivity with other tissues FABP is < 0.005%.72'73 The use of these newer
assays might show an accurate picture of the true distribution of H-FABP in the
various tissues outside the heart.
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3.4.1 The rationale for the use of heart fatty acid binding protein
as a marker for the early diagnosis ofmyocardial injury
The rationale for the use of H-FABP as a marker for the early diagnosis of
myocardial injury is based on the following features; (1) The presence of this soluble
protein in the myocardium in high concentration; (2) Virtual confinement to the
cytoplasmic space; (3) Small molecular size; (4) Relative tissue specificity. The
relative distribution of H-FABP outside the heart has been equated with that of CK-
MB;6? and (5) Early release into plasma and urine (within 2 hours) after onset of
myocardial injury. Heart-FABP bears a considerable resemblance to myoglobin (a
well accepted early marker of myocardial injury within 6 hours) in terms of size,
location within the cell, release and clearance kinetics. However, H-FABP is more
cardio-specific and this advantage makes it more suitable cardiac marker than
myoglobin.74'110;125
3.4.2 Measurement of heart fatty acid binding protein and normal
range
The method of measurement is based on sandwich enzyme linked immunosorbent
assay (ELISA) using two monoclonal antibodies specific for the H-FABP.23'63'72'75'76
The reasons for using immunological methods for measurement are; (1) Heart-FABP
is non-enzyme protein and measurement using enzyme activity is not possible; (2)
Using functional capacity of binding fatty acids is also not possible due to the
presence of albumin (another fatty acids binding protein) in a large concentration in
the serum; and (3) Other methods that require prior extraction of H-FABP could
introduce inaccuracies ofmeasurements.
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The normal ranges reported for H-FABP in plasma and serum are assay and method
dependent. Tanaka et al (1991) has reported the normal range for H-FABP to be 0.0 -
2.8 jug/1;77 Wodzig et al (1997) reported 0.3 - 5 p.g/1 as the normal limit;72 and Tsuji
et al (1993) used 3 pg/1 [normal range 0.0 - 0.6 pg/1].79 One study used a cut-off
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concentration of 19 pg/1 [mean ± 2 SD of controls]. Fatty acid binding proteins
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from heart and striated muscle are reported to be similar. ' Heart-FABP is not
likely to be found in the blood stream under normal conditions. The normal plasma
H-FABP is likely to be due to the continuous release of this protein from damaged
skeletal muscle cells.
3.4.3 Plasma heart fatty acid binding protein and acute myocardial
infarction
Heart-FABP was introduced by Glatz in 1988 as a potential novel biochemical
marker for the early diagnosis of AMI.81 This assumption was soon confirmed in
many studies.60,65'78'82'83'77'110 Under normal conditions H-FABP is not present in
plasma or interstitial fluid, but is released into the blood upon cellular injury. The
cytoplasmic to vascular concentration ofH-FABP is of the order of 200,000:1.84 The
plasma concentration of H-FABP under normal conditions is < 5 pg/l. This makes
the plasma estimation of H-FABP suitable for the early detection and quantification
ofmyocardial tissue injury. The H-FABP is released into plasma within 2 hours after
symptom onset and is reported to peak at about 4-6 hours and return to normal base
line value in 20 hours.8" Within the period of 30 - 210 minutes after symptom onset,
H-FABP has > 80% sensitivity for the diagnosis of AMI.78 Within the interval of 0 -
6 hours after symptom onset, the other cardiac markers such as CK, CK-MB mass or
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activity, cTnl and cTnT will only be starting to accumulate in the plasma, and their
or
sensitivity has been reported to be around 64%.
3.4,4 Urinary heart fatty acid binding protein and acute
myocardial infarction
Urinary indicators of myocardial injury are almost unknown and only myoglobin has
O/- OO
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been tried as a urinary indicator of myocardial injury. " Heart-FABP is eliminated
from the circulation by the kidney but the precise mode of renal handling ofH-FABP
is unknown. A rise in serum and urine H-FABP concentration above normal values is
• 77
seen in patients who present with AMI as early as 1.5 hours after symptom onset.
Studies in animals have also shown decreased myocardial tissue content and rising
plasma and urine concentrations of H-FABP very early after coronary artery
ligation.60'129 Measurement of plasma or urine concentration of H-FABP was
diagnostic ofAMI as early as 30 minutes after ligation.
Assays that measure H-FABP in urine samples were able to accurately diagnose
patients with AMI and provide reliable estimation of infarct size.89 The measurement
of infarct size from urinary H-FABP may be influenced by several factors like renal
blood flow, perfusion pressure, glomerular filtration rate, tubular absorption, and
diseases of the kidney. Measurement of urinary and plasma H-FABP in the presence
of kidney diseases may lead to underestimation and overestimation respectively of
the size of infarct due to impairment of excretion of H-FABP.128 Heart-FABP
circulates for longer time (> 25 hours) after AMI in the presence of renal failure.78
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Several sensitive assays that can measure H-FABP in urine samples are
available.76'77'79'89
3.4.5 Limitations of heart fatty acid binding protein assays
The human skeletal muscle FABP has been reported to be identical or very similar
to that of H-FABP.71 The 'H-FABP' content of skeletal muscle is variable and is
reported to range between 0.05 - 0.2 mg/g wet weight of tissue, depending on muscle
type.80'90 Skeletal muscle damage during the course of AMI e.g. intramuscular
injections, electric cardioversion, and traumatic cardiopulmonary resuscitation may
result in the leakage of H-FABP and this could interfere with the results of the
assays.90 Diagnosis of AMI in these groups of patients using H-FABP alone can be
difficult. Heart-FABP is increased in the plasma of healthy volunteers after strenuous
exercise as a result of release from skeletal muscle, but in these patients the ratio of
myoglobin to H-FABP is above the 6% cut-off value considered specific for skeletal
muscle injury.91 One study however did not report any increase of H-FABP in urine
or serum in a patient with crush injury, whereas myoglobin was markedly elevated.77
Surgery (both cardiac and non-cardiac) causes elevation of H-FABP concentration.
Heart-FABP is excreted by the kidney and renal insufficiency results in decreased
clearance of H-FABP thereby elevating the concentration and prolonging the
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circulation time. In situations ofAMI and renal failure, measurement of plasma H-
FABP could lead to overestimation of myocardial infarct size, and could interfere
with its use for the detection of re-infarction.128 Fortunately most of these (if not all)
could be ruled out by careful attention to history taking and routine blood tests like
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urea and creatinine to exclude renal failure and should not interfere with the
specificity ofH-FABP assay for the vast majority for clinical purposes.
3.4.6 ISOFORMS OF HEART FATTY ACID BINDING PROTEIN
Heart-FABP could be an ideal early marker of myocyte injury in ACS if there is an
isoform of this protein that is 100% specific to the heart. Several investigators have
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addressed the possibility for the existence of possible isoforms ofH-FABP. Glatz et
al (1985) isolated FABP from the human heart. This protein had molecular weight of
15000 Dalton; isoelectric point of 7.5; and the amino acid sequence was not
reported.94 Unterberg et al (1986) reported the isolation ofH-FABP with a molecular
weight of 15500 Dalton; PI of 5.3; and amino acid sequence (2 residues of
cysteine).95 Offner et al (1988) also reported the isolation of H-FABP with a
molecular weight of 14768; PI of 5.25; and amino acid sequence (contains no
cysteine residues). These results suggest that isoforms of H-FABP may exist in the
human heart. This view is also supported by some animal studies in rats by the
finding that the nucleotides sequence of two rat hearts FABP cDNA differ in the 5'
and 3' untranslated regions. Existence of H-FABP isoforms have also been reported
in bovine species.96"98
There is still some lack of clarity as to whether FABP from heart and skeletal muscle
are identical or very closely related. In an abstract Said and Schatz (1986) reported
the purification of FABP from rat muscle and heart.99 Although immunologically
related the proteins were different as judged by their ultraviolet spectra,
electrophoretic mobility, and their capacity to bind fatty acids. Fatty acid binding
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protein from heart and skeletal muscle show a strong cross reactivity (80%) with
each other in immunochemical studies and therefore must be similar or closely
related.71 Other investigators have claimed both proteins to be similar.100'101 Further
studies using more sensitive techniques are needed to resolve this matter.
3.4.7 Heart fatty acid binding protein and myoglobin
Myoglobin has been introduced as a marker for the early diagnosis of AMI within
3 hours after symptom onset.102"106'123 In a study by Bhayana (1994) myoglobin was
found to be superior to CK-MB mass and cTnT for ruling out AMI within the period
of 3 - 6 hours after symptom onset.107 Myoglobinuria has long been known to be
useful in the diagnosis of AMI.86'108 Myoglobin and H-FABP share many key
features;109 (1) Low molecular weight proteins (17 and 15 Kda respectively); (2)
Found in abundant concentrations in the cytosol of myocardial cell; (3) Provide
substrate for mitochondrial oxidation (oxygen and fatty acids respectively); and (4)
Both are released within 2 hours after symptom onset, peak early (6 hours) and return
to normal base line concentration within 24 hours.
Both proteins are present in the heart and skeletal muscle in different concentrations.
The concentration ofmyoglobin in heart and skeletal muscle is 2.5 and 4.0 mg/g wet
weight of tissue respectively. The H-FABP concentration in heart and skeletal
muscle is 0.5 and 0.05 - 0.2 mg/g wet weight of tissue respectively.90'109 The
myoglobin content of skeletal muscle is twice that of the heart. The H-FABP content
of skeletal muscle is only 10 - 50% of that of the heart. The normal plasma
concentration ofH-FABP (< 5 pg/1) is 10 to 15 fold lower than that ofmyoglobin (20
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- 80 jug/1). Heart-FABP is therefore more cardio-specific than myoglobin and
because of this superior specificity, the use of H-FABP as a marker for the early
diagnosis ofAMI seems preferable.74'109'110
The normal ratio of myoglobin to H-FABP in myocardium is about 5, whereas the
ratio of myoglobin to H-FABP in skeletal muscle is in the order of 21 - 70
(depending on muscle type).90 The main disadvantage of myoglobin and H-FABP as
early markers of myocardial injury is lack of total specificity due to their presence in
skeletal muscle. Severe skeletal muscle injury may result in the release of both
proteins in sufficient quantity to interfere with the specificity of the assay. Both
proteins are released into plasma after injury at about the same time and in a ratio
similar to the concentration of the proteins in the tissue of origin, therefore the
measurement of the myoglobin to H-FABP ratio could be a useful index for the
discrimination between cardiac and skeletal muscle damage.
A myoglobin to H-FABP ratio that is around 5 is considered to be specific for the
heart and a ratio between 21 - 70 is more specific for skeletal muscle damage.90 The
combination of the two markers in a ratio has been reported by some investigators to
increase the diagnostic specificity for the diagnosis of AMI more than relying on
either marker alone. However, the use of this ratio should not be a rigid criterion as
overlaps do occur. Some investigators did not support additional value of myoglobin
to H-FABP ratio over the measurement ofH-FABP alone.90'112'110
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3.4.8 Heart fatty acid binding protein and unstable angina
Heart-FABP may be useful for the identification of patients with UA. However, there
have been no detailed studies evaluating its usefulness for the diagnosis, or risk
stratification in patients with UA. In a study by Tsuji (1993) using H-FABP with a
normal range of 0.0 - 0.6 pg/1 and an upper limit of normal of 3 pg/1, in patients
suspected with a diagnosis of UA, the concentration of H-FABP was 3.5 ± 1.7 pg/1.
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In patients with AMI the range was 12.3 ± 9.6 pg/1. Other investigators have also
observed an increase in H-FABP serum concentration in UA patients.110 One study
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reported that H-FABP was normal in a patient diagnosed with UA. In this study a
relatively high upper limit of normal concentration was used (19 pg/1) and this high
cut-off concentration may have affected the sensitivity or could be due to UA
without myocardial necrosis. At present we have limited information on the
ischaemic threshold at which H-FABP leaks out. Preliminary results from our pilot
study have suggested a possible role for H-FABP in the diagnosis of UA. There is a
need for studies that are properly designed to look specifically at the role ofH-FABP
for the diagnosis of patients with UA.
3.4.9 Heart fatty acid binding protein and acute myocardial
infarction after surgery
Surgery is associated with various complications. Peri-operative or post-operative
development of AMI is one of more serious. The risk of peri-operative AMI with
major non-cardiac surgery is only 1 - 2% in patients over 40 years. This risk
• • 113increases to 3 - 10% in elderly patients and those with cardiovascular diseases. In
cardiac surgery peri-operative myocardial injury is the most common cause of
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morbidity and mortality. The diagnosis of peri-operative or post-operative AMI
poses a challenge in cardiology. The ECG may show non-specific ST segment and T
wave changes only. The diagnosis of AMI using biochemical markers in the setting
of surgery is difficult because there are many factors that could interfere with the
tests. Inflammation and per-operative trauma could lead to the release of markers
from the myocardium as well as from skeletal muscle. The ability of the cardiac
markers to diagnose myocardial injury will depend primarily on their cardiac
specificity and on the surgery itself i.e. cardiac or non-cardiac. In non-cardiac
surgery the marker that is cardiac specific will detect myocardial injury, because its
concentration in the blood is low or undetectable before surgery and its source of
release after surgery is the heart only.
The situation is different after cardiac surgery because there is damage to the heart as
well as to other tissue structures including skeletal muscle. The release of markers is
from both infarcted cardiac tissue (as a result of vessel occlusion) and the injured
non-infarcted cardiac tissue (as a result of surgical trauma). In this setting the post¬
operative concentration of the specific marker is set to increase even in the absence
of AMI due to the traumatic release as a result of the surgery itself. This will require
a careful validation of a cut-off value to diagnose AMI and to take into account this
'expected' increase in the cardiac marker concentration.
Heart-FABP has been shown to peak early and may be useful for the early detection
ofmyocardial injury after surgery. The plasma concentration of H-FABP is increased
relatively early compared to CK-MB and cTnT after aortic declamping in CABG
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surgery. The time to reach the peak concentration was significantly shorter for
plasma H-FABP [1.4 ± 0.5 hours] than for CK-MB [2.5 ± 0.5 hours] or cTnT [6.6 ±
1.3 hours].115 Similar finding were also reported in other studies.116 Heart-FABP was
not increased in low-risk patients after CABG surgery without cardiopulmonary
bypass.117 The discriminative value of myoglobin to H-FABP ratio for the detection
of AMI after cardiac surgery is less clear and ranged between [11.3 ± 4.7] to [32.1
±13.6].90
3.4.10 Heart fatty acid binding protein and detection of reperfusion
Establishment of reperfusion in the infarct-related artery is associated with
significant reduction in morbidity and mortality. However, thrombolytic treatment is
• • • 118* 137associated with successful reperfusion in only 50 - 80%. ' New alternative
treatment options are being examined to try to see the best way to deal with patients
who do not reperfuse after the first course of thrombolytic treatment.119"121 Clinical
trials are now underway randomising patients who do not reperfuse to either another
course of thrombolytic treatment, PCI, or conservative treatment.
In clinical practice reperfusion is ascertained indirectly by the reliance on clinical
features such as disappearance of chest pain, resolution of ST segment elevation, and
occurrence of reperfusion arrhythmias (e.g. accelerated idioventricular rhythm,
bradycardia, and atrioventricular block).122 The reliance on clinical features alone is
not sensitive for the detection of reperfusion. Heart-FABP has been reported to be a
sensitive marker for the detection of reperfusion after thrombolytic treatment. Abe et
al (1996) has demonstrated that a rise of H-FABP ratio greater than 1.5 or more
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(compared to pre-treatment concentration), 30 minutes after thrombolytic treatment
is associated with 100% accuracy for the detection of reperfusion. This accuracy
drops to 94% at 60 minutes after thrombolytic treatment. The advantage of using
H-FABP is that reperfusion is ascertained very quickly and in some studies as early
as 15 minutes. In a study by Ishii et al (1995) the predictive accuracy of H-FABP
ratio > 1.8 for the detection of reperfusion within 60 minutes of the initiation of
treatment was 93% at 15 minutes, 98% at 30 minutes, and 100% at 60 minutes after
reperfusion.124 The few other studies that examined the role of H-FABP for the
• • • 125detection of reperfusion also support this view.
3.4.11 Heart fatty acid binding protein and detection of re-
infarction
Re-infarction is a well-recognised complication of initial AMI. This may be
attributable to re-occlusion of the infarct-related artery after an initial successful
reperfusion or to a vessel occlusion at another site. Re-infarction can manifest as a
recurrence of chest pain or haemodynamic deterioration such as hypotension, acute
pulmonary oedema, and arrhythmia with or without new ST segment changes. In the
presence ofAMI, recurrence of chest pain with or without ST segment changes could
be misinterpreted and without a confirmatory test, the diagnosis of re-infarction
could be missed. Re-infarction carries a worse prognosis, and necessitates further
intervention with thrombolytic treatment, PCI, or urgent CABG. It is vital that this
complication is recognised and appropriate interventions implemented. The most
conclusive method for the confirmation of re-infarction is coronary angiography.
Alternatively, the diagnosis of re-infarction can be confirmed by cardiac markers
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measurement. The high sensitivity, simplicity, cost and safety profile make cardiac
markers a practical option for the detection of re-infarction.
The ideal marker that can detect early re-infarction must be released early and
cleared rapidly from the circulation, thus permitting a quick return to pre-infarction
level. Heart-FABP fulfil these features appearing within 3 hours after infarction,
peaks early at about 5 hours and returns to base line concentration in about 20 hours
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after symptom onset. Re-infarction is shown by a rapid rise in H-FABP
concentration in serum compared to the previous value. Heart-FABP can detect re-
infarction if it occurs 10 hours after symptom onset.90 The other cardiac markers like
CK-MB, cTnl, cTnT, and LDH take several days to return to the pre-infarction level,
and thus are not reliable for the detection of re-infarction.
3.4.12 Heart fatty acid binding protein and estimation of infarct
size
The measurement of infarct size after AMI can have important prognostic
111.1 TiC. 107
implications. ' ' It may also have therapeutic applications in the selection of
patients for the implementation ofACE inhibitor or anticoagulation treatment. Those
patients with large infarcts who are deemed at higher risk for complications such as
congestive cardiac failure, adverse remodelling of the ventricles or intramural
thrombosis may be selected for these treatment options. The measurement of infarct
size however is not done routinely. This may be partly due to the complicated blood
sampling protocol that is both prolonged (over several days) and time consuming, but
is necessary to establish a complete time-concentration curve profile used in this type
ofmeasurement.
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In clinical practice infarct size is estimated indirectly (or qualitatively) by methods
like nuclear perfusion imaging, echocardiography (wall motion abnormalities,
measurement of ejection fraction), ECG changes (like the number of leads involved
or the presence of conduction abnormalities in anterior infarction), the presence of
heart failure, and by reference to the maximum rise of cardiac markers
concentrations after infarction. Accurate measurements of infarct size is possible
using nuclear studies but are again not a practical option for routine use, because it is
expensive, requires high technology and exposes patients to radiation.
Cardiac markers offer an alternative possibility for the estimation of infarct size. The
rapid and quantitatively robust release of H-FABP into plasma after symptom onset
and its rapid clearance from the circulation within 24 hours, makes it potentially
suitable for the early estimation of infarct size, provided that blood is sampled
198 •
sufficiently frequently. Sohmiya et al (1993) showed good correlation between
myocardial infarct size measured from plasma H-FABP and infarcted myocardium
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estimated from triphenyl tetrazolium chloride (TTC) staining.
A study by Glatz et al (1994) using H-FABP for the early estimation of infarct size,
showed good correlation between H-FABP, CK-MB and a-hydroxybutyrate
dehydrogenase (a-HBDH) for the estimation of infarct size. The advantage of H-
FABP is that, this measurement is completed much earlier than the other two




3.4.13 Excretion of heart fatty acid binding protein
It is not clear at present whether H-FABP reaches the circulation trans-endothelially,
via the lymphatic system or both, after its release from the cell into the intercellular
space. The rapid appearance in blood may suggest the former route. The route of
elimination from the circulation is assumed to be the kidney. This assumption was
based on direct and indirect evidence. The indirect evidence comes from
observations in clinical studies. (1) Patients presenting with AMI demonstrated rising
levels of plasma and urine H-FABP within 1.5 hours after symptom onset.79 (2)
Patients with renal insufficiency have raised levels of H-FABP, and the circulation
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time is prolonged compared to those who have normal renal function. '
The direct evidence comes from radioactive iodine-H-FABP excretion studies in
animals. The compound is concentrated within the kidney and appears in the bladder
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within very short period after intravenous injection. However, the reported amount
of radioactive H-FABP excreted in the urine is variable. One study reported that only
14 - 29% of the total intravenous dose injected was excreted in the urine. The total
clearance was 0.33 ml/min and the half-life value of total elimination is estimated to
1 9Q
be 270 minutes. A study by Sohmiya (1993) reported only 6.5 ±1.0 recovery of
the radioactive H-FABP in the urine, and a disappearance half-time was 27.5 ± 8.4
minutes. They suggested that the administered H-FABP might be degraded
elsewhere in the body and the undegraded H-FABP is excreted in the urine. The
authors concluded that their results were comparable to the excretion studies of
myoglobin (known to be excreted by the kidney).130 More studies are required to
establish the exact route of elimination from the intercellular space and the
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circulation. Moreover, the metabolism of H-FABP has not yet been fully elucidated
and is necessary to study the metabolism and excretion ofH-FABP under normal and
disease conditions.
3.4.14 Pathological confirmation of acute myocardial infarction
USING ANTI-HEART FATTY ACID BINDING PROTEIN ANTIBODIES ON AUTOPSY
MATERIALS
Pathological confirmation of AMI is possible using autopsy materials of the heart.
The diagnosis can be established microscopically or macroscopically using
immunohistochemical methods. Haematoxylin & Eosin (H&E) staining of the tissue
sections establish the microscopic diagnosis, whereas the macroscopic diagnosis is
based on nitrue blue tetrazolium (NBT) staining methods. This macroscopic
technique reflects the intracellular activity of the enzyme dehydrogenase. In viable
tissue this enzyme is able to convert the NBT into dark blue insoluble pigment
ni
(formazan), while infarcted tissue remains unstained. These two methods are only
positive after at least 4-6 hours after AMI.
Anti-H-FABP has been used for the confirmation of AMI on autopsy materials.
Using anti-H-FABP it was possible to diagnose infarcts less than 4 hours old. In all
biopsies that were positive by either H&E or NBT staining, the anti-H-FABP
staining showed an absent or noticeably decreased staining of H-FABP in these
tissues. Some biopsy material from patients with AMI who died within 4 hours were
positive using anti-H-FABP but the H&E and NBT staining were negative. The
authors of the study concluded that anti-H-FABP antibody is more sensitive than
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either H&E or NBT staining methods for the detection of subtle changes of AMI or
very small or very recent (< 4 hours) AMI on autopsy materials. '
3.5 DISCUSSION AND SUMMARY
Heart-FABP is a novel protein with potential for the early diagnosis of AMI, early
detection of re-infarction, detection of reperfusion, and early estimation of infarct
size. However, there is still some skepticism in the clinical practice about its
additional value compared to the currently available markers such as myoglobin,
CK-MB and troponins. Many studies have convincingly shown that the latter
markers (with the exception of myoglobin) are relatively insensitive for the early
detection ofAMI in the first 6 hours after symptom onset.
Heart-FABP is a small protein that is abundant in the heart and has low
concentrations in the blood and in tissues outside the heart. It appears in the blood as
early as 1.5 hours after symptom onset, peaks around 6 hours and returns to base line
values in 24 hours. These features of H-FABP make it an excellent marker for the
detection of AMI. A consistently negative serial samples within 6 hours after
symptom onset can be used to rule out AMI with great confidence. Measurement of
H-FABP before and at 30 or 60 minutes after the administration of thrombolytic
treatment can detect reperfusion of the infarct-related artery with high sensitivity and
permit further reperfusion therapy to be planned for those patients who do not
reperfuse successfully. Early re-infarction is a well-recognized complication after
initial infarct. Given the release kinetics of H-FABP it is more suited for the
detection of re-infarction than other markers. The accurate estimation of myocardial
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infarct size has important prognostic and therapeutic applications. Heart-FABP can
provide a reliable estimate of infarct size. The advantage of H-FABP over other
markers is that this measurement can be provided within 24 hours of admission.
Anti-H-FABP antibodies may also have a role in the pathological confirmation of
AMI. This is especially so when there is a high clinical suspicion of AMI but the
FI&E and NBT staining are negative. It is premature to attach specific clinical value
for the detection of AMI from measurement of H-FABP in the urine. Further studies
are needed to examine and establish the exact renal handling and metabolism of H-
FABP under normal and disease states. Until such essential details are available it
can only be assumed that, if H-FABP is excreted mainly by the kidney, urinary H-
FABP might offer an alternative and important method for the detection of AMI.
Urinary H-FABP testing might be useful as a qualitative test for general practitioners
to rule in or rule out AMI in the community.
Heart-FABP distribution outside the heart has been equated with that of CK-MB,
which is currently regarded as the gold standard marker for the diagnosis of AMI.65
Creatine kinase-MB lacks the required sensitivity to be of value for the very early
diagnosis of AMI in the first 3 hours after symptom onset. During this interval the
sensitivity of CK-MB and H-FABP for the diagnosis of AMI was 20% and 91.4%
respectively.79 Heart-FABP shares many key features with myoglobin but is more
cardio-specific because its concentration in the skeletal muscle is only a fraction of
that ofmyoglobin. The normal concentration of H-FABP in the blood is 10 - 15 fold
lower than myoglobin. As compared to the troponins, H-FABP is less cardiac
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specific. The value of cTnT and cTnl for the late diagnosis of AMI and for the
diagnosis and prognosis and risk stratification of patients with UA is well-
established. However, these markers have little role in the early diagnosis ofAMI i.e.
within the first 6 hours after symptom onset. They achieve their greatest sensitivity
and specificity in the interval 12-16 hours after symptom onset. Creatine kinase-MB
isoforms (CK-MB1 to CK-MB2 ratio) have also been reported to be sensitive early
markers for the diagnosis of AMI within 6 hours. So far there have been no studies
comparing H-FABP and CK-MB isoforms for the early diagnosis of AMI. The
initiation of such study is very important and will help provide useful comparison
between these two early markers.
Summary
Heart-FABP is a sensitive marker for the detection of AMI but is not 100% cardiac
specific, because of its presence in tissues outside the heart. However the features of
H-FABP, which combine very early release after onset of symptoms and relative
cardiac specificity, makes it one of the markers with great potential. Serial
measurement of H-FABP within 24 hours after symptom onset can; (1) Define
patients with AMI who need CCU admission; (2) Distinguish patients who reperfuse
their infarct-related artery from those who do not and in need of further intervention
as early as 30 minutes after starting thrombolytic treatment; (3) Detect re-infarction
if it occurs 10 hours after symptom onset; (4) Permit accurate estimation of
myocardial infarct size and thus provide information concerning prognosis.
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4.1 MEASUREMENT OF HEART FATTY ACID BINDING PROTEIN
4.1.1 Heart fatty acid binding protein antibody
The H-FABP antibody used for the assay of H-FABP in serum was purchased from
HyCult biotechnology b.v (Hbt HK401, Cambridge-UK). The Hbt human H-FABP
ELISA kit is intended for the quantitative and qualitative measurement of natural
human H-FABP in plasma or serum and in autopsy materials respectively. The
principal of the assay is based on a sensitive, non-competitive ELISA of the antigen
capture type (Sandwich ELISA) (Figure 1). The analytical sensitivity of the assay
determined by 24 replicates of the sample dilution buffer within one ELISA plate
was 0.206 ± 0.047 pg/1 (mean ± 2SD (i.e. 97.5 percentile) = 0.301 pg/1). The assay
has a measurable concentration range of 0.25 - 25 pg/1 and shows no cross reactivity
with human intestinal or liver FABP.1
4.1.2 Principles of the test
Diluted samples and standards are incubated together with peroxidase conjugated
second antibody (tracer) in microtiter wells coated with antibodies recognising
human H-FABP. During this incubation, human H-FABP is captured by the solid
bound antibody. If human H-FABP is present in the sample, the tracer antibodies will
bind to the captured H-FABP. Unbound material present in the sample and excess
tracer is removed by washing, and substrate tetramethylbenzidine (TMB) is added to
the wells. Colour develops proportionally to the amount of H-FABP present in the
sample. The enzyme reaction is stopped by the addition of citric acid and the
absorbence at 450 nm is measured with a spectrophotometer. A standard curve is
obtained by plotting the absorbence versus the corresponding concentrations of
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defined standards. The human H-FABP concentration of diluted samples with
unknown concentrations, which are run concurrently with the standards, can be
determined from the standard curve. The final concentration of H-FABP in the
sample is obtained by multiplying the value obtained by the dilution factor.
I" antibody
+ Antigen + 2nd antibody +
'Catcher' 'Detector'
Substrate
Figure 1. Direct ELISA method (capture or sandwich type). A - the
monoclonal H-FABP antibody is immobilised on the microtiter plate. The
sample containing H-FABP is incubated with this antibody, b - the H-FABP
protein present in the sample adhere and is bound by the immobilised H-FABP
antibody, c - incubation of the wells with a second H-FABP antibody labeled
with an enzyme, thus the H-FABP become sandwiched between the two H-
FABP antibodies. The second H-FABP antibody is directed against different
epitope of the H-FABP protein, and d - the last step involves incubation of the
complex with a substrate solution suitable for the enzyme, followed by stopping
the enzyme reaction and spectrophotometric reading of the wells.
4.1.3 Materials for heart fatty acid binding protein measurement
Concentrated wash buffer (20 ml) containing Tween 20; concentrated dilution buffer
(5 ml); protein stabilised phosphate buffered saline; preservative, 2-chloroacetamide;
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freeze-dried human H-FABP standard concentration, approximately 60 ng/ml in
protein stabilised buffer; freeze-dried tracer, peroxidase-conjugated antibody to
human H-FABP in protein stabilised buffer; tetramethylbenzidine Substrate (6 ml);
substrate buffer (6 ml); blocking solution (22 ml) containing citric acid 2.0 M;
ELISA Plate (96 wells) coated with anti-human H-FABP antibody (12 strips per
plate); Frame for microwell strips and adhesive covers for microtiter plates.
4.1.4 Preparations
Samples and reagents are brought to room temperature (18 - 25°C) before use. Heart-
FABP microtiter plates are removed from the storage bags and the strips to be used
are numbered with a laboratory marker. Unused test wells are returned to the storage
bag with desiccant, sealed and stored at 2 - 8°C. The standard and tracer are
reconstituted by an injection of 1 ml distilled water into each vial. The concentrated
dilution buffer is diluted by adding 5 ml of concentrated dilution buffer to 50 ml with
distilled water, which is enough for 96 tests. The tracer is reconstituted by adding 5
ml of the dilution buffer to the vial of reconstituted tracer. Twenty milliliters of 20X
concentrated wash buffer is diluted with 400 ml of distilled water, which is enough
wash buffer for 96 tests.
4.1.5 Assay protocol
1- Preparation of the heart fatty acid binding protein standard series. The
standard series is made by diluting the reconstituted standard in dilution buffer in
polypropylene tubes in order to achieve a standard range from approximately 250 to
25,000 pg/ml (0.25 - 25 pg/1). Eight polypropylene tubes are used numbered 1 - 8.
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Tube 8 is set aside with 250 jul dilution buffer and used as control value. Tubes 2-7
are filled with 150 pi dilution buffer. One hundred microlitres reconstituted standard
is transferred to tube number 1 and diluted 2:5 further by mixing well and pipetting
100 pi over to tube 2 and again 100 pi to the next tube and so on until tube number 7.
Tubes 1 - 8 are used as the standards in the assay.
2- Dilution. Serum samples to be tested are diluted 1:10 in dilution buffer in
polypropylene tubes. The desired number of marked tubes is filled with 180 pi
dilution buffer. Twenty microlitres serum is added to the corresponding tube.
3- Fifty microlitres of the diluted tracer is added to each well.
4- Subsequently 50 pi in duplicate is transferred from each standard, each unknown
diluted sample and the controls to the assigned wells, following the scheme on
previously prepared data collection sheet. A clean pipette tip is used for each
transfer.
5- An adhesive cover is applied to the tray. The tray is gently taped to eliminate any
air bubbles trapped in the wells.
6- The tray is incubated for 60 minutes at room temperature.
7- The TMB colouring solution is prepared just prior to the end of the incubation
period by mixing 6 ml TMB with 6 ml substrate buffer in a clean container, which is
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enough for 96 tests. Tetramethylbenzidine substrate solution is kept in the dark (i.e.
wrapped in aluminum foil) and used within 15 minutes after preparation.
8- Washing. The adhesive cover is removed carefully. The plate is emptied by
inverting the plate and shaking contents out over the sink. The plate is kept inverted
and taped dry on a thick layer of tissues. Two hundred microlitres of diluted wash
buffer is added to each well, left for 20 seconds, and the plate is emptied as above.
The washing process is repeated three times, and then the plate is emptied to remove
the remaining wash buffer.
9- One hundred microlitres of the prepared TMB substrate solution is added to each
well.
10- The tray is covered with the adhesive cover and incubated for 15 minutes at room
temperature (18 - 25°C) avoiding exposure to strong light (i.e. wrapped in aluminum
foil or placed in dark space).
11- The reaction is stopped by adding 100 pi of blocking solution with the same
sequence and timing as used in step 9. The tray is gently tapped to mix the solutions
in the wells and to eliminate any air bubbles trapped in the wells.
12- The tray is placed in a spectrophotometer and the absorbence is measured at 450
nm following the instructions provided by the instrument manufacturer.
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4.2 MEASUREMENT OF CREATINE KINASE MUSCLE BRAIN MASS,
CARDIAC TROPONIN I, MYOGLOBIN, AND CARDIAC TROPONIN T
Measurement of cardiac markers CK-MB mass, cTnl, and myoglobin were
performed on the Stratus CS stat flourometric analyser machine using commercially
available assays (Dade Behring - Germany), according to the manufacturer
instructions. The method of measurement for all markers is based on the sandwich
ELISA described previously. The essential materials required to perform the analysis
(e.g. solid-phase antibody, glass fibre paper, substrate wash solution) are assembled
into small test packs (3x6x1 centimetre), each containing all the reagents for one
test, which are ready and easy to use. These test packs are bar-coded and are inserted
in the Stratus CS together with the sample for measurement of the particular cardiac
marker.
The Stratus CS machine is fully automated and is designed for low volume sample
analysis. It can perform one test in 13 minutes or 4 tests in 22 minutes. The accuracy
and reproducibility of the Stratus CS assays for the measurement of CK-MB mass,
myoglobin and cTnl have been validated previously.2"6 The cTnl used in this assay is
of the second generation type, which is highly sensitive. The analytical sensitivity of
cTnl is 0.03 ng/ml with a measurement range of 0.0 - 50 ng/ml.7 The previous
generation of cTnl assays (for use on Opus Plus- Dade Behring) had a sensitivity of
0.5 ng/ml.8 The minimum detection limit of CK-MB mass assay is 0.3 ng/ml.9 The
assay range is 0.4 - 150 ng/ml. The assay range of myoglobin is 1 - 900 ng/ml and
the analytical sensitivity is 1 ng/ml.10
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Frozen samples were allowed to thaw slowly at 2 - 8°C and at room temperature, and
were analysed within one hour. The samples were mixed thoroughly by pipetting the
sample in and out gently a couple of times, or inverting the tube several times. The
mixed samples were then centrifuged at 6000 rotations per minutes (r.p.m) for 1 -
5 minutes to remove any debris or clot materials that may still be present in the
serum. After centrifugation, 400 pi of sample was transferred into a sample cup for
analysis. Samples with values above the assay range were diluted with pooled human
serum (PHS), a gift from Mr. Simon Palker, SCIPAK-Kent. Nine hundred and fifty
microlitres of PHS was added to 50 pi of sample (1:10 dilution). This dilution factor
was taken into account in the final reporting of the results. This dilution serum has no
cTnl proteins, but has a small trace concentration of myoglobin (33 pg/1) and CK-
MB mass (1.4 pg/1). A correction factor was made for all the diluted samples
according to the following equation (1:10 dilution).
The Final concentration (pg/1) = measured value (pg/1) - 9 [Y] (pg/1)
Y- represents the concentration of proteins in the dilution serum.
There was a good correlation between concentrations of samples diluted with PHS
and those diluted with dilution packs provided specifically by Dade Behring for
dilution with these assays [r = 0.988, p < 0.0005]. The coefficient of variations (CV)
was always less than 10%. The use of other dilution methods that do not contain any
marker proteins were not successful. Several dilution methods like phosphate
buffered saline (PBS) [PH - 7.4] alone; PBS [PH - 7.4] containing 0.1% bovine
serum albumin; and normal saline were used. With all these dilution methods the CV
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was unacceptably high [> 10%]. These dilution methods are not suitable for this type
ofmeasurement and are not recommended with these assays.
The dilution materials come in bar-coded dilution packs similar to the test packs, and
each marker has its own specific dilution packs (e.g. cTnl DilPak, for dilution with
cTnl test packs). The instrument will automatically perform 1:5 dilution of the
sample. The results obtained will already be corrected for the dilution factor. The
dilution packs provided by Dade Behring were not used with samples above the
assay range for the following reasons; (1) There was good correlation between
results obtained by using dilution packs and those obtained by using PHS, thus
obviating the need to use dilution packs; (2) The use of dilution packs doubled the
cost of the analysis. The cost of the dilution pack was the same as the cost of the test
packs itself; (3) Use of dilution packs will double the time required to complete the
analysis. Since the machine can accommodate a maximum of four test packs at one
time (e.g. 2 test packs and 2 dilution packs or 4 test packs). This time delay is
avoided by using previously diluted samples; and (4) Dilution was only needed in a
small fraction of samples.
The Stratus CS has to pass through stringent checks before being used for the
analysis of samples." First, the machine is kept in check daily by running system
checks (equivalent to electronic quality control). This ensures good alignment of
components, and the right pressure and temperature. The system check is completed
in 5 minutes. Second, having passed this check test, the machine is calibrated for
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each assay. The instrument will automatically perform the calibration update
procedure using calibration packs (CalPak), and three test packs for each cardiac
marker to generate an updated calibration curve. After calibration, the recovered
value is calculated from these stored calibration curves. The calibration is stable for
three months. The machine must pass calibration before it can allow analysis to
proceed. Third, having passed calibration for that particular assay, quality controls
are run first to ensure a successful calibration. Three levels of quality control
materials (Table 1) were used for each marker protein [Dade TRU-liquid cardiac
control level 1, 2, and 3].12 Quality control were run twice daily (two different levels)
with each batch of tests, at the beginning and end of each run, to ensure no drift. All
quality control values fell within the acceptable ranges.
Cardiac-TnT was analysed on Elecsys 2010 immunoanalyser using commercially
available assays (Roche - Germany). The detection limit of cTnT assays was 0.01
ng/ml. Quality control [Elecsys PreciControl CARD 1 and 2] were run with each
batch of tests. All quality control concentrations fell within the acceptable ranges
[0.117 - 2.03 ng/ml] and [3.92 - 6.26 ng/ml]. The analysis was performed by
specially trained medical staff. The clinicians caring for the patients were unaware of
the results of the markers in the study, and the person as performing the analysis was
unaware of the clinical outcome or the routine tests e.g. CK-MB, and troponins.
4.3 VALIDATION OF NORMAL RANGES AND PRECISION OF ASSAYS
The normal reference ranges quoted by the manufacturer for CK-MB mass [0.6 - 3.5
pg/l], cTnl [0.0 - 0.06 pg/1], myoglobin [20 - 82 pg/1], cTnT [< 0.01 pg/1], and H-
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FABP [< 5 pg/1] were validated by assaying the normal ranges of 20 healthy blood
donors samples [ 10 males and 10 females] obtained from the blood donor unit. The
mean concentrations ± SD of these markers were CK-MB mass = 1.52 ± 0.8 pg/1,
cTnl = 0.015 ± 0.006 pg/1, myoglobin = 41.5 ± 13.3 pg/1, cTnT = 0.011 ± 0.002 pg/1,
and H-FABP = 6.86 ± 2.21 pg/1 [n = 46, 22 females and 24 males]. The 99th
percentile of control values for these assays were cTnl = 0.1 pg/1, CK-MB mass =
4.5 pg/1, and myoglobin = 95 pg/1. Quality control materials (Dade TRU-liquid
cardiac control level 1, 2, and 3, Elecsys PreciControl CARD 1 and 2) were used to
test the precisions of these assays (Table 1).
Within-assay (intra-assay) CV for Stratus CS were tested by measuring quadruplicate
of three levels (level 1-3) four times (n = 16), and between-assay (inter-assay) CV
were tested by measuring the three levels on 16 different days. Similar method was
used to test the CV for cTnT assays. As shown in Table 1, the CV of these assays
was within the acceptable 10% limit. The stability of calibration on Stratus CS was
tested by running two levels of quality controls (level 1 and 3) for 12 weeks. The CV
were cTnl [level 1 = 7.1%, level 3 = 5.3%], CK-MB mass [level 1 = 5.5%, level 3 =
6.0%], and myoglobin [level 1 = 7%, level 3 = 6.9%]. The calibration curve was
stable for up to three months. Patients' samples in level 2 and 3 (Table 1) were used
to check for H-FABP drift across the ELISA plate. These samples were assayed in
two rows in the ELISA plate, in the middle and edge. There was no significant drift
across the plate or at the edges. The inter-assay precision for H-FABP at the
concentrations ranges 47.46 ± 9.39 pg/1 was 19.8%. The average recovery ofpurified
human H-FABP, added to human plasma was 90.6 - 105.5% (Table 2).
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Level CK-MB CTnl CTnT Myoglobin H-FABP
Level 1 (jj.g/1) 3-4.5 0.24 - 0.36 0.117-2.03 38-57 11.1 ±0.9
Within-assay CV (%) 2.9 7.4 4 4.7 7.8
Between-assay CV (%) 4.5 6.8 9.1 5.8 -
n 16 16 10-31 16 10
Level 2 (pg/1) 11.3-16.9 4.6 - 6.9 3.92-6.26 157 - 235 19.4 ±2
Within-assay CV (%) 2.8 7.2 5.5 3.2 10
Between-assay CV (%) 7 6.7 7.8 3.4 -
n 16 16 10-31 16 10
Level 3 (pg/1) 47-71 13-19 _ 405 - 608 235 ± 13.7
Within-assay CV (%) 6.2 4.9 - 5.7 4.8
Between-assay CV (%) 4.8 4.0 - 7.26 -
n 16 16 - 16 10
Table 1. This table illustrates the concentrations of the various quality
controls at each level (1,2, and 3), and the precision (coefficients of variations) of
the assays at that particular concentration.
Sample H-FABP added (pg/1) H-FABP recovered ((ig/1) H-FABP % recovery
A 55 58 105.5
B 96 87 90.6
C 179 183 102.2
D 220 200 90.9
Table 2. Shows the percentage recovery of purified H-FABP added to human
plasma.
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4.4 RECRUITMENT OF PATIENTS WITH ACUTE MYOCARDIAL
INFARCTION
Patients with an initial diagnosis of AMI admitted to the CCU, the Royal Infirmary
of Edinburgh between September 1999 and March 2000, were included in the study.
The purpose of the study was explained to the patients or members of the family and
informed consent was obtained before beginning the study. The recruitment process
started within 20 minutes of patients' arrival in the A&E department, before being
admitted to the CCU and before the administration of thrombolytic therapy.
Thereafter, five serial blood samples were taken at 0 hour (at presentation), 2 hours,
4 hours, 8-10 hours, and 16-24 hours after presentation. Blood samples were
processed and serum was stored until analysis. All patients underwent serial clinical
evaluations by the CCU team. Standard 12-lead ECGs were obtained on arrival and
in the CCU at least once each day. Serum CK, and CK-MB activity ± cTnl were
routinely measured at admission, at least twice daily within the first 24 hours, and
once daily for the first three days.
4.4.1 Inclusion and exclusion criteria
Patients presenting with chest pain suggestive of AMI were evaluated by A&E
department physician. The evaluation includes rapid history taking and very brief
physical examination and recording of 12-lead ECG. The time of onset of symptoms
was carefully recorded for each patient at the time of presentation. Patients were
included in this study if they presented within 6 hours after the onset of symptoms,
and had significant elevation of ST segment or new Q waves or other ischaemic
changes highly suggestive of AMI on the admission ECG (e.g. suspected posterior
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AMI), and prolonged ischaemic chest pain (often combined with radiation of pain to
the left arm) in combination with transpiration, nausea, vomiting and/or shortness of
breath. A total of fifty-six patients were included in this study. Eleven patients were
later excluded from the analysis because of incomplete blood samples (four patients),
inconclusive diagnosis of AMI (two patients), delayed presentation more than six
hours after the onset of symptoms (three patients), or had cardiac arrest during the
first 24 hours requiring repeated DC cardioversion ± prolonged cardiopulmonary
resuscitation (two patient). The final study population consisted of forty-five patients
admitted within 6 hours after the onset of chest pain with confirmed AMI.
In addition to the above mentioned four specific exclusion criteria [i.e. incomplete
blood sampling protocol, delayed presentation, cardiac arrest at presentation, and
inconclusive diagnosis], patients were also not eligible for the study if: (1) They had
recent severe muscle trauma or repeated intramuscular injection; (2) They had acute
or chronic skeletal muscle disorders; (3) They had recent major surgery, CABG or
AMI (< 1 month), because of the associated prolonged healing inflammatory process
involved. Patients with recent AMI may have sustained release of troponins for
several weeks; (4) They had any evidence of renal impairment defined as a creatine
and urea concentration rise above 138 mmol/1 and 8 mmol/1 respectively. This may
interfere with the excretion of H-FABP and myoglobin leading to prolonged and
exaggerated concentration rise; or (5) They had biochemical hypothyroidism as
reflected by thyroxine (T4) concentration < 8 pmol/L and thyroid stimulating
hormone (TSH) concentration >3.5 mU/L.
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Patients who were admitted to CCU with suspected AMI and were later diagnosed
with non-Q wave myocardial infarction or unstable angina were included in these
study groups (see later).
4.4.2 Diagnosis of acute myocardial infarction
The diagnosis of AMI was established independently by a consultant cardiologist
without knowing serum concentrations ofH-FABP, myoglobin, CK-MB mass, cTnT
or cTnl in the study. The diagnosis was based on the criteria set by the WHO and
• it
must include at least two of the following three findings. (1) Clinical history of
ischaemic chest pain >30 minutes in duration. (2) Evolution of typical changes in at
least two adjacent leads of the ECG, appearance of new Q waves > 1 mm wide and 2
mm deep or an R wave increment leading to an R/S ratio > 1 in leads VI and V2
defined as Q wave AMI or ST segment elevation > 2 mm 0.08 seconds after J point
persisting for at least 24 hours. (3) Time-dependent rise in routine concentration of
CK and CK-MB activity (CK > 400 IU/L, and CK-MB activity > 6%) and
subsequent fall. In addition, if patients had evidence of recent coronary artery
occlusion at angiography, this was taken with the above criteria to support the
diagnosis ofAMI.
4.5 RECRUITMENT OF PATIENTS WITH ACUTE CHEST PAIN (NON-Q
WAVE MYOCARDIAL INFARCTION, UNSTABLE ANGINA, AND
ATYPICAL/ANGINAL CHEST PAIN)
Consecutive patients presenting with acute chest pain to the Royal Infirmary of
Edinburgh between September 1999 and March 2000 were included in the study.
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Patients were principally recruited from the acute receiving medical unit, a few
patients were recruited from the acute chest pain clinic, CCU, and cardiology wards.
The study was explained to each patient and informed consent was obtained from
each participant. Thereafter, five serial blood samples were collected by
venepuncture or via in situ venflon (if this access existed) at 0 hour (at presentation),
2 hours, 4 hours, 8-10 hours, and 16-24 hours after presentation [see patients'
classification page 188].
4.5.1 Inclusion and exclusion criteria
The time of onset of symptoms was carefully recorded for each patient at the time of
presentation. Patients were included in the study if they presented with chest pain
suggestive of myocardial ischaemia [> 20 minutes in duration] within 7 hours after
symptoms onset with or without ECG changes suggestive of ischaemia. There was
no age limit and no specific entry criteria of ischaemic changes on the admission
ECG. The intention was to study a broad and unselected group of patients
representing all forms of chest pain [and ECG changes] that is commonly
encountered in the A&E department that require early admission to hospital.
Patients were not included in the study if they had delayed presentation more than 7
hours after symptom onset. A total of sixty patients were initially included in this
study. Five patients were later excluded from the analysis due to incomplete blood
sampling protocol. The final study population consisted of fifty-five patients. None
of the patients in this group had any of the additional exclusion criteria listed under
section 4.4.1.
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4.5.2 Diagnosis of non-q wave myocardial infarction, unstable
ANGINA, AND ATYPICAL/ANGINAL CHEST PAIN
The final diagnosis of patients in these groups was established independently by a
consultant cardiologist. Unstable angina symptoms were defined as; (1) Symptoms of
angina at rest; (2) New onset (< 2 months) of angina on minimal exertion and
increasing severity; (3) Recent (< 2 months) acceleration of angina from previously
stable pattern, as reflected by an increase in severity to at least Canadian
Cardiovascular Society Classification III.
Unstable angina was diagnosed when patients had two or more of the following
criteria without a clear-cut ECG changes of infarction [section 4.4.2] or cardiac
markers (CK or CK-MB) elevations diagnostic of AMI; (1) Ischaemic chest pain >
20 minutes in duration; (2) Transient ST segment elevation > 1 mm 0.08 seconds
after J point less than 30 minutes in duration; (3) Transient or persistent ST segment
depression > 1 mm 0.08 seconds after J point in two adjacent leads; (4) Symmetrical
or asymmetrical T wave inversion > 1 mm excluding T wave inversion in leads III,
AVR, and VI only; and (5) Evidence of routine cardiac markers rise to level above
the upper limit of normal [cTnl > 0.1 pg/1 or cTnT > 0.1 pg/1] in the absence of CK
and/or CK-MB rise diagnostic of AMI [see below]. Patients were diagnosed as
having non-Q wave MI if they had one or more of the criteria listed above and in
addition, they had evidence of myocardial necrosis as reflected by CK elevation
greater than 400 IU/L and CK-MB activity > 6% and subsequent fall.
Patients were diagnosed as having atypical or anginal chest pain if they had all the
following criteria; (1) Typical or atypical presentation of chest pain (such as chest
116
pain which differed in character, location, duration, severity, unusual associations,
relieving or precipitating factors from that of typical ischaemic pain); (2) No
significant ECG changes of ischaemia; and (3) No rise in routine CK, CK-MB or
cTnl concentrations.
4.6 RECRUITMENT OF PATIENTS IN THE ANGIOPLASTY GROUP
The study population consisted of a consecutive series of patients recruited from the
cardiology programmed investigation unit, the Royal Infirmary of Edinburgh
between March and October 1999. These were scheduled admissions for elective
angioplasty with or without stenting. Ethical approval for the study was obtained
from the local ethical committee. The study was explained to each patient and a
written informed consent was obtained. Thereafter, five serial blood samples were
collected from each patient at 0 hour (base line concentration, pre-angioplasty) and at
1 hour, 2 hours, 4 hours and 16-24 hours after angioplasty. Patients in this group
were followed-up for 20 - 26 months after angioplasty. End points include the
development of complications like angina, UA, AMI, target and non-target vessel
PCI, CABG, and death.
4.6.1 Inclusion and exclusion criteria
The study group consisted of patients who were referred to our centre for elective
angioplasty for both stable angina pectoris [defined as chest pain on exertion relieved
with rest] not well controlled on current medications and UA [see section 4.5.2 page
116 for definition ofUA]. There was no specific age limit in the study. Patients who
had angioplasty and a continuous balloon inflation time for a minimum of 60 seconds
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or more with or without stenting [single or multiple] constituted 91.25% of the study
group. The remaining patients had an inflation time between 30 - 60 seconds with or
without stenting. Patients who had an angioplasty other than elective [e.g. rescue
angioplasty, primary angioplasty, salvage angioplasty, or emergency angioplasty]
were not eligible for this study.
A total of eighty-four patients were initially included in the study. Two patients with
increased cardiac markers concentration before angioplasty [i.e. base line or pre-
angioplasty sample] were later excluded from the study. This was to ensure normal
base line concentration for cardiac markers before the start of the study. Two more
patients were later excluded [one with mild renal impairment and one with
hypothyroidism]. The final study population consisted of eighty patients. The
diagnosis of complications during angioplasty was made independently by two
cardiologists. None of the patients in this group had any of the additional exclusion
criteria listed under section 4.4.1.
4.7 BLOOD SAMPLING PROTOCOL
Healthy blood donors
Blood samples were collected from 20 healthy blood donors at the blood donor
centre. An information sheet was given to each donor and a written consent was
obtained. Only one sample was obtained from each participant and these samples
were utilised for; (1) The exploration of the normal limit for H-FABP; (2) To
validate the normal range quoted by the manufactures for CK-MB mass, myoglobin,
cTnT, and cTnl.
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Mixedpopulation of ischaemic heart disease patients
Blood was also collected from 20 inpatients attending the Royal Infirmary of
Edinburgh. This group consisted of a heterogeneous population with various medical
disorders and various risk factors for ischaemic heart disease but without active
presentation and without chest pain. One sample was obtained from each patient. The
purpose of this group was to explore the true concentration of CK-MB mass, cTnl,
cTnT, myoglobin, and H-FABP in this population with a mixed medical background
but without active symptoms of ischaemia.
Pre andpost cardiac catheterisation controls
Pre and post cardiac catheterisation blood samples were also collected from 12
patients undergoing cardiac catheterisation studies (ventriculography and coronary
angiography) without angioplasty. The purpose of this control group is to study the
effects (if any) cardiac catheterisation studies (without angioplasty) had on the
release of the different markers after the study. It also validates any changes in
cardiac marker concentrations after angioplasty procedures and excludes diagnostic
procedures (diagnostic catheters manipulations) and mechanical trauma as the cause
of cardiac markers release. Three samples were obtained from each participant at 0
hours (before cardiac catheterisation), and at 2 hours and 16-24 hours after the
procedure.
In all the above groups and the study populations, blood samples were handled in
exactly the same way. Five millilitres of blood was collected by venepuncture into a
standard Starstedt Monovette serum tube. The blood sample was allowed to clot at
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room temperature (18-25 °C) for 1 hour. It was then centrifuged at 4 °C at 3000
r.p.m for 10 minutes. The resulting serum was divided into small aliquots and stored
in microcentrifuge tubes (ELKay) at - 70 °C until analysis.
4.8 VALIDATION OF THE SAMPLING PROTOCOL
The sampling protocol for the AMI and UA groups of 0 hour, 2 hours, 4 hours, 8-10
hours, 16-24 hours after presentation to hospital has been validated in other
studies.14 The angioplasty group sampling protocol is slightly different i.e. 0 hour
(before angioplasty), and at 1 hour, 2 hours, 4 hours, and 16-24 hours. This was
based on the fact that most controlled animal and human studies that have looked at
the early release ofH-FABP have shown that this marker peaks at about 4 hours after
myocardial injury.15 Thus this sampling protocol is ideal for detecting the changes in
concentrations in the very early stages after myocardial injury.
4.9 RECEIVER OPERATOR CHARACTERISTIC CURVE ANALYSIS
The cut-off concentrations selected for the various cardiac markers in these studies
were based on the following considerations. First, the normal concentrations of these
markers were established in healthy blood donor and normal control groups without
ACS. Second, the best cut-off concentrations for each marker were established from
a series of receiver operator characteristic (ROC) curve analyses in the four groups of
patients with ST elevation MI (STEMI), non-ST elevations MI (NSTEMI), UA, and
atypical/anginal chest pain.16
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Two different cut-off concentrations were chosen for each marker. The first cut-off
concentration discriminates between patients with myocardial injury [UA, NSTEMI
and STEMI] and those without myocardial injury [healthy blood donors, control
group, and non-ischaemic chest pain group]. The second cut-off concentrations were
used to discriminate between patients with myocardial injury [UA] from those with
myocardial infarction [NSTEMI and STEMI]. These two cut-off concentrations were
used to measure the sensitivity in Chapter 6 and Chapter 7.
The following cut-off concentrations were chosen to discriminate between patients
with myocardial damage (ACS) and those without evidence of myocardial damage,
CK-MB mass > 5 pg/1 [area under ROC curve (AUC) = 0.869, p < 0.0005, 95%
confidence interval (CI) = 0.839 - 0.9, sensitivity = 71.7%, specificity = 100%], cTnl
>0.18 pg/1 [AUC = 0.974, p < 0.0005, 95% CI = 0.962 - 0.987, sensitivity - 80%,
specificity = 100%], cTnT > 0.1 jug/1 [AUC - 0.906, p < 0.0005, 95% CI = 0.881 -
0.932, sensitivity =65.2%, specificity = 100%], myoglobin > 95 p.g/1 [AUC = 0.867,
p < 0.0005, 95% CI = 0.836 - 0.898, sensitivity = 68.5%, specificity = 100%], and H-
FABP > 16 pg/1 [AUC = 0.894, p < 0.0005, 95% CI = 0.861 - 0.926, sensitivity =
81.8, specificity = 86%] (Figure 2).
The following cut-off concentrations were selected to discriminate patients with UA
from patients with MI. Values above these concentrations indicate the presence of
myocardial infarction, CK-MB mass > 8 pg/1 [AUC = 0.915, p < 0.0005, 95% CI =
0.887 - 0.943], cTnl > 0.6 pg/1 [AUC = 0.905, p < 0.0005, 95% CI = 0.876 - 0.934],
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cTnT > 0.4 jug/1 [AUC = 0.821, p < 0.0005, 95% CI = 0.781 - 0.861], myoglobin >
107.5 pg/1 [AUC = 0.881, p < 0.0005, 95% CI = 0.845 - 0.918], and H-FABP > 21.5
[AUC = 0.833, p < 0.0005, 95% CI = 0.775 - 0.891]. Figure 2 shows ROC curves
that were used to derive some of these cut-off concentrations. Sensitive and specific
cut-off concentrations are associated with a large area under the ROC curve, and the
cut-off concentrations tend to cluster in the left upper comer indicating high rate of
true positive and few false positive test results.16
ROC Curve
1 - Specificity (False Positive)
Figure 2. Shows ROC curves for the various cardiac markers used in the
study. The total area under the curve is significant and the cut-off
concentrations are mainly clustered in the left upper corner, both features




Analyses were performed using SPSS™ (Statistical Package for Social Sciences,
Pittsburgh statistical software, version 10). Values were expressed as mean ± SD.
The correlation coefficient was calculated by Spearman's Rank order correlation
(rho). Chi-square test was used to explore the group differences with respect to
categorical variables. For two by two tables Yate's correction for continuity was
applied to compensate for overestimations. For categorical variables that had an
expected cell frequency less than five, fisher's exact probability test was used
instead. Mann-Whitney U test was conducted to compare the mean score for the
continuous variables in the angioplasty cTnl positive and negative groups. A one¬
way repeated measure analysis of variance (ANOVA) or Friedman's test was
conducted to compare the mean concentrations of cardiac markers (CK-MB mass,
cTnl, cTnT, myoglobin, and H-FABP) at time 0 (at presentation or pre-angioplasty)
and at 1,2, 4, and 16-24 hours after angioplasty and at 2, 4, 8 - 10 and 16-24 hours
after presentation. Post-hoc comparisons between times were performed. For
multiple comparisons conducted in post-hoc a Bonferroni adjustment was used. A p
value < 0.05 was considered statistically significant.
The sensitivity, specificity, positive predictive value (PPV), and negative predictive
value (NPV) for each cardiac marker [H-FABP, CK-MB mass, myoglobin, cTnT,
and cTnl] for the diagnosis of AMI were measured at each time point after
presentation. The sensitivity for the detection of non-Q wave MI, UA and
complications during angioplasty was also calculated. Sensitivity is defined as; the
number of samples above cut-off concentration in AMI divided by the number of
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sample in AMI. Specificity is defined as; the number of samples below the cut-off
value in non-AMI divided by the number of samples in non-AMI. Positive predictive
values is defined as; the probability of an AMI being present in the presence of a
single marker result above the upper reference limit of the marker for each time
point. Negative predictive values is defined as; the probability of an AMI not being
present in the presence of a single marker result below the upper reference limit for
each time point. The calculations of sensitivity, specificity, PPV, and NPV were
based on the following equations:
True positive sample
Sensitivity = x 100%
True positive sample + false negative sample
True negative sample
Specificity = x 100%
True negative sample + false positive sample
True positive samples
PPV = x 100%
True positive samples + false positive samples
True negative samples
NPV = x 100%
True negative samples + false negative samples
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THE DETECTION OF COMPLICATIONS DURING PERCUTANEOUS
CORONARY INTERVENTION USING CARDIAC MARKERS HEART
FATTY ACID BINDING PROTEIN, CREATINE KINASE MUSCLE BRAIN




Percutaneous coronary intervention represents a widely accepted revascularisation
procedure and a clinical model of induced ischaemia. After its introduction in 1964,
PCI has since been used in the treatment of many patients with stable angina,
unstable angina, and acute myocardial infarction.1 Between 1987 and 1996 the
number of PCI procedures in the United Kingdom has increased to about 20,000
procedures per year and in the United States over 300,000 procedures are performed
per year. In patients with recurrent angina after coronary artery bypass grafting, PCI
of narrowed saphenous vein grafts is often considered since the peri-operative
mortality associated with a second bypass operation is higher than that associated
• • 2 •with the initial operation [5 - 10% vs 1 - 2%]. Percutaneous coronary intervention
provides effective relief (90%) of stable angina in most patients with single vessel
coronary artery disease.3'4
Among patients with UA who are treated medically, 1 - 5% die and 2 - 10% sustain
AMI before they are discharged from hospital.5"7 Percutaneous coronary intervention
in UA is associated with 84% angiographic success rate (defined as < 40% residual
luminal narrowing) and is usually considered if aggressive medical therapy fails.8 In
subjects with evolving AMI, percutaneous coronary intervention is associated with a
one year survival of 90 - 97%.9 When compared with thrombolytic therapy, PCI may
be advantageous in patients considered to be at high risk i.e. those with massive
anterior AMI, and in patients with tachycardia, in AMI complicated by cardiogenic
shock, and in patients with contraindications to thrombolytic treatment.9'10 The
success rate of PCI is lower in patients with UA, advanced age, and low ejection
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fraction (EF).11 The success rate of PCI is also lower with stenoses that are long,
eccentric, angulated, calcified, located at the ostium or the site of a branch point, or
associated with intraluminal thrombus.12
5.2 COMPLICATIONS OF PERCUTANEOUS CORONARY
INTERVENTION
Percutaneous coronary intervention is in general considered a safe procedure,
• 48
occasionally complications occur, including AMI [3 - 5%], ' the need for
emergency CABG [3 - 7%],13'14 and death [0.9%].15 These events are usually caused
by extensive arterial dissection, intracoronary thrombosis or both with resultant
vessel occlusion. Acute or abrupt closure occurs in 2 - 8% of patients undergoing
PCI and accounts for most of the short-term morbidity and mortality associated with
1617PCI. ' In 75% of patients with abrupt closure, it occurs within minutes after PCI
when they are still in the catheterisation laboratory, in the other 25% it usually occurs
• • IR
within 24 hours after PCI. Ultrasound imaging has shown that dissection of the
arterial wall is detected in 50 - 80% of patients who have undergone successful
PCI.19;20
The consequences of abrupt closure vary widely depending on; (1) The size of the
occluded vessel; (2) The extent of myocardium at risk; (3) The presence or absence
of good collaterals; and (4) The duration of the occlusion. Patients with adequate
collaterals perfusion of the occluded vessel may have abrupt closure without chest
• • • 17
pain, ECG abnormalities or haemodynamic compromise. More commonly, abrupt
closure is accompanied by chest discomfort and ECG evidence of ischaemia and
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requires immediate revascularisation of the occluded vessel (by repeated PCI ± bail
out stents or emergency CABG) to prevent or limit myocardial damage. Ten per cent
of patients with extensive coronary arterial dissection after PCI require emergency
bypass surgery, sustain AMI, or die. Small dissection (not compromising flow or
91 •
lumen) are only associated with 2% complications. Other complications of PCI
include coronary vessel perforation, rupture or injury, re-stenosis of the dilated
vessel, UA, arrhythmias including ventricular fibrillation, coronary artery
99 •
spasm/elastic recoil, hypotension/hypertension and embolism. Side branch
occlusion occurs in 5% of side branches that are adjacent to a dilated coronary
stenosis.23
5.3 BIOCHEMICAL MARKERS OF MYOCARDIAL INJURY AND
PERCUTANEOUS CORONARY INTERVENTION
Uncomplicated angioplasty is not associated with any significant cardiac markers
release in the majority of patients, because the duration of coronary occlusion and
subsequent myocardial ischaemia is brief and usually well tolerated by the
myocardium.24,2:1 However, the development of new and more sensitive cardiac
markers has increased the numbers of patients diagnosed with myocardial injury after
PCI. Myocardial infarction diagnosed by elevation of cardiac markers is relatively
common and is reported in approximately 7.7 - 15% of patients undergoing PCI.26
These infarclets, which were initially thought to be benign, were associated with
• 97 9Q*Tn
increased risk of future complications. " ' " Minor increases of CK and CK-MB
after an apparently successful coronary intervention have been reported in 5 - 15%
and 11.5 - 26% of cases respectively.27'30'34"36'40'50 Creatine kinase-MB elevation after
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PCI was associated with increased risk for cardiac death and AMI during follow-
Cardiac-Tnl and cTnT are more sensitive and specific markers of myocardial injury
and have been shown to be independent predictors of early and late adverse clinical
outcomes in patients with ACS. ' ' " Elevations of cardiac troponins were
detected in 13 - 44% of patients undergoing pel.33 38-40 Some of the increases in
cardiac markers have been correlated with clinical variables e.g. low EF,31 or
procedural variables e.g. total inflation time, side branch occlusion, the use of
stents and the occurrence of in-hospital complications (e.g. AMI).41 Increased cTnT
concentration post-PCI was correlated with a higher incidence of complex lesion
morphology [73% of patients], intracoronary thrombus [29%], abrupt closure [10%],
and side branch occlusion [15%] during angioplasty.42
There are still some unresolved issues concerning the role of these cardiac markers in
interventional cardiology clinical practice. There is little information on the
relationship between cardiac markers elevations after PCI and; (1) Correlations with
demographic, angiographic and procedural variables; (2) Correlations with long-term
complications. Also the definition of myocardial injury following PCI using
biochemical markers is not clear. For CK and CK-MB, some studies have
recommended the use of concentrations 1.5-3 times the upper limit of normal.26'27'31
There is also little information about the best marker(s) that will define myocardial
injury post-PCI especially with regards to cTnl and cTnT and the optimum cut-off
concentrations that carry prognostic value. Some investigators used concentrations
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above the normal cut-off value of the assays (e.g. > 0.1 jj.g/1 for cTnl). Others
suggested that values twice or three times the upper limit of normal are associated
with more significant complications.34'48 Heart-FABP is a novel cardiac marker
introduced for the early identification of myocardial damage after AMI.43 The value
of H-FABP as an early marker for the identification of myocardial damage during
PCI has not yet been studied.
5.4 AIMS OF THE STUDY
1- Examine the relation between elevations of cardiac markers (H-FABP, cTnT,
cTnl, CK-MB mass, and myoglobin) post-PCI and complication rates during and
after PCI.
2- Determine whether elevated cardiac markers (H-FABP, cTnT, cTnl, CK-MB
mass, and myoglobin) post-PCI are related to demographic, angiographic and
procedural variables.
3- Compare and contrast the release kinetics of the new cardiac marker H-FABP in
this model of induced ischaemia with standard markers of myocardial damage
(cTnT, cTnl, CK-MB mass, and myoglobin) and determine whether H-FABP has
advantage in terms of early release characteristics.
5.5 PATIENTS AND METHODS
5.5.1 Study population
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The patients group consisted of a consecutive series of 80 patients. The recruitment
process of patients in this group, the inclusion and exclusion criteria are described in
details in Chapter 4 materials and methods pages 117 - 118. Five serial blood
samples were obtained from each patient at 0 hour i.e. basal or pre-angioplasty and at
1 hour, 2 hours, 4 hours, and 16 - 24 hours post-angioplasty. The following cardiac
markers cTnl, cTnT, CK-MB mass, myoglobin, and H-FABP were measured at each
time point, and the changes between basal and maximum post-angioplasty cardiac
markers concentrations were compared. A control group of 12 patients who
underwent coronary angiography without angioplasty at the same period were also
included and analysed consecutively. These were patients who had coronary artery
disease (CAD) but were not found suitable for angioplasty. The purpose of this
control group is to validate the results and exclude diagnostic procedure as the cause
of cardiac markers elevation.
5.5.2 Methods
Patients were categorised into two main groups according to the presence (cTnl
positive) or absence (cTnl negative) of elevated cTnl concentrations >0.18 pg/1. The
frequency of abnormal results was determined for each marker. The concordance and
discordance and the predictive accuracy of the different cardiac markers (cTnT,
myoglobin, CK-MB mass, and H-FABP) for complications were compared between
the two groups. Base line and maximum post-procedural cardiac markers
concentrations changes in the two groups were compared and related to
demographic, angiographic and procedural variables. The two groups were also
compared with respect to the frequency of complications during PCI and the in-
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hospital period post-procedure. Patients were followed-up for approximately two
years after discharge from hospital and the numbers of cardiac events in each group
were compared. Patients were also classified into cTnT, CK-MB mass, myoglobin,
and H-FABP positive (increased above cut-off concentrations) and negative (below
cut-off concentrations) groups and compared in a similar manner to cTnl positive
and negative groups. The diagnosis of complications during angioplasty was made
by two cardiologists. The diagnosis ofAMI in this group was based on the presence
of two or more of the following findings; (1) Clinical history of typical chest pain >
30 minutes in duration; (2) Evidence of ischaemic ECG changes such as ST segment
elevation or new Q wave or left bundle branch block; (3) Time-dependent rise in
concentrations of CK and CK-MB activity (CK > 400 IU/L, CK-MB activity > 6%)
and subsequent fall; (4) Evidence of new vessel occlusion at angiography within 24
hours of PCI.44
Patients were classified as UA if they had one of the following presentations,
symptoms of angina at rest; new onset (< 2 months) exertional angina; recent (< 2
months) acceleration of stable angina as reflected by an increase in severity.45 The
diagnosis of in-hospital recurrent ischaemia was based on chest pain associated with
transient ST segment and/or T wave changes without cardiac markers elevation
diagnostic of AMI. Angiographic success was defined according to the American
College of Cardiology/American Heart Association (ACC/AHA) task force guideline
on angioplasty as < 50% residual diameter stenosis and without the occurrence of
19
death, AMI, or the need for emergency bypass operation. Clinical success was
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defined as Angiographic success without in-hospital complications (death, AMI,
emergency CABG, or ischaemia driven repeat PCI).
5.5.3 PERCUTANEOUS CORONARY INTERVENTION
Diazepam (10 mg) was given orally as a pre-medication. The angioplasty procedure
was performed under local anaesthesia using the Judkins transfemoral approach and
conventional techniques of intracardiac recording and pacing. Ten thousands units of
heparin (or a slightly modified dose if the patient already received some heparin)
were given at the start of the procedure. A guide wire was then introduced into the
artery. A 6 - 7 French guide catheter (2 - 2.3 mm in diameter) is advanced through
the sheath to the ostium of the coronary artery to be dilated. With the guide catheter
positioned in the coronary ostium, angiography of the diseased artery is assessed
using multiple angiographic views to visualise the stenosis and the arterial segment
proximal and distal to it. A flexible guide wire (0.25 - 0.46 mm in diameter) is then
advanced through the guide catheter, navigated across the stenosis and positioned in
the distal arterial segment. The guide wire is navigated by rotating and advancing its
angulated tip. With the guide wire across the stenosis, the deflated balloon catheter is
advanced over the wire and positioned at the stenosis. The position of the guide wire
and balloon catheter is confirmed periodically by visualisation of the artery as
contrast material is injected through the guide catheter. Once positioned, the balloon
is usually inflated for 20 - 60 seconds at 6 - 8 atmospheres of pressure with a mixture
of saline and contrast materials, so that the inflation can be visualised
fluoroscopically. Occasionally other inflation variables are used. If the stenosis is
adequately dilated the guide wire and balloon catheter are removed. If the dilation is
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not adequate the guide wire remains across the stenosis and the balloon catheter may
be replaced by a larger one, or a coronary stent is deployed using higher pressures
(10 - 12 atmospheres of pressure). When the inflation has been completed, a final
angiogram is obtained to confirm the result is satisfactory and the other segments of
the artery including branches have not been compromised.
Electrocardiographic monitoring using leads I, II, and III were used to monitor the
patients during PCI. Heart rate, systolic and diastolic blood pressure were monitored
continuously throughout the procedure. When indicated, extra readings of diastolic
and systolic blood pressure were taken by an automated machine (Dinamap).
Intracoronary nitroglycerin (0.2 mg) was given during the procedure as required for
pain or suspected coronary spasm. Cyclomorphine (2.5 - 5mg) was given
intravenously as required for chest pain. Base line 12-lead ECG was recorded before
angioplasty and immediately after angioplasty. Intravascular ultrasound and pressure
wire studies were undertaken in selected patients to assess the success of angioplasty
and guide further intervention or to assess the degree of complications. After PCI,
patients were monitored at the programmed investigations unit or CCU, depending
on the occurrence of complications during the procedure. In patients with chest pain
after PCI, additional 12-lead ECG were recorded to diagnose myocardial ischaemia
and infarction and additional blood samples for CK, CK-MB, or cTnl measurements
were collected as part of the routine monitoring of patients. After PCI and stenting
most patients were started on either ticlopidine, clopidogrel, abciximab or
combinations of these treatments and the study did not interfere with this protocol.
Abciximab was used mostly on a rescue basis. Following the procedure, patients
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were reviewed during the first 24 hours. Clinical notes, blood tests and ECGs were
also reviewed.
5.5.4 Follow-up protocol
Out of hospital clinical outcomes for up to 26 months were obtained by serial
telephone interviews by research nurses. The following were considered as cardiac
complications; hospitalisation for cardiac events (angina, UA, and heart failure),
target and non-target vessel revascularisation, CABG, AMI, and death. The degree of
angina control post-PCI was also assessed by the patient reporting whether his/her
angina is worse, better or unchanged since PCI. The diagnosis of these events during
follow-up was based on hospitalisation records and documented discharge
summaries according to the guidelines mentioned earlier.
5.5.5 Laboratory analysis
Peripheral blood samples for serum analysis were collected in white Starstedt
Monovette vacutainer tubes. The blood samples (5 mis) were taken through a
peripheral line (intravascular access). The extracted samples were allowed to clot at
room temperature for 1 hour and then centrifuged at 4 °C, and the resulting serum
was divided into small aliquots and frozen at - 70 °C until analysis. Routine urea and
electrolyte were reviewed to exclude renal failure. Cardiac-Tnl, CK-MB mass, and
myoglobin were analysed on Stratus CS flourometric analyser machine (Dade
Behring), using commercially available test materials as described in Chapter 4
pages 106 - 109. Heart-FABP was analysed by an ELISA method using
commercially available assays (Hycult - Cambridge) as described in Chapter 4 pages
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101 - 105. Cardiac-TnT were analysed on Elecsys 2010 using commercial assays
(Roche - Germany) as described in Chapter 4 page 109.
The optimal cut-off concentrations of cardiac markers were based on ROC curve
analysis between patients with and without complications after PCI, and also
considerations of cardiac markers concentrations in the normal healthy blood donor
group, the control group, and the basal or pre-angioplasty concentrations. The
following cut-off concentrations were used to indicate myocardial injury following
angioplasty (cTnl >0.18 pg/1 [AUC = 0.753, SE = 0.03, 95% CI = 0.693 - 0.813,
sensitivity = 41.2%, specificity = 92%], cTnT > 0.1 jag/1 [AUC = 0.672, SE = 0.037,
95% CI = 0.599 - 0.746, sensitivity = 23%, specificity = 99.7%], CK-MB mass > 5
p.g/1 [AUC - 0.656, SE = 0.036, 95% CI = 0.586 - 0.726, sensitivity = 14%,
specificity = 98.1%], myoglobin > 95 pg/1 [AUC = 0.654, SE = 0.034, 95% CI =
0.588 - 0.721, sensitivity = 30%, specificity = 90%], and H-FABP > 16 pg/1 [AUC =
0.683, SE = 0.038, 95% CI 0.609 - 0.758, sensitivity = 42%, specificity = 92.7%]).
All these cut-off concentrations were associated with statistically significant areas
under the curve (p < 0.0005). The AUC for cTnl was greater than other markers.
Cardiac-Tnl was also the most frequent abnormal marker and was therefore chosen
for comparison in this study.
5.5.6 Statistical analysis
Continuous variables were presented as mean ± SD. Comparisons between cTnl
positive and negative groups demographic, angiographic and procedural variables
were conducted by the Mann-Whitney U test for continuous variables and chi-square
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or Fisher's exact test for categorical variables. Comparison of serial cardiac markers
(CK-MB mass, cTnl, cTnT, myoglobin, and H-FABP) mean concentrations changes
at 0 hour (before angioplasty) and at 1,2, 4, and 16-24 hours after angioplasty was
conducted by Friedman test. Comparison between basal and maximum concentration
of cardiac markers in the control and angioplasty groups was compared with
Wilcoxan Signed Rank Test. Correlations between the concentration changes of cTnl
and cTnT, CK-MB mass, myoglobin, and H-FABP in the cTnl positive group was
studies by Spearman's Rank order correlation. Significance was defined as p value <
0.05. The rate of event-free survival was estimated from the Kaplan-Meier survival
method and was compared with the log rank test. The sensitivity, specificity, positive
predictive value and negative predictive value for the detection of complications
were determined for each cardiac marker.
5.6 RESULTS
The study group included 21 females (26%) and 59 males (74%). The mean age of
the group was 61.1 ± 7.5 years. The control group consisted of 12 patients, 5 females
and 7 males, mean age 61.9 ± 8.7 years. The serum concentrations CK-MB mass,
myoglobin, cTnl, H-FABP, and cTnT in the angioplasty and the control groups were
determined and compared. There were no significant releases of any of the cardiac
markers in the control group who had angiography procedure alone without
angioplasty (Figure 1). This provides evidence that exclude diagnostic procedure as
the cause of cardiac trauma and support angioplasty as the primary cause of cardiac
markers release. There was also no significant difference in cardiac markers
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Figure 1. This graph illustrates the concentrations of cTnl, CK-MB mass, H-
FABP, cTnT and myoglobin before and after angiography. There was no







Figure 2. Illustrates the differences in serum concentrations between the
healthy blood donor group and the control group.
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The following demographic, angiographic and procedural variables were analysed in
every patient. The ratios of these variables in cTnl positive and cTnl negative groups
were compared. Demographic data included age, sex, type of angina, prevalence of
risk factors, previous cardiac events and interventions, and current treatments.
Angiographic variables that were analysed included type of CAD i.e. single or
multiple vessels CAD, the anatomic site of angioplasty, type ofPCI i.e. single or
multiple vessels PCI, and the ejection fraction. Procedural variable included balloon
dimensions, the total numbers of balloon inflations per procedure, total duration of
inflations, maximum inflation time and pressure, and the total duration of PCI. Other
variables included, the incidence and type of complications reported by the operator
during PCI, complications reported within the first 24 hours period post-PCI, the
numbers of stents used and the reason for stenting, the use of intravascular
ultrasound during PCI, the reported clinical and angiographic successes and the type
of antiplatelet treatment post-PCI.
Four patients were excluded from the analysis because of an initial increase in cTnl
concentration in the pre-angioplasty sample, suggesting another cause for the
increase in cTnl e.g. active ischaemia. Out of these four patients, three had further
increase in cTnl concentration in subsequent samples post-PCI compared to base
line. One patient had elevated cTnl concentration of 0.75 pg/1 in the base line
sample. The value remained relatively unchanged throughout the sampling period.
There was no complication reported during PCI. The myoglobin concentration was
also markedly increased in this patient (range 201 - 317 pg/1). Creatine kinase-MB
mass concentration was normal. This patient was a diabetic and his renal function
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showed a slightly raised urea (7.7 mmol/1) and creatinine (131 mmol/1). He had
severe angina poorly controlled with medications, with angina occurring every night
at rest and on minimal exertion. The elevated cTnl concentration is most probably
due to UA with minor myocardial damage. One patient was biochemically
hypothyroid with TSH of 52 mU/L and T4 of 5 pmol/L. The pre-angioplasty sample
showed increased concentration of myoglobin of 104 pg/1, which remained elevated
throughout. Creatine kinase-MB mass concentration was normal but cTnl was only
abnormally increased at 16-24 hours post-PCI (0.27 pg/1). The slight increase in
myoglobin could be due to a subclinical myopathy that is often associated with
uncontrolled hypothyroidism. Cardiac-Tnl being more specific to the heart can
differentiate myoglobin rise due to myocardial injury and other injuries.
Out of the 80 patients studied, 10 [12.5%] developed ST segment changes, or T wave
inversion or new conduction abnormality and chest pain suggestive of ischaemia
during angioplasty, 15 [18.75] developed chest pain but no reported ECG changes of
ischaemia. Fifty-five [68.75%] patients had no chest pain or ECG changes reported
during PCI (Table 1). Eleven out of the 55 patients were given Cyclomorphine (2.5 -
5 mg) as prophylaxis at the beginning of angioplasty and this may have affected the
frequency of chest pain reporting in this group during PCI.
No. of patients (%) Clinical findings
10 (12.5) Had ECG changes of ischaemia and chest pain
15 (18.75) Had chest pain but no ECG changes of ischaemia
55 (68.75) Had no chest pain or ECG changes of ischaemia reported
Table 1. Illustrates the percentages of patients with chest pain ± ECG changes
of ischaemia during angioplasty.
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Table 2 shows the basal and maximum concentrations of cardiac markers in the
control and angioplasty groups. There was no difference between the basal
concentrations in the two groups. However, the maximum concentrations were
significantly elevated in the angioplasty group only [p < 0.001] (Table 2). Cardiac-
Tnl showed the most frequent abnormal values. The maximum increase in cTnl
concentration occurred at 16 - 24 hours. In 37 out of 80 patients (46.25%), cTnl
concentration was >0.18 pg/1. An increase in cTnl concentration [> 0.06 - < 0.17
pg/1] was observed in 22 patients (27.5%). Myoglobin was the second most frequent
abnormal marker. Myoglobin was increased in 14 (17.5%) patients, H-FABP was
increased in 6 (13.3%) patients, and CK-MB mass in 9 (11.25%) patients. The
concentrations changes of cTnl at 16 - 24 hours were closely correlated to changes in
CK-MB mass [r = 0.784, p < 0.0005] at 16 hours, cTnT [r = 0.529, p < 0.001] at 16
hours, myoglobin [r = 0.484, p < 0.002] at 4 hours, and H-FABP [r = 0.612, p <
0.002] at 2 hours. In all cases where CK-MB mass, cTnT, H-FABP or myoglobin
were elevated, cTnl was also elevated.
Control group Angioplasty group
Marker(s) Basal \ag/l Maximum |xg/l Basal \xg/l Maximum yg/l
H-FABP 6.86 ±2.21 8.00 ±2.50 9.70 ±5.8 30.0 ± 15.12
CK-MB mass 2.55 ± 1.2 2.22 ± 1.1 1.60 ± 1.2 23.70 ±29.10
Myoglobin 54.5 ±24.7 51.3 ±23.9 54.8 ±33.4 113.78 ±60.0
CTnl 0.065 ± 0.054 0.058 ± 0.054 0.04 ± 0.04 1.44 ±3.61
CTnT 0.011 ±0.003 0.012 ±0.007 0.01 ±0.003 0.49 ±0.61
Table 2. Illustrates basal and maximum concentrations of the different cardiac
markers in the control and angioplasty groups.
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As compared with cTnl, cTnT was increased in only 6 (7.5%) patients, and five of
them had significant complications. Cardiac-TnT was elevated to concentrations
between 0.01 - 0.06 pg/1 in 36 patients, and between > 0.06 - < 0.1 pg/1 in 4 patients.
The complications reported in these two groups were in 10 and 3 patients
respectively. All 6 patients with cTnT > 0.1 pg/1 and the 13 patients in the last two
groups had cTnl >0.18 pg/1. There was a contrast between cTnl and cTnT peak
concentrations levels. In two patients who had PCI complicated by AMI, the cTnl
concentration was 19.77 and 6.66 pg/l, and the corresponding cTnT concentration
was 1.68 and 0.66 p.g/1 respectively. This may reflect different standardisation
between the two assays. In the cTnl negative group [43 patients, 53.75%], no
increase in cTnl, cTnT or CK-MB mass concentration was observed. Myoglobin was
elevated in two patients, and H-FABP (concentration = 21 pg/1) in one patient. The
PCI procedure in one of the two patients with elevated myoglobin (myoglobin =117
jug/1, cTnl = 0.15 pg/1) was complicated by minor dissection but no complications
were reported in the other patient, or in the patient with elevated H-FABP.
The release patterns of cardiac markers in the cTnl positive group are shown in
Figure 3. These markers were significantly elevated compared with the base line
concentrations. Peak concentrations of H-FABP, myoglobin, cTnl, cTnT, and CK-
MB mass were achieved at 2 hrs, 4-16 hrs, 16-24 hrs, 16-24 hrs, and 16-24 hrs
respectively. This release pattern shows the early release characteristics feature of H-


























Figure 3. These graphs illustrate the release patterns of CK-MB mass,
myoglobin, cTnT, H-FABP, and cTnl before (0 hour), and at 1, 2, 4, and 16 - 24
hours after angioplasty in the cTnl positive group. There was a significant
change in cardiac markers concentrations before and after PCI.
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Concomitant increases of all markers were associated with more peri-procedural and
post-procedural adverse events, and the higher the concentration the more frequent
and more serious were the complications (Table 3). Out of the 3 patients with
elevations in all five cardiac markers, 2 developed AMI and 1 had major equipment
failure. One patient with simultaneous increase in cTnl and CK-MB mass had an
important dissection during PCI. Two of the 7 patients with elevations in cTnl and
myoglobin had complications including dissections, transient vessel closure (TVC),
side branch occlusion (SBO) and recurrent chest pain requiring revascularisation. Of
the remaining five, 2 had minor dissections and 3 had no complications reported.
Two patients had simultaneous increases of cTnT and cTnl, one patient had major
dissection with SBO and bail out stents, and the other patient died 4 days after
catheterisation from massive stroke.
Eighteen patients had an increase in cTnl concentration alone. Eight patients had
some complications during PCI, whereas in 6 patients no specific complications were
reported during PCI. However, in these patients the angioplasty procedure was
described as technically difficult and prolonged or the lesion was complex, and three
patients had failure of stent deployment, sudden drop of blood pressure after sheath
removal, and limb ischaemia post-procedure. Two patients in this group had total
occlusion of the vessels and two had osteal lesions. In 4 patients with cTnl elevations
[range 0.18- 0.65 ju.g/1] no specific complications were reported to explain this rise.
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The use of newer and potent antiplatelets treatment after PCI was liberal in this
group of patients. Fifty-five patients (68%) received some form of antiplatelets
treatment after stenting. Thirty-one patients (56.4%) received ticlopidine, 15 (27.3%)
received clopidogrel, 5 (9.1%) received Abciximab and ticlopidine, and 4 (7.2%)
received Abciximab and clopidogrel. The demographic and angiographic data of the
cTnl positive and negative groups are shown in Table 4 and 5. Patients in the cTnl
positive group were older (p < 0.02). The type of proceeding angina, antianginal
treatment and the prevalence of risk factors were similar between the two groups.
# Patients (37) # CM elevated Complication(s)
3 I, T, MB, Myo, H-FABP 2- AMI.
1-major equipment failure. *
4 MB, I, Myo
1-AMI.(H-FABP increased in this patient)
2-major dissection ± SBO.
1-minor dissection.
1 I, T, MB Bradycardia + T wave inversion on ECG.
7 I, Myo
2- major dissection ± TVC ± bail out stent.
2-minor dissections.
3-no complications reported.
1 1, MB Major dissection.
2 I,T 1-major dissection ± SBO ± bail out stent.
1 -see text.
1 I, H-FABP Major dissection ± TVC ±bail out stent.
18 I 5-major dissection ± TVC ± bail out stent.
3-minor dissection ± coronary spasm.
6- complex lesion ± prolonged procedure
± minor technical problems.
4- no reported complications.
Table 3. Shows the classifications of patients with elevated cTnl (n = 37) into
subgroups. In each subgroup the numbers of elevated cardiac markers are
shown a long with the complication(s) reported in each subgroup.
Abbreviations: CM, cardiac markers; I, T, MB, H-FABP, and Myo means cTnl,
cTnT, CK-MB mass, heart fatty acid binding protein, and myoglobin
respectively; AMI, acute myocardial infarction; SBO, side branch occlusion;
TVC, transient vessel closure. * In this patient the angioplasty balloon catheter-
tip was lost inside the coronary artery.
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There was a non-significant increase in the frequency of hypertension, previous
AMI, and multiple vessels CAD in the cTnl positive group. Only a few patients (11)
had multiple vessels PCI and there was no difference in cardiac markers release
between the two groups. There was a small difference related to the anatomical site
of angioplasty with increased cTnl with angioplasty in the left anterior descending
artery territory. Clinical and angiographic successes were reported more frequently in
the cTnl negative group [95% vs 73%, p < 0.013], and [95% vs 81%, p < 0.04]
respectively (Table 4 and 5).
Tnl positive group Tnl Negative group
Demographic data (N = 37) (N = 43) P value
Age (yrs) 64.35 ± 9.22 59.1 ±7.47 0.02
Sex:
Male 26 (70) 33 (77) NS
Female 11 (30) 10(23) NS
Type ofangina:
Stable angina 19(51) 26 (43) NS
Unstable angina 14(38) 17(40) NS
Atypical angina 4(11)
Risk Factors:
Smoking 24 (65) 27 (63) NS
Diabetes Mellitus 3 (8) 8(19) NS
Hypercholestrolaemia 27 (73) 37 (86) NS
Hypertension 18(49) 14(33) NS
Family history of IHD 16(43) 23 (53) NS
Cardiac Events:
Previous PCI 10(27) 16(37) NS
Previous CABG 4(11) 3(7) NS
Previous AMI 15(41) 14 (33) NS
Current treatment:
Nitrates 14 (38) 22 (51) NS
P-Blockers 22 (60) 29 (67) NS
Ca antagonists 23 (62) 23 (53) NS
Aspirin 36 (97) 43 (100) NS
K+ channel openers 3 (8) 4 (9) NS
Table 4, Shows the demographic data of patients with and without elevated
cTnl. Abbreviations: Tnl, cardiac troponin I; P, probability value; yrs, years;
IHD, ischaemic heart disease; PCI, percutaneous coronary intervention; CABG,
coronary artery bypass grafting; AMI, acute myocardial infarction.
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Multiple vessel PCI 5(14) 6(14) NS
Left ventricular EF (%) 62±12 65±14 NS
Clinical success) 27 (73) 41 (95) 0.013
Angiographic success 30(81) 41 (95) 0.04
Table 5. This table shows the angiographic data of patients with and without
elevated cTnl. Abbreviations: Tnl, cardiac troponin I; P, probability value;
CAD, coronary artery disease; PCI, percutaneous coronary intervention; LAD,
left anterior descending artery; LCX, left circumflex artery; RCA, right
coronary artery; EF, ejection fraction.
Table 6 illustrates the procedural variables. There was a significant difference
between the two groups with respect to occurrence of the following; chest pain ±
ischaemic ECG during PCI [51.4% vs 13.9%, p < 0.004]; numbers of stents used [42
vs 32, p < 0.019]; and use of intravascular ultrasound during PCI [16% vs 2%, p <
0.045]). These variables were more frequent in the cTnl positive group. Total
duration of PCI [56.9 ± 38.3 vs 42.31 ± 19.2 minutes], and total numbers of balloon
inflations per procedure [6.4 ± 4.6 vs 4.81 ± 2.8] were increased in cTnl positive
group but not statistically significantly. There was no difference between the groups
related to the number of lesions treated, balloon size, inflation time and pressure, and
the antiplatelet regimes after PCI.
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Tnl positive group Tnl Negative group
Procedure data II (N = 43) P value
Chest pain ± ECG changes ofischaemia 19 (51.4) 6(13.9) 0.004
Procedure information:
Number oflesions dilated (per patient) 46(1.24) 41 (1.24) NS
Number ofvessels dilated (per patient) 41 (1.11) 40(1.21) NS
Balloon diameter (mm) 3.3 ±0.56 3.12 ±0.45 NS
Total number of balloon inflation (n) 6.4 ± 4.6 4.81 ±2.8 NS
Total time of balloon inflation (minutes) 3.77 ±4.18 3.41 ±2.86 NS
Maximum inflation time (seconds) 50.12 ±26 55.24 ± 24.34 NS
Maximum inflation pressure (Pa) 11.21 ±3.34 10.45 ±3.56 NS
Total duration of procedure (minutes) 56.9 ±38.3 42.31 ± 19.2 NS
Major complications during PCI:
Major dissection 10(27) 1 (2) 0.004
Side branch occlusion 5 (13.5) 2(5) NS
Transient vessel occlusion 7(19) 1 (2) 0.022
Major technical failure 1 (3) 0(0) NS
Bail out stent 7(19) 0(0) 0.003
Minor complications during PCI:
Minor dissection 8(21.6) 7(16) NS
Coronary spasm/ elastic recoil 2 (5.4) 5(12) NS
Minor technical failure 1 (3) 2(5) NS
Post-procedural complications (24h):
AMI. 3(8) 0(0) 0.042
Angina with re-catheterisation 5 (13.5) 1 (2) NS
Angina without re-catheterisation 1 (3) 2(5) NS
Emergency CABG. 0(0) 0(0) -
Total number of stents 42 32 0.019
Reason for stenting:
Stent for dissection 15 (40.5) 8(17) 0.05
Stent for sub-optimal result 12(32.4) 15 (35) NS
Elective stent 3(8) 6(14) NS
Bail out stent 7(19) 0(0) 0.003
Use ofIVUS during PCI 6(16) 1 (2) 0.045
Post-procedural treatment:
Ticlopidine 11 (30) 20 (47) NS
Clopidogrel 8 (22) 7(16) NS
Abciximab + Ticlopidine 3(8) 2(5) NS
Abciximab + Clopidogrel 3(8) 1 (2) NS
Table 6. Illustrates the procedural variables in patients with and without
elevated cTnl. Abbreviations: Tnl, cardiac troponin I; P, probability value;
CAD, coronary artery disease; PCI, percutaneous coronary intervention; mm,
millimetre; Pa, Pascal; AMI, acute myocardial infarction; IVUS, intravascular
ultrasound.
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The frequency and types of complications reported during and after PCI were
significantly increased in the cTnl positive group. Out of the 37 patients in this group
23 (62%) had complications compared to only 14 out of the 43 patients (32.5%) in
the cTnl negative group (p < 0.03). These complications included one or
combination(s) of the following; major dissection [27%, p < 0.004]; side branch
occlusion [13.5%, p = NS]; transient vessel occlusion [19%, p < 0.022]; bail out
stents [19%, p < 0.003]; AMI [8%, p < 0.042]; major technical failure [3%, p = NS];
angina requiring re-catheterisation [13.5%, p = NS]; and minor dissection [21.6%, p
= NS]. One patient had major technical failure of equipment during angioplasty. The
balloon tip snapped-off inside the coronary artery and was snared with difficulty. The
corresponding cTnl, CK-MB mass, cTnT, H-FABP, and myoglobin concentrations
were elevated in this patient 1.5, 5.9, 0.23, 31, and 129 p.g/1 respectively.
Fourty-two stents were used in this group compared to 32 stents in the cTnl negative
group. Thirteen stents (31%) were used mostly on bail out bases. The increased
frequency of stents in this group was mostly to treat dissections [40.5% vs 17%, p =
0.05], The use of stents for elective and sub-optimal angioplasty results was slightly
more in the cTnl negative group [49% vs 40.4%]. Seven patients had bail out stents,
which were all used to treat major dissection ± acute vessel closure. Two of the 7
patients subsequently developed AMI (cTnl, cTnT, CK-MB mass, H-FABP, and
myoglobin mean concentrations were 13.23, 1.17, 68.4, 38.5, and 216 pg/1
respectively) and the cTnl, cTnT, CK-MB mass, and myoglobin mean concentrations
were elevated in the remaining 5 patients (1.2, 0.1, 5.75, and 102.6 pg/1
respectively).
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Six patients had intravascular ultrasound investigation or pressure wire studies
performed during PCI, compared with one patient only in the cTnl negative group.
All of them had cTnl elevation after PCI. This increase was due to another apparent
complications ± intravascular ultrasound in 3 patients, but in 2 patients no
explanation for the rise in cTnl could be detected other than uncomplicated
angioplasty and intravascular ultrasound use. The mean concentrations of cTnl in
these two patients was slightly raised at 0.185, whereas cTnT, CK-MB mass, H-
FABP and myoglobin remained below the cut-off point 0.076, 2.1, 14.3, and 91.5
pg/1 respectively. One patient was admitted with massive stroke two days after
intravascular ultrasound investigation, and he died four days after the event. Creatine
kinase-MB mass and H-FABP concentrations in this patient were normal, but cTnl,
cTnT, and myoglobin were elevated (0.39, 0.14, and 123 pg/1 respectively). This
patient had no complications and the cause of death was not related to PCI.
Three patients developed AMI after PCI (1 Q wave and 2 non-Q wave AMI). The
concentrations of cardiac markers in these patients were significantly elevated
compared to the normal base line values. Heart-FABP was the first marker to appear
in significant concentrations after AMI. Peak concentrations ofH-FABP, myoglobin,
CK-MB mass and troponins occurred at 2 hours, 4 hours, 16 - 24 hours, and 16 - 24
hours respectively after angioplasty. These release patterns were similar to the
release patterns seen in Figure 3. Heart-FABP reached diagnostic concentrations for
AMI 1 - 2 hours post-angioplasty. The diagnosis of AMI based on myoglobin, CK-
MB mass, and troponins can be established at 2 - 4, 4 - 16, and 4-16 hours
respectively (Figure 4).
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Figure 4. Shows the release patterns of cTnT, cTnl, CK-MB mass, H-FABP,
and myoglobin at 0 hour (before angioplasty), and at 1, 2, 4, and 16 - 24 hours
post-angioplasty, in patients with AMI after PCI. Diagnostic concentrations for
AMI were noticed between 1 - 2, 2 - 4, 4 - 16, and 4-16 for H-FABP, myoglobin,
CK-MB mass, and cTnl respectively.
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Five patients had SBO during angioplasty. In 3 patients, this complication followed
an extensive dissection. Out of the 5 patients, 2 developed AMI, 2 had considerable
chest discomfort and ST segment depression ± T wave inversion, and in one patient
SBO was asymptomatic. Cardiac-Tnl concentration was elevated in all patients. The
mean cTnl increase in these three groups was 14.7 pg/1, 1.73 ju.g/1, and 0.18 p.g/1
respectively. Creatine kinase-MB mass, and myoglobin were increased in three
patients, whereas H-FABP and CTnT were increased in two patients only. In the
cTnl negative group two patients had asymptomatic SBO, but there was no increase
in cardiac markers in any of them.
The release patterns of cTnl, cTnT, CK-MB mass, FI-FABP, and myoglobin in the
cTnl negative group are shown in Figure 5. There were no significant increases in
cardiac markers concentrations compared to base line values. This group included 43
patients with cTnl <0.18 p.g/1. Fourteen patients (32.5%) in this group developed
complications during PCI. However, the frequency and severity of complications in
this group were considerably lower than cTnl positive group. These complications
include one patient with major dissection, two patients with transient side branch
occlusion, and one patient with transient vessel closure. The types of complications
reported in the remaining 10 patients were minor dissections, coronary spasm, elastic
recoil, and minor technical problems.
Patients were also divided into cTnT, CK-MB mass, myoglobin, and H-FABP
positive and negative groups, depending on the presence or absence respectively of
concentrations rise above the respective cut-off values. These groups were then
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compared in exactly the same manner as patients in cTnl positive and negative
groups. There were similar findings across most of these groups. The most
significant and consistent predictors of elevated concentrations were increased age,
development of chest pain ± ischaemic ECG changes, occurrence of in-hospital
complications, occurrence of major complications during PCI (major dissection, side
branch occlusion, transient vessel closure, and AMI), angina with re-catheterisation,
bail out stents, number of stents used to treat dissection, and the use of intravascular
ultrasound. These variables were significantly elevated across most cardiac markers
positive groups. Clinical and angiographic successes were increased in cardiac
markers negative groups.
In a separate analysis, patients were classified according to the degree of
complications reported during or after PCI into 3 groups. Group I, includes patients
who had no complications (NC); group II, includes patients with minor
complications (MC), and group III, includes patients with major complications (C).
The types of complications are outlined in Table 7. In group I, a total of 43 patients
had no complications reported during PCI, 29 patients (67.5%) had cTnl <0.18 pg/1
and 14 patients (32.5%) had elevated cTnl >0.18 p.g/1. In group II, 16 patients had
minor complications during PCI, 6 patients (37.5%) had elevated cTnl
concentrations, whereas 10 patients (62.5%) had no cTnl elevation. In group III,
cTnl was elevated in 17 out of 21 patients (81%).
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Figure 5. These graphs illustrate the release patterns of CK-MB mass,
myoglobin, eTnT, H-FABP, and cTnl before (0 hour), and at 1, 2, 4, and 16 - 24
hours after angioplasty in the cTnl negative group. There was no significant
change in cardiac markers concentrations before and after PCI.
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Table 8 below illustrates the three different groups of patients. The percentage of
patients with elevated cTnl concentration increases proportionally in relation to the
degree of complications reported during or after PCI. The proportion of patients with
cTnl > 0.18 p.g/1 was 32.5%, 37.5%, and 81% for the group with NC, MC, and C
respectively. The maximum increase in cTnl concentration occurred in the group
with major complications (mean = 2.64 pg/1). The maximum concentration of cTnl
in the other two groups was < 0.96 pg/1. The frequency of abnormal elevation for the
other markers in these three groups is shown in Table 8 (cTnT [C = 23.8%, MC =
0%, NC = 2.3%], CK-MB mass [C = 33.3%, MC = 6.3%, NC = 2.3%], H-FABP [C
= 33.3%, MC = 0, NC = 5.3%], and myoglobin [C = 38.1%, MC = 18.7, NC = 7%]).
Based on these data, the sensitivity, specificity, PPV, and NPV of the various cardiac
markers for the detection of complications during angioplasty are shown in Table 9.
Table 9A shows these values when the analysis was conducted specifically to detect
major complications during angioplasty (patients with minor complications excluded,
see Table 7 and 8). Cardiac-Tnl has the highest sensitivity (81%) and negative
predictive accuracy (88%) compared to cTnT, CK-MB mass, H-FABP, and
myoglobin. However, the specificity and PPV of the latter markers was significantly
better than cTnl. The low specificity (67.5%) and PPV (55%) of cTnl was due to the
inclusion of patients with no reported complications (NC, n = 14) but with cTnl
concentrations >0.18 pg/1. Cardiac-TnT, H-FABP, myoglobin, and CK-MB mass
were highly specific (93 - 97.6%), and elevation of these markers were correlated
with the presence of major complications. However, this superior specificity and
positive predictive accuracy was markedly offset by poor sensitivity (24 - 38.1%)
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and low NPV for major complications. The corresponding sensitivity and other
values for all cardiac markers are shown Table 9A.
Table 9B, shows repeated analysis for the detection of any complications (major and
minor) during angioplasty (See Table 7 and 8). There was an overall reduction in
sensitivity and NPV for all markers. This reduction could be explained by the
inclusion of many patients in the minor complications group with evidence of
myocardial damage at angiography but without any significant release of cardiac
markers. Cardiac-Tnl was still the most sensitive marker (62%). Cardiac-TnT and
CK-MB mass retained the highest specificity and the lowest sensitivity for the
detection of minor and major complications. Heart-FABP performance closely
resembled those ofCK-MB mass, but with a reduced NPV.
The reduction in NPV of H-FABP (46%) is due to the inability of this marker to
differentiate patients with small damage to the myocardium in the minor
complication group. Overall, in terms of sensitivity, specificity, PPV and NPV for
the detection of complications during PCI, the performance of H-FABP, CK-MB
mass, cTnT, and myoglobin were closely related. In patients with major
complications there was a strong correlations between concentrations changes of
cTnl at 16 hours and changes of CK-MB mass [r = 0.832, p < 0.0005] at 16 hours,
cTnT [r = 0.672, p < 0.002] at 16 hours, myoglobin [r = 0.640, p < 0.002] at 4 hours,
and H-FABP [r = 0.705, p < 0.003] at 1 hour.
157
Minor complications (MC) Major complications (C)
Coronary spasm Major dissection
ECG changes of ischaemia only Transient vessel occlusion
Complex lesion or prolonged procedure (> 60 minutes) Acute myocardial infarction
Minor dissection (not compromising lumen) Major side branch occlusion
Elastic recoil Bail out stent
Minor technical complication e.g. failure of stent
deployment, balloon burst
Major equipment failure
Asymptomatic small vessel side branch occlusion
Table 7. Shows the types of minor and major complications in the two groups
of patients.
Groups # Patients CM CTnl CTnT CK-MB Myoglobin H-FABP*
status mass
I-NC 43 + 14(32.5) 1 (2.3) 1 (2.3) 3(7) 1 (5.3)
~ 29 (67.5) 42(100) 42 (97.7) 40 (93) 18(94.7)
II-MC 16 + 6 (37.5) 0(0) 1 (6.3) 3 (18.7) 0(0)
- 10(62.5) 16(100) 15(93.7) 13 (81.3) 11 (100)
III-C 21 + 17(81) 5 (23.8) 7(33.3) 8(38.1) 5 (33.3)
~ 4(19) 16(76.2) 14(66.6) 13 (61.9) 10(66.7)
Table 8. This table illustrates the three different groups of patients without
complications (NC), with minor complications (MC) and with major
complications (C). The total numbers of patients (# patients) in each group and
cardiac marker (CM) status i.e. (+) above cut-off concentration or (-) below cut¬
off concentration is shown in the first three columns. The numbers and
percentages of patients with cTnl, cTnT, CK-MB, myoglobin and H-FABP
above and below the respective cut-off point are also shown. *These calculations
were based on a slightly modified numbers of patients.
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9A Statistical values for the detection ofmajor complicaltions
CTnl CTnT CK-MB Myoglobin H-FABP
Sensitivity 81 24 33 38.1 33
Specificity 67.5 97.6 98 93 94.7
Positive predictive value 55 83 87.5 73 83
Negative predictive value 88 72 75 75.5 64
9B Statistical values for the detection of any complications (minor and major)
CTnl CTnT CK-MB Myoglobin H-FABP
Sensitivity 62 13.5 22 29.7 19.2
Specificity 67 97.6 97.6 93 94.7
Positive predictive value 62 83 88.8 78.5 83
Negative predictive value 67 56.7 59.2 60.6 46
Table 9. Shows the sensitivity, specificity, positive predictive value and
negative predictive values of the various cardiac markers for the detection of;
(9A) major complications only; and (9B) any complications (major or minor)
during angioplasty.
Patients were then divided into positive complications group (had any complications
during PCI, minor or major, n = 37) and negative complications group (no reported
complications, n = 43) and compared. The following demographic, angiographic and
procedural variables were correlated with the presence of complications during PCI
(previous angina pectoris [p = 0.05], previous AMI [p < 0.04], any previous cardiac
event i.e. CABG, PCI, and AMI, [p < 0.013], use of stents for dissection [p < 0.005],
total numbers of stents used [p < 0.006], use of intravascular ultrasound [p < 0.005],
total duration of procedure [p < 0.001], total numbers of balloon inflations [p <
0.035], total time of balloon inflation [p < 0.041], increased cTnl concentrations [p <
0.002], increased CK-MB concentrations [p < 0.01], increased myoglobin
concentrations [p < 0.001], and increased H-FABP concentrations [p < 0.001]).
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After discharge, clinical follow-up was available in 79 out of 80 patients (98.75%).
Mean follow-up period was 22.3 ±1.7 months (range 20 - 26 months). Only one
patient were lost to follow-up, and had not been seen as either inpatients or
outpatients at the Royal Infirmary of Edinburgh since discharge following their PCI
procedure. Patients in the positive and negative cTnl groups had similar periods of
follow-up (22.6 ± 1.5 vs 23 ± 1.2 months). The incidence of adverse clinical events is
summarised in Table 10 A. Patients who had cTnl elevation post-PCI had a non-
statistically significant higher incidence of complications (angina pectoris, UA, and
non-target vessel revascularisation) than patients without post-procedural cTnl
elevation. Seventeen patients (46%) in the cTnl positive group had one or more
clinical event(s) during the follow-up period compared with 12 patients (28%) in the
cTnl negative group. The total number of clinical events per group in the cTnl
positive and cTnl negative group was [29/37 (78%)] vs [21/43 (48%)] respectively, p
= NS.
The prevalence of uncontrolled angina in the cTnl positive group was not statistically
different. Seventeen patients (46%) described their angina after PCI as unchanged or
worse, compared to 12 patients (28%) in the cTnl negative group. Three patients who
were included in the cTnl negative group had several adverse clinical events during
follow-up (worsening of their angina, target and non-target vessel PCI, and CABG),
despite uneventful PCI. Their cTnl concentration was between 0.08 - 0.11 pg/1,
which suggests that even a small rises of cTnl may carry prognostic significance and
are associated with adverse clinical events post-PCI. There were three deaths in total,
one death in the cTnl positive group and two deaths in the cTnl negative group.
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Total No. with uncontrolled angina 17 (46) 12 (28) NS
Total No. ofpatients with events(%) 17(46) 12(28) NS
Total No. of events per group 29 (78) 21 (48) NS
Average duration offollow-up (months)) 22.6 ± 1.5 23 ± 1.2 NS
Patients lost to follow-up 0 1







Referredfor CABG 3(50) 3(4) 0.004
Table 10. Table 10 A shows the degree of angina control and the numbers of
adverse cardiac events after > 20 months of follow-up. Numbers between
brackets indicate the percentages. Table 10 B shows a similar analysis for a
subgroup of patients with cTnT positive and negative groups with respect to
referral for CABG. See text for explanation. Abbreviations are similar to Table
4.
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All deaths were not related to cardiac complications. There were also no statistical
differences between the frequency of these cardiac events when patients were
compared with respect to CK-MB mass, myoglobin, and H-FABP positive and
negative groups. Surprisingly cTnT was highly predictive of the need for CABG on
long-term follow-up. Although the total numbers of patients who had CABG in each
group were similar (i.e. three patients in each group), the high statistical significance
between the two groups can be appreciated when these numbers were translated into
percentages of the overall number of patients with cTnT elevation post-PCI. Fifty per
cent of patients with elevated cTnT after PCI were referred for CABG compared to
only 4% of patients with normal cTnT after PCI (p < 0.004, Table 10 B). There were
no other statistical differences between cTnT positive and negative groups when
other cardiac events (see table 10 A) were compared between the two groups.
The time-dependent effect of post-procedural cTnl elevation on late clinical outcome
was assessed using Kaplan-Meier survival analysis. There was a significant
decrement in event-free survival with more recurrent angina, myocardial infarction,
repeat PCI, and CABG in the group of patients who had cTnl elevations during
angioplasty. The mean event-free survival for the group with cTnl elevation and
those without cTnl elevation was 16.92 months [SE = 1.66, 95% CI = 13.67 - 20.18,
median = 23 months] vs 20.67 months [SE = 1.64, 95% CI = 17.46 - 23.88, median
= 27 months] respectively (p < 0.03). Event-free survival was also decreased in cTnT
and H-FABP positive groups. There were no event-free survival differences when
CK-MB mass or myoglobin positive and negative groups were compared (Figure 6).
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Figure 6. Shows the Kaplan-Meier event-free survival analysis for the two
groups of patients with cTnl elevation (cTnl +) and without cTnl elevations
(cTnl -) during angioplasty.
5.7 DISCUSSION
The frequency and prognostic value of elevation of cTnl, cTnT, CK-MB mass,
myoglobin, and H-FABP were evaluated in 80 patients undergoing elective PCI. The
significance of H-FABP as marker with potential for early detection of myocardial
injury was also studied and compared with other standard markers. Heart-FABP has
been shown in this study to be the most important early marker of myocardial injury.
Its concentration was significantly elevated within 1 - 2 hours following myocardial
injury and the concentration had returned to normal within 16-24 hours. The
frequency of cTnl increases post-PCI in patients with complications was much
163
higher than that seen with myoglobin, CK-MB mass, H-FABP, and cTnT (62 % vs
29.7 %, 22%, 19.2%, and 13.5 % respectively). No patients with complications post-
PCI had an increase in cTnT, CK-MB mass, H-FABP or myoglobin without
concomitant increase of cTnl. Cardiac-Tnl was the most useful marker for the
detection and quantification of PCI related complications. This reflects superior
sensitivity of cTnl for the detection of small releases of myocardial proteins after
PCI, which were undetectable using some less specific markers.
Previous AMI or angina, increased use of stents, use of intravascular ultrasound, total
numbers of balloon inflations, total time of balloon inflation, total durations of PCI,
and increased cTnl, CK-MB mass, myoglobin, and H-FABP concentrations were
variables that correlated with occurrence of complications during PCI. Old age, peri-
procedural angina or ECG changes of ischaemia, major dissection, transient vessel
closure, and AMI correlated with significant cardiac markers release during PCI. The
major In-hospital adverse coronary events were AMI and angina driven
revascularisation. Patients with AMI demonstrated profound increases in cardiac
markers concentrations post-PCI. Heart-FABP was the earliest marker that can detect
evolving AMI post-PCI within 1 - 2 hours. The diagnosis of AMI using myoglobin,
CK-MB mass, and troponins can be established at 2 - 4 hours, 4-16 hours, and at 4 -
16 hours post-PCI respectively.
Patients who develop chest pain post-PCI are often assessed by re-catheterisation to
exclude serious complications especially early re-occlusion of dilated vessels.
Sometimes patients with chest pain are subjected to this invasive procedure
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unnecessarily. The use of an early marker such as H-FABP may help cardiologist to
select the most appropriate groups of patients with chest pain, in the early post-PCI
period, for early investigations to ascertain the diagnosis of AMI and re-establish
early reperfusion. No serial blood samples were taken between 4 hours and 16-24
hours or beyond 24 hours. Therefore, the time to peak concentration for each marker
(with the exception ofH-FABP) and the time taken to return to base line could not be
estimated accurately. It is possible that CK-MB mass and troponins concentration
may have peaked earlier than 16-24 hours, if serial measurements between 4 hours
and 16-24 hours were performed in this study. Ricchiuta et al (2000) has reported
that CK-MB and cTnl peak concentrations occurred at about 12 hours post-PCI.46
The maximum concentration ofmyoglobin was noticed at 4 hours. It is possible that
the true peak concentration of myoglobin may be somewhere between 4-16 hours.
Serum H-FABP concentration reached peak level within 1.4 ± 0.5 hours after
reperfusion following aortic declamping in CABG surgery.51 This early peak of H-
FABP after coronary reperfusion was similar to the early peak obtained for H-FABP
after PCI in this study.
There were different concentrations rise of cTnl and other markers and different
symptoms in different subgroups of patients with SBO. These differences may be
related to the size of the side branch vessel, the extent of collaterals, and the duration
of occlusion. The occurrence of asymptomatic SBO, and also absence of cardiac
markers concentration rise following documented SBO has been reported before. '
Cardiac-Tnl was found to be the most sensitive marker for detecting and quantifying
the degree of myocardial damage following SBO. Cardiac markers were also
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increased in the groups that had more stents and intravascular ultrasound
investigations. Cardiac markers concentration are elevated in some patients after PCI
procedures involving stenting.36'48 However, the increase in cardiac markers was
probably not related to the use of stents per se, but indirectly reflects more
complications e.g. dissection in this group, and the increased use of stents were to
combat these complications. This is supported by the absence of significant cardiac
markers elevation in the cTnl negative group that used thirty-two stents. It is not
clear whether the use of intravascular ultrasound or pressure wire studies during PCI
contributes to myocardial injury. The results of this study suggest that patients who
were investigated by these methods during PCI should have cTnl testing afterwards
to exclude myocardial damage.
Cardiac-Tnl was increased in a small numbers of patients who had no complications
reported during PCI. This inevitably led to low specificity and positive predictive
accuracy for the detection of complications. The reason for the low specificity and
PPV reported in this study was based on the assumption that patients with elevated
cTnl concentrations and without any reported complications were considered "false
positive" results. Cardiac-Tnl is a very sensitive and totally cardiac specific marker
and any increase in its concentrations should mean myocardial damage. The reliance
on cardiac markers for the detection of myocardial damage during PCI is better than
reliance on visual assessment alone.
The reasons for an elevated cTnl concentration in the absence of visible
complications during angioplasty may be due to; (1) The formations of small thrombi
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at the angioplasty site that may subsequently embolise to small distal arteries leading
to small areas of focal necrosis; (2) Inability of contrast angiography to detect
complications. Indeed, intravascular ultrasound has been shown to be much more
sensitive for the detection of coronary dissection after PCI compared with contrast
angiography (83% vs 27%).19 Sherman et al (1986) showed that coronary
angiography detected the absence of complex lesions and thrombus in normal
vessels, but it detected only one of four complex lesions and one of seven thrombi in
diseased arteries. They concluded that angioscopy frequently reveals complex
plaques or thrombi not detected by coronary angiography;54 (3) May be due to
observers variability in complications reporting e.g. small dissection that is not
clearly visible or missed on visual angiography assessment alone; and (4) May be
due to mechanical trauma to the heart caused by guide wires manipulations within
the coronary arteries.
Some of our results were similar to previously published findings. The majority of
patients who had uncomplicated angioplasty had no significant increase in cardiac
markers. This finding was similar to the study published by Hunt et al (1991) who
found no increase in the concentrations ofCK-MB mass and cTnl in 22 patients who
had successful elective angioplasty.25 In our study we found no apparent
explanations for cTnl increases in 27% of patients (CK-MB mass = 3%, myoglobin =
8%), which was similar to findings published by Garbarz et al (1999). They have
reported 34% increases in cTnl concentrations in their study, which were not
accounted for by complications during PCI.41 The increases in cTnl, cTnT, CK-MB
mass in the group with SBO was in agreement with the results published by Talasz
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and Genser.30'32 These investigators reported an increase in cTnl, cTnT and CK-MB
mass concentrations in patients with SBO even when this complication was
asymptomatic.
The total frequency of cTnl rise (46.25%) in this study was slightly higher than that
reported by Karim et al (1995) 44% and many of the other studies.38'41 This could be
explained by the use of second generation cTnl sensitive assays (< 0.03 p.g/1) and the
use of a relatively low cut-off concentration (> 0.18 p.g/1) to indicate myocardial
injury post-PCI. The frequency ofCK-MB mass elevation in our study (11.25%) was
lower than that reported previously (15 - 26%). Some of the differences in CK-MB
mass results could be related to differences in assay methods used and to the
inclusion and exclusion criteria. The use of CK-MB assays based on enzyme activity
can give false positive results in the presence of interference (e.g. haemolysis), and
may lead to overestimation of patients with positive results especially in the lower
cut-off concentration range used in most of these studies.
In addition, some of the earlier studies included patients with recent UA and AMI
events undergoing emergency PCI, and some studies did not perform base line
measurement of CK-MB concentration.35'42'50 Many of these patients may have
increased base line cardiac markers concentrations as a result of the acute event and
it is difficult or impossible to differentiate rises due to complications of angioplasty
procedure from those due to the acute events. Kugelmass et al (1994) reported
elevated CK-MB in 11.5% of patients following elective PCI, and there were no
clinical sequels over two years follow-up. However, in a small subset with a greater
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elevation of CK-MB, there was a trend towards decreased late survival compared to
patients without CK-MB elevation. They also reported common CK-MB elevation
after coronary stenting.36
Patients with increased cardiac markers concentrations had more frequent
complications on long-term follow-up (p = NS). An increased frequency of cardiac
events on long-term follow-up (angina, PCI, CABG) were noticed in some patients
who had very small increases of cTnl concentration (0.08 - 0.1 p.g/1), which suggest
that even small increases of cTnl may have a significant prognostic value and may
reflect more diffuse or extensive CAD. Heeschen et al (1999) found that the rate of
death and AMI, in 42% of patients with UA and cTnl > 0.08, occurred in 25.5% of
cTnl positive patients compared to 2.9% of cTnl negative patients during 30 days of
follow-up.
Long-term complications in patients with elevated cardiac markers post-PCI have
been suggested by Abdelmejuid and others.27'29'31'47 However, these investigators
reported more frequent and more serious complications (e.g. death and AMI) than
this reported by us. These differences could be related to several factors. First, the
duration of follow-up. The follow-up period in our study was relatively short
compared to the study by Abdelmejuid (3-5 years, in some patients up to 8.5 years).
This assumption is strengthened by the fact that short-term (3-8 months) follow-up
studies of patients with elevated cardiac markers post-PCI have failed to detect
significant long-term complications.34 The follow-up period in our study was
intermediate and although an increased but non-significant positive correlation with
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future complications was found, it is possible that if the follow-up was extended over
a prolonged period of time (e.g. > 3 years), more noticeable complication differences
between the two groups may have been detected.
Second, increased use of stents. The use of stents was more frequent in the group of
patients with elevated cardiac markers concentrations. The use of stents to treat
complications during angioplasty e.g. dissections may alter the short-term risk of
further progression to more serious complications. The long-term benefits of stents in
preventing further coronary restenosis and events are also well established. Third, the
use of antiplatelets therapy. The use of newer and more potent antiplatelets regimes
(ticlopidine, clopidogrel, Abciximab) was also high in our group of patients (68%).
The clinical benefits of these antiplatelets compounds in reducing the progression to
AMI and death in patients with myocardial injury is well-established.58"60 It may be
that the combinations of improved modern techniques of angioplasty and the liberal
use of stents and potent antiplatelets treatment could have affected the long-term risk
of further complications as compared to conventional PCI alone without antiplatelets
treatment or stenting during or post-procedure. Despite the fact that there were no
statistically significant differences between the numbers of events, there was still a
significant difference with respect to event-free survival between groups with and
without elevations of these markers after angioplasty.
Increases in cTnT after PCI had been described previously.40'48 Ravkilde et al (1994)
found moderate increases in CK-MB mass [range 10-20 pg/l] in 6 of 23 patients
(26%) undergoing visually successful PCI, whereas only 3 (13%) showed cTnT
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elevation [range 0.25 -1.3 pg/1].40 In this study, the percentage of positive cTnT
results [range 0.1 - 1.68 pg/1] after PCI was only 7.5%. A third generation cTnT
assays that were very sensitive (< 0.01 pg/1) and specific were used. Some of the
previous studies used a lower cut-off concentrations with these assays e.g. > 0.04
pg/1 or > 0.06 pg/1, to indicate the presence of myocardial injury post-PCI.42'53
Increased cTnT > 0.06 |Ltg/l were found to be associated with increased risk of death
and AMI (10.5%) compared to cTnT < 0.06 pg/1.53 As mentioned earlier, cTnT
concentration between > 0.06 - < 0.1 pg/1 was associated with complications in 75%
of patients. Based on ROC analysis a cut-off concentration of cTnT > 0.06 pg/1 was
slightly more sensitive and equally specific to cTnT > 0.1 pg/1 for the detection of
complication. Depending on whether the cut-off concentration selected was > 0.1
pg/1 or > 0.06 pg/1, the frequency of abnormal cTnT elevations was 7.5% and 12.5 %
respectively, which is consistent with previous reports. Even by lowering the cut-off
concentration to > 0.06 pg/1, there was still a discrepancy between the frequency and
magnitude of abnormal cTnT and cTnl elevations.
Most studies that compared both markers post-PCI did also report some discrepancy
between the results of these two markers.48 The sensitivity of cTnT for the detection
of major complications in this study was considerably lower than that of cTnl (24%
vs 81%). In this model of controlled myocardial injury, this difference may be either
due to delayed leakage of cTnT from myocardial tissue into the blood within this
relatively short sampling period, or due to differences in assay methods. Unlike cTnT
assay which is well standardised, there are several cTnl assays. The normal
concentrations of these assays can vary by up to twenty-fold. Depending on which
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cTnl assay was used, some discrepancy between the results of these two markers is
expected. Despite the low sensitivity of cTnT, the specificity and positive predictive
value for the detection of complications was very high. Event-free survival of
patients with elevated cTnT concentrations was significantly lower than those
without cTnT elevations after angioplasty. Cardiac-TnT was also associated with
increased risk of CABG on long-term follow-up. Thus validating the prognostic
significance of cTnT elevations post-PCI.
The reporting of clinical and angiographic success may be overestimated by reliance
on visual assessment alone.19'54 Even in the absence of reported complications during
angioplasty, cardiac markers elevations can still be detected (sometimes as high as
2.12 pg/1, for cTnl) and these elevations may be associated with long-term
complications. Measurements of cardiac markers post-PCI will be a useful adjunct to
angioplasty and will help detect patients with subtle myocardial damage and may
guide further management. For example, twelve patients (32%) with elevated cTnl in
our study did not receive any form of antiplatelets (other than aspirin) during or after
PCI. The cTnl concentrations range in these patients were 0.18-2.12 pg/1. Eight out
of these 12 patients had worsening of their angina or further cardiac events during
follow-up. Patients with acute coronary syndromes and elevated troponins are known
to benefit from long-term treatment with antiplatelet therapy e.g. clopidogrel.58-60
The availability of cardiac markers results in these patients may influence
management decisions. These patients may be selected for long-term antiplatelet
therapy and this treatment may alter their long-term outcome.
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Finally, it is important to consider the impact of the new definition of AMI on our
group of patients. The new definition of AMI published in year 2000 jointly by the
ESC/ACC states that, AMI should be diagnosed in any patients with cTnT or cTnl
concentration > the 99th percentile of control value on at least one occasion or
maximum value of CK-MB mass exceeding the 99th percentile of a control group on
two successive samples or exceeding twice the upper limit of normal on one
occasion.49 The 99th percentile value for cTnl assays on Stratus CS was 0.1 pg/1.
Based on this new definition, 47 patients (58.75%) with elevated cTnl in this study
will fulfil the 'biochemical' diagnosis of AMI. The incorporation of this new
definition ofAMI in clinical practice will have several important implications.
(1) Safety issues. The use of this definition will detect many patients who had
suffered small damages to the myocardium or occasionally in patients with visually
successful angioplasty (as in this study), but with small cardiac markers elevations.
Classifying these patients as suffering from AMI as a result of PCI will add great
concerns to the safety of angioplasty. This will inevitably have a negative impact on
the wider and growing applications of this popular intervention.
(2) Social and psychological implications. Many patients will be labelled as suffering
from AMI even if the damage was slight and sometimes symptomless. This will add
considerable amount of stress to the patients and their families.
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(3) Financial and economic implications. Labelling patients with small increases of
cTnl as suffering from AMI will have many important financial consequences to the
patient and the economy such as loss ofjobs, sick leaves, and insurance.
(4) Legal implication. Sometimes PCI is undertaken to improve the coronary
anatomy e.g. treating very severe discrete stenosis noticed at angiography even if the
patient had few and stable symptoms. The diagnosis of AMI following such
situations will provide grounds for litigations. This may incur huge financial losses
on the part of health services and will have a negative impact on the patient-doctor
relationship.
5.7.1 SUMMARY
This study has confirmed an early release characteristic feature of H-FABP (within
one hour) compared with myoglobin (and other markers) following PCI-related
myocardial damage. Heart-FABP measurements at 1 hour (or thereafter) post-PCI in
patients with suspected complications may offer the best early chance of detecting
serious myocardial damage such as evolving AMI, that may necessitate investigation
by re-catheterisation in the first few hours post-PCI. Provided that serial
measurements were done, myoglobin may offer reliable indication of AMI at 2 - 4
hours post-PCI, whereas CK-MB mass, cTnl or cTnT are reliable between 4-16
hours. In general, H-FABP was equally sensitive and specific to CK-MB mass,
myoglobin and cTnT for the detection of complications post-PCI. However, the
overall sensitivity of all these markers for the detection of complications was
considerably lower than that of cTnl.
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Cardiac markers may play a significant role in detecting and quantifying myocardial
damage during angioplasty and may have important clinical applications. As
compared with CK-MB mass, myoglobin, H-FABP, and cTnT, cTnl has emerged as
the most sensitive marker for the detection ofmajor complications (major dissection,
SBO, TVC, and AMI) in patients undergoing PCI. This reflects superior sensitivity
of cTnl assays used by Stratus CS. Cardiac-Tnl was also abnormally elevated in
patients with minor complications and in patients without reported complications
post-PCI. The use of cTnl post-PCI offers a reliable detection of myocardial damage
that is sometime not obvious by visual contrast angiographic assessment alone. The
adjunctive measurements of cardiac markers post-PCI also provides important
prognostic informations and could help identify certain groups with elevated cardiac
markers concentrations that might benefit from long-term treatment with newer
antiplatelets therapy. The ability of cTnl to detect subtle and subclinical damage to
the myocardium may provide a sensitive tool for evaluating the impact of future
antiplatelet therapy, newer angioplasty devices and stents during PCI. Measurements
of cTnl 16-24 hours post-PCI should be part of the routine management of patients
following elective PCI.
5.7.2 Limitations of the study
(1) The study had no additional confirmatory test e.g. pathological examination or
intravascular ultrasound that can verify independently the magnitude of irreversible
ischaemic damage as a result of angioplasty in patients with elevated cardiac markers
concentrations and in those with and without reported complications. (2) The
interpretation of sensitivity results are also influenced to a greater extent by the
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diagnostic threshold selected for each marker and it is possible that the most sensitive
threshold for troponins may have detected cytosolic release not necessarily
irreversibly injured myocyte. At present we have no reliable method that will define
the ischaemic threshold for reversible and irreversible ischaemic injury.
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CHAPTER 6
THE DIAGNOSTIC VALUES OF SERIAL CARDIAC MARKERS HEART
FATTY ACID BINDING PROTEIN, CREATINE KINASE MUSCLE BRAIN
MASS, CARDIAC TROPONIN I, CARDIAC TROPONIN T, AND
MYOGLOBIN IN THE MANAGEMENT OF PATIENTSWITH UNSTABLE
ANGINA AND NON-Q WAVE MYOCARDIAL INFARCTION
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6.1 INTRODUCTION
Acute coronary syndromes encompass a spectrum of conditions with sudden cardiac
death at one end of the spectrum and silent ischaemia at the other end. In between it
ranges successively through AMI, non-Q wave MI, UA, and stable angina. Unstable
angina, which is at the centre of this spectrum, describes a heterogeneous population
with single or multiple vessel coronary artery disease, with or without prior
myocardial infarction, and with uncertain outcome. Historically, UA is identified in
the presence of one or more of the following features in the absence of clear-cut ECG
changes and enzyme rise diagnostic of AMI; (1) Angina at rest or minimal exertion;
(2) A relatively new onset of angina brought on by minimal exertion; and (3)
Crescendo angina i.e. more severe/prolonged/frequent episodes of angina
superimposed on pre-existing pattern of stable effort-related angina.1
Non ST elevation non-Q wave MI is a condition that is interposed between ST
elevation MI and UA. It is defined clinically when there is an increase in cardiac
markers proteins consistent with infarction and ischaemic ECG changes, in the
absence of the characteristic persistent ST segment elevation or new Q waves.2 The
term 'non-Q wave MI' will be used throughout the remaining of this chapter to refer
to this condition. Unstable angina and non-Q wave MI represent unstable coronary
artery disease and are usually classified together under non-ST elevation ACS. In the
early stages, the identification and distinction between these two conditions is
difficult, based on clinical history and ECG changes alone. There are also no
distinguishing features at angiography. However, this distinction is less important
therapeutically, because the two conditions are usually treated in a similar manner,
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although the risks of coronary events differ.4 These conditions are associated with
initial lower incidence of death, but the long-term (1 year) outlook is similar to
patients with Q wave MI.5
6.1.1 Epidemiology and pathophysiology
Unstable angina accounts for about 130,000 admissions annually in the United
Kingdom.6 The rate of death or non-fatal myocardial infarction at 6 months for UA
and myocardial infarction without ST elevation is 12.2%.7 It is also estimated that
55% of CCU beds are occupied by patients with UA. The incidence of non-Q wave
MI (compared to Q wave MI) over the past 20 years is also rising.9 Most patients
(85%) with UA and non-Q wave MI have obstructive atherosclerotic coronary artery
lesions as the underlying disease process. Episodes of angina are believed to follow
atherosclerotic plaque rupture or erosion with subsequent platelet activation and
• *12
aggregation to form platelet thrombus or white thrombus.
Platelet aggregation causes the release of thromboxane A2, which is a platelet pro-
aggregator and vasoconstrictor leading to further reduction of coronary blood flow.
Exposure of thrombogenic materials beneath the intima (lipid, collagen, and tissue
factor) to circulating blood stimulates the coagulation process and the deposition of
fibrin to form red thrombus. Activation of platelets and subsequent formation of
platelet thrombus is thought to play a greater component in the pathogenesis of UA
and non-Q wave MI.14 The presence of thrombi in these conditions had been
demonstrated at autopsy, angioscopy and angiography examinations.10"14
Intraluminal thrombus can be detected by angiography in 70% of patients with UA.15
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6.1.2 Treatment
There is evidence that aspirin and unfractionated heparin (UFH) are beneficial in the
treatment of patients with UA and non-Q wave MI, and are associated with a
significant reduction in subsequent rate of death and re-infarction.16'17 The
introduction and subsequent evaluation of low molecular weight heparin in
controlled clinical trials, had showed better efficacy and safety profile compared to
UFH.1 ' Low molecular weight heparin have better bioavailability, predicted
efficacy, lower incidence of side effects (e.g. thrombocytopenia, major bleeding), can
be self-injected by patients, and does not require blood monitoring. The use of
LMWH was associated with 20% reduction in the incidence of death, MI, and
recurrent angina as compared with UFH.20
With better understanding of the biochemistry and pharmacology of platelet
functions, it is now well understood that aspirin alone has limitations as the sole
antiplatelet treatment in UA and non-Q wave MI. Platelet activation can occur via
several different other receptors or metabolic pathways that are not affected by
aspirin (Figure 1). The activation of glycoprotein GP Ilb/IIIa receptor on the platelet
is the final common pathway of platelet activation, which leads to the binding of
fibrinogen and cross linking of platelets to form thrombus.4 The development of new
and more potent antiplatelets (e.g. GP Ilb/IIIa inhibitors, clopidogrel), that block
different receptors in the platelet activation pathways had been a major advance in
the potential armament of agents used in the treatment of patients with UA and non-




Figure 1. This schematic diagram shows the different receptors and metabolic
pathways that activate platelets and the antiplatelet sites of action.
Since the only differentiating factor between UA and non-Q wave MI is positive
cardiac markers concentrations consistent with infarction. The availability of cardiac
markers that are sensitive and specific for the early identification of myocardial
injury is very important and will help distinguish these two groups in the early phase
from other causes of chest pain. When this information is combined with the clinical
history and ECG changes at admission, this may help guide further management in
these high-risk groups. Heart fatty acid binding protein is a novel marker protein
with potential for the very early identifications of patients with AMI.24 Heart-FABP
and myoglobin are both very early markers of myocardial injury within the first 3
hours. Heart-FABP is considered more cardio-specific than myoglobin. This
advantage may be utilised for the early identifications of patients with UA and non-Q
wave MI. The diagnostic value of H-FABP in patients with non-ST elevation ACS
has not been studied before.
186
6.1.3 AIMS OF the STUDY:
1. Compare and contrast the sensitivity and the predictive value of the new cardiac
marker H-FABP for the early diagnosis of myocardial injury within 7 hours in
patients with suspected UA and non-Q wave MI, with standard markers CK-MB
mass, cTnT, cTnl, and myoglobin and determine whether H-FABP has an advantage
in terms of early release kinetics in this group of patients.
2. Examine the clinical benefits from implementations of serial cardiac markers
testing in the acute setting in patients with chest pain and their impact on patients'
management. Several examples will be used to illustrate the clinical benefits of these
markers in each group.
3. Study the additional diagnostic value of serial cardiac markers testing for the early
diagnosis ofMI in patients without the classical ST segment elevation. Whether their
selective use in such cases can influence further decisions on reperfusion therapy.
Several examples will be used to illustrate this.
6.2 PATIENTS AND METHODS
6.2.1 Patients and treatment
The recruitment of patients in this group, the inclusion and exclusion criteria, and the
diagnostic criteria are all described in details in Chapter 4 materials and methods
pages 114 - 117. Patients were treated in a conventional manner for UA and non-Q
wave MI using bed rest, oxygen, and antianginal treatment with or without (3-
Blockers, nitrates, and calcium antagonists. Intravenous nitroglycerin was given to
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control ongoing chest pain. All patients were given 300 mg of aspirin at admission
followed by a daily dose of 75mg. Patients were also given enoxaparin, which is the
standard LMWH used in our unit in a specified protocol adjusted to body weight.
Coronary angiography was not part of the protocol and it was done at the discretion
of the responsible cardiologist. The results of angiography were used to support the
discharge diagnosis. The discharge diagnosis was made by the consultant
cardiologists in charge of these patients.
6.2.2 PATIENTS' CLASSIFICATION
Based on clinical history, admission ECG and routine cardiac markers and other
investigations during admission, patients were divided into three main groups. Group
1, included patients with non-Q wave MI. Group 2, included patients with UA.
Group 3, included a heterogeneous population of patients with mixed medical
diagnoses other than UA and non-Q wave MI. Patients in group 3 were referred to as
'atypical/anginal chest pain'. Five serial blood samples were collected from each
patient at 0 hour (presentation), and at 2 hours, 4 hours, 8-10 hours, and 16-24
hours after presentation. Creatine kinase-MB mass, cTnl, cTnT, myoglobin, and H-
FABP were measured in each sample. The sensitivity of each cardiac marker using
two different cut-off concentrations were measured at each time after presentation
and compared. These selected cut-off concentrations were based on receiver operator
characteristic curve analysis (Chapter 4 pages 120 - 122), that best discriminate
patients with myocardial injury (UA and NSTEMI) and patients without myocardial
injury (normal controls and atypical/anginal chest pain), and those that discriminate
patients with UA from patients with NSTEMI.
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6.2.3 Analysis of cardiac markers
The analysis of CK-MB mass, myoglobin, and cTnl was done on Stratus CS. The
Stratus CS, from Dade-Behring-Germany, is a flourometric enzyme immunoassay
analyser for quantitative determination of CK-MB mass, cTnl, and myoglobin. The
test system is designed to analyse closed routine samples tubes containing
anticoagulated whole blood (lithium-heparin). Alternatively, this system can analyse
pre-processed plasma or serum specimens placed into sample cups. For separation of
the plasma from whole blood samples, the centrifugation step is incorporated into the
test system. Tests to be performed are selected by introducing bar-coded test packs.
Up to four test packs can be introduced for each sample. All required reagents are
enclosed within the test packs, which are transferred by disposable pipette tips.
Dilution can be performed automatically by adding test-specific dilution packs. The
test system utilises radial partition immunoassays technology, which have been
enhanced through the use of monoclonal capture antibody coupled to Starburst®
dendrimers. The cTnl specific antibodies used are identical to those used on the
Stratus II, and likewise are capable of detecting both free and complexed cTnl.26 The
dendrimer technology provides for better presentation and functionality of the
capture antibody on the glass fibre solid phase surface used in the assay. This in turn
leads to more efficient capture of the target antigen.
The assay process is initiated by applying the dendrimer-antibody reagent onto the
glass fibre matrix to form a reaction zone, which serves to capture the analyte of
interest. Centrifuged plasma/serum is then added, followed by the first incubation
period. Thereafter, the alkaline phosphatase-labelled second antibody is applied to
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the matrix, followed by a second incubation period. The unbound labelled antibody
reaction is removed from the reaction zone by radial illusion using the substrate wash
reagent. Captured phosphate-labelled antibodies convert the included enzyme
substrate into a fluorescent product that permits quantitative measurement of the
cardiac markers by front surface fluorescent measurement. The result of all three
cardiac markers is available within 18 minutes. The coefficients of variations for
cTnl were 4.5%, and 6.5% at 0.1 p.g/1, and 0.82 pg/1 respectively. The detection limit
was 0.01 pg/1. The 97.5% of a control healthy population was 0.08 pg/1.27 The
normal base line concentration of cardiac markers had been explained previously in
Chapter 4 pages 109 - 110.
6.2.4 Statistical analysis
Values were expressed as mean ± SD. Chi-square tests were used to explore the
group differences with respect to categorical variables. Kruskal Wallis H test was
conducted to compare continuous variables and mean cardiac markers concentrations
differences in the three groups (non-Q wave MI, UA and atypical/anginal groups).
Friedman tests were used to analyse variations of cardiac markers concentrations
over time (0 hour, 2 hours, 4 hours, 8-10 hours, and 16-24 hours). Significant
results are indicated by probability values less than or equal to 0.05. The best cut-off
concentrations were established from ROC curve analysis.
6.3 RESULTS
Out of 55 consecutive patients presenting with acute chest pain, 14 patients (26%)
had non-ST elevation non-Q wave MI (group 1), 20 patients (36%) had UA (group 2)
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and 5 patients (9%) had stable angina. In the remaining 16 patients (29%), 3 were
diagnosed with chest pain, 3 had ischaemic heart disease, 4 patients had
muskeloskeletal or gastrointestinal related chest pain and in 6 patients the discharge
diagnoses were atypical/possible angina in two patients, congestive cardiac failure in
one patient and in the remaining three patients the exact diagnoses of chest pain were
not clear. The last 21 patients constituted group 3. The demographic data of the
patients in these three groups is shown in Table 1. The study group consisted of 37
males (67%) and 18 females (33%). The non-Q wave MI group included 9 males and
5 females. The mean age and time to presentation in group 1 was 67.36 ± 11.34 years
and 5.3 ± 1.28 hours respectively. The time to presentation and the mean age in
groups 2 and 3 was similar to patients in group 1. All patients in these three groups
presented with chest pain < 7 hours after symptom onset.
The prevalence of cardiac disease (CABG, PCI) and risk factors (high blood pressure
and high cholesterol) was slightly increased in the non-Q wave MI group but not
statistically significant. The systolic blood pressure at presentation was different
between the three groups (p < 0.024). Patients with non-Q wave MI and UA had
more typical presentations with ischaemic chest pain (p < 0.027). The type and
distribution of ECG changes on admission are also shown in the table. The
commonest ECG changes at presentation were ST segment depression and T wave
inversion (47%). Six patients (11%) had transient ST segment elevation noted at
some stage on the ECG. In 33% there were no acute ECG changes and in 7% there
were other ECG changes e.g. arrhythmias and left bundle branch block. The
distributions of ischaemic changes were in the anterior, inferior, and lateral leads
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39.5%, 39.5%, and 18% respectively. Both non-Q wave MI and UA groups received
similar treatment with pharmacological agents e.g. aspirin, LMWH, and antianginal
medications. One patient was initially given tissue plasminogen activator (tPA) for
suspected AMI, which was later discontinued because of insufficient grounds for
thrombolysis.
There was more frequent use of PCI in the UA and non-Q wave MI groups compared
to atypical/anginal group (46% vs 5%). Seventeen patients (31%) were investigated
by angiography, and in nine patients (53%) angiography was followed by PCI,
because of severe stenosis in one of the coronary arteries or vein grafts. Coronary
angiography was undertaken mostly in patients with repeated admissions for angina,
for ongoing chest pain ± ECG changes of ischaemia, and in patients with elevated
cardiac markers concentrations. In group 1, four patients had angiography followed
by angioplasty in 3 patients (75%). In group 2, eight patients had angiography
followed by angioplasty in 5 patients (62.5%). In group 3, five patients had
angiography followed by angioplasty in one patient only (20%). Seventy-eight per
cent (78%) of patients who had angioplasty had significant cardiac markers
elevations. In patients who had coronary angiography without angioplasty, 75% had
normal cardiac markers concentrations.
Table 1 (opposite). Shows the demographic data of patients with non-Q wave
MI, UA and anginal/atypical chest pain. Abbreviations: UA, unstable angina;
MI, myocardial infarction; SD, standard deviation; CABG, coronary artery
bypass grafting; PCI, percutaneous coronary intervention; DM, diabetes
mellitus; HTN, hypertension; FHX of IHD, family history of ischaemic heart
disease; HR, heart rate; BP, blood pressure; ST, T, Q, are ST segment, T wave
segment and Q wave segment of the electrocardiogram (ECG); NS, not
significant. See text for explanation.
192
Demographic data Non-Q wave MI UA Angina/atypical P value
Group I Group 2 Group 3
No. Patients 14 20 21
Age (years) 67.36 ± 11.34 67.45 ± 12.31 64.55 ± 9.54 NS
Sex:
Male 9(64) 16 (80) 12 (57) NS
Female 5(36) 4(20) 9(43) NS
Time to presentation (hours) 5.3 ± 1.28 5.63 ± 1.17 5.0 ± 1.95 NS
Previous cardiac history:
Angina 9(64) 10(50) 15(71) NS
UA 3(21) 3(15) 4(19) NS
AMI 6(43) 10 (50) 8(38) NS
CABG 5(36) 2(10) 5(23) NS
PCI 4(29) 2(10) 3(14) NS
Riskfactors:
DM 2(14) 3(15) 2(10) NS
HTN 5(36) 4(20) 3(14) NS
Smoking:
Smoker 5 (36) 3(15) 9(43) NS
Ex-smoker 1(7) 8(40) 2(10) NS
Non-smoker 8(57) 9(45) 10(48) NS
High cholesterol 10(71) 9(45) 13 (62) NS
FHx oflHD 3(21) 1(5) 6(29) NS
Haemodynamics at
admission:
HR 75.56 ± 17.99 66.92 ± 11.18 77.0 ± 16.35 NS
Systolic BP 133.22 ±34.26 151.92 ± 17.93 134.67 ± 10.49 0.024
Diastolic BP 71.44 ± 18.44 74.92 ± 11.7 79.0 ± 13.99 NS
Chest pain:
Typical ischaemic pain 13 (93) 17(85) 13 (62) 0.027
Atypical chest pain 1(7) 3(15) 8 (38)
ECG changes at admission:
Transient ST elevation 3(21) 2(10) 1 (5)*
ST depression 7(50) 7(37) 0
T wave changes 2(14) 7(37) 3(14)
Other ECG changes 1(7) 1 (5) 2(10)
No acute changes 1(7) 2(10) 15(71)
Old Q waves present 1(7) 5(25) 6(29)
ECG leads involved:
Anterior 1 (7) 8 (40) 1 (5)
Inferior 4(29) 5(25) 1 (5)
Anterior-lateral 3(21) 0 0
Inferior-lateral 1(7) 1 (5) 1 (5)
Posterior 1(7) 0 0
Lateral 2(14) 3(15) 1 (5)
Treatment:
Pharmacologic + PCI 3(21) 5(25) 1 (5)
Pharmacologic - PCI 11 (79) 15 (75) 20 (95)
Hospital stay:
Average admission (days) 8.57±3.69 5.21±2.95 3.95±2.16 0.0005
Total duration (days) 120 102 80
Table 1. Shows the demographic data of patients in this group.
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The serial concentrations of CK-MB mass, cTnl, cTnT, H-FABP, and myoglobin in
the non-Q wave MI group are shown in Table 2, and are represented graphically in
Figure 2. The concentrations of these markers were markedly elevated and showed
significant concentration changes over time. Heart-FABP and myoglobin peak
concentrations were achieved at 2 hours and the concentrations of these markers had
decreased to normal levels at 16 - 24 hours after presentation. For CK-MB mass, the
peak concentration occurred at 8 - 10 hours. The maximum increase in cTnl and
cTnT occurred late at 16 - 24 hours (Table 2). The concentrations of CK-MB mass,
cTnl, and cTnT were still present in significant levels at 16-24 hours. Most of the
patients in this group had typical history of ischaemic chest pain (93%), and positive
ECG changes of ischaemia (ST segment shift or T wave inversion) were present in
86% at or during admission.
Of the 20 patients in the UA group, 85% presented with typical history of ischaemic
chest pain, and 84% had ST-T segment changes of ischaemia on the ECG at or
during admission (Table 1). The concentrations (mean ± SD) of cardiac markers in
the UA group are shown in Table 3 and are represented graphically in Figure 3. The
release patterns of cardiac markers in patients with UA followed closely those seen
in patients with non-Q wave MI. Flowever, the maximum concentration rise of these
markers was only a small fraction of that seen in patients with non-Q wave MI
(compare Table 2 and Table 3). There were significant concentration changes over
time for the groups of patients that had elevated cardiac markers concentration as
reflected by low probability values (Table 3). The concentrations of cardiac markers
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in UA and non-Q wave MI groups were not directly related to either the severity of
chest pain or to the types of ischaemic ECG changes at admission.
P value
Marker(s) Ohr 2hrs 4hrs 8-10hrs 16-24hrs
CK-MB mass (mean) 26.16 43.82 68.48 94.41 48.85
0.0005
± SD (ug/l) 24.89 31.55 49.09 63.55 37.67
CTnl (mean) 4.53 8.09 10.27 17.66 19.66
0.0005
± SD (ug/l) 4.78 7.37 6.69 15.62 17.07
CTnT (mean) 0.56 0.89 1.21 1.69 2.41
0.0001
± SD (ug/l) 0.55 0.85 1.19 1.31 1.53
Myoglobin (mean) 291.71 347.57 338.79 284.29 173.79
0.001
± SD (ug/l) 208.03 212.00 214.95 254.62 145.52
H-FABP (mean) 46.79 124.36 110.86 93.21 33.41
0.007
± SD (ug/l) 35.94 117.77 99.39 79.71 29.87
Table 2. This table shows cardiac markers concentrations (mean ± SD) in the
non-Q wave MI group at 0, 2, 4, 8 - 10, and 16-24 hours after presentation.
These values are represented graphically in Figure 2. There were significant
cardiac marker concentration changes over time as reflected by the very low
probability values.
Early exclusion ofacute myocardial infarction
The importance of concomitant serial cardiac markers testing in this group is
illustrated in the following example: This was a 60 years old man who had had
previous MI. He had a transurethral resection of the prostate 3 weeks prior to
admission. The admission ECG showed Q waves, with ST elevation < 2 mm
anteriorly. The diagnosis was thought to be STEMI and he was considered a
candidate for thrombolytic therapy. Due to some concerns regarding recent surgery
and the absence of reciprocal ST segment depression, he was treated with non-
thrombolytic pharmacologic agents instead. An echocardiogram revealed a large
anterior apical aneurysm. The ST elevation in this patient could be due to UA, non-Q
195
wave MI, evolving ST elevation MI, or a misleading sign due to the aneurysm itself.
He presented within 6 hours after symptom onset, which was sufficient time for
some of the early markers to appear in blood. Normal H-FABP or myoglobin
concentration at admission would rule out AMI reliably.
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Figure 2 continued on page 197.
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Figure 2. These graphs illustrate the release pattern of CK-MB mass, cTnl,
cTnT, H-FABP, and myoglobin in patients with non-Q waveMI.
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All five cardiac markers measured at admission were normal. By doing serial cardiac
markers testing, it was clear that this patient's symptoms were most probably due to
UA rather than AMI (cTnl = 0.3 p.g/1, cTnT = 0.14 pg/1, myoglobin, H-FABP and
CK-MB mass were all normal). Thus, the more serious diagnoses could be ruled out
early, and this would avoid any confusion of treatment. This patient requires
antithrombotic and antiplatelet treatment and not thrombolytic therapy. This example
also illustrates the superior sensitivity of cardiac troponins for the diagnosis of UA
compared to the less specific markers like CK-MB mass, myoglobin, and H-FABP.
P value
Marker(s) Ohr 2hrs 4hrs 8-10hrs 16-24hrs
CK-MB
mass 3.57 4.48 4.20 3.82 3.24
0.001
± SD (ug/l) 2.86 3.92 3.60 3.09 1.82
CTnl 0.14 0.22 0.29 0.30 0.26
0.015
± SD (ug/l) 0.12 0.19 0.25 0.24 0.23
CTnT 0.07 0.07 0.11 0.12 0.14 0.001
± SD (ufl/1) 0.06 0.07 0.09 0.10 0.13
Myoglobin 78.70 94.20 91.70 76.45 65.60 0.001
± SD (ug/l) 53.65 79.62 74.65 49.53 31.94
H-FABP 16.25 26.50 20.55 19.27 11.33 0.007
± SD (ug/l) 14.33 23.50 18.51 15.07 8.06
Table 3. This table shows cardiac markers concentrations (mean ± SD) in the
UA group at 0, 2, 4, 8 -10, and 16 - 24 hours after presentation. These values are
represented graphically in Figure 3. There were significant concentration
changes over time for all markers in the groups with elevated concentration.
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Figure 3. These graphs illustrate the release pattern of CK-MB mass, cTnl,
cTnT, H-FABP, and myoglobin in patients with UA.
Twenty-one patients were included in the anginal/atypical chest pain group. The
majority of patients had previous cardiac events. From a clinical point of view, these
patients will be in a high clinical category of suspicion for ACS if they present with
chest pain. Sixty-two per cent had typical ischaemic chest pain at presentation, but
38% of patients had atypical chest pain. Comparatively, there were fewer ECG
changes in this group compared to patients in the UA and non-Q wave MI groups.
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Only 28% had mild ECG changes of ischaemia (three patients had mild T wave
flattening or T wave inversion < 1 mm, one patient had old ST elevation, and two
patients had transient conduction abnormalities). Table 4 and Figure 4 illustrate the
release patterns of the different cardiac markers in this group. The concentrations of
these markers remained below the diagnostic thresholds throughout the sampling
period. Only one patient had mildly elevated H-FABP concentration (24 pg/1). It can
be seen from Table 4 that irrespective of the clinical history or the minor ECG
changes, cardiac markers testing can reliably rule out serious myocardial damage
very early after admission.
Marker(s) Ohr 2hrs 4hrs 8-10hrs 16-24hrs P value
CK-MB
mass 1.89 1.95 1.97 1.97 1.91
0.204
± SD (ujj/I) 0.83 0.81 0.82 0.91 0.84
CTnl 0.03 0.03 0.03 0.03 0.03
0.664
± SD (nq/l) 0.02 0.02 0.02 0.02 0.01
CTnT 0.01 0.01 0.01 0.01 0.01
0.077
± SD (jxg/l) 0.01 0.01 0.01 0.01 0.01
Myoglobin 46.90 45.38 45.67 43.80 45.19
0.525
± SD (ug/|) 14.38 13.60 15.64 13.92 14.73
H-FABP 7.33 6.67 8.22 7.78 5.89
0.837
± SD (ng/l) 5.00 4.53 6.53 7.14 5.35
Table 4. This table shows cardiac markers concentrations (mean ± SD) in the
anginal/atypical chest pain group at 0, 2, 4, 8 - 10, and 16 - 24 hours after
presentation. These values are represented graphically in Figure 4. There were
no significant concentration changes over time as reflected by probability values
> 0.05.
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Figure 4 continued on page 203.
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Figure 4. These graphs illustrate the release pattern of CK-MB mass, cTnl,
cTnT, H-FABP, and myoglobin in patients in patients with anginal/atypical
chest pain.
The values of serial cardiac markers testing in decision-making regarding patients'
management will be highlighted by describing two examples from the
atypical/anginal chest pain group.
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MildECG changes and early pre-discharge exercise tolerance test
This was a 58 years old lady with multiple risk factors. She had typical presentation
with ischaemic chest pain, which lasted more than five hours. The ECG showed mild
T wave inversion in VI, III, and aVf. Initially she was treated as a case of UA with
pharmacologic agents. The next day of admission when all the informations
including cardiac markers results were available, it became clear that she did not
suffer any serious cardiac insult. The repeat ECGs revealed that the T wave inversion
was an old finding and remained unchanged and the routine cardiac markers were
normal. She underwent an exercise tolerance test that was normal as well. She was
discharged following all these reassuring investigations. Cardiac markers
concentrations were normal in all samples, which would have ruled out any
underlying serious cardiac damage soon after presentation. This information may be
utilised to plan management. An exercise tolerance test could have been arranged
earlier and this would have shortened the duration of admission (5 days).
Avoiding unnecessary invasive investigations
Another example of mild T wave changes on admission was a lady with a clear
history of crescendo angina, which lasted for more than one hour. She was treated as
UA with pharmacologic agents. Routine cardiac markers results the next day were
normal including CK and cTnl. She underwent coronary angiography, which showed
normal coronaries. Serial cardiac markers testing in this patient were completely
normal throughout the 24 hours sampling period. In this patient who is considered at
low-risk of further ischaemic events, investigation by invasive coronary angiography
in the first instance is not warranted. Less invasive investigations e.g. exercise
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tolerance test during admission or as an outpatient may be more appropriate. Serial
testing at admission may help guide the use of coronary angiography to the most
appropriate group of patients at high-risk from further ischaemic events.
The sensitivities of cardiac markers for the detection of high-risk patients with non-Q
wave MI and UA at 0 hour, 2 hours, 4 hours, 8-10 hours, and 16-24 hours after
presentation, using two different cut-off concentrations (as described in Chapter 4
pages 120 - 122) are shown in Table 5. Table 5A and 5B illustrate the sensitivities of
cardiac markers using the following cut-off concentrations, CK-MB mass >5.0 pg/1,
cTnl >0.18 p.g/1, cTnT > 0.1 pg/1, H-FABP >16 pg/l, and myoglobin > 95 p.g/1.
These cut-off concentrations discriminate (based on ROC curve analysis) patients
with myocardial injury (UA and NSTEMI) and patients without myocardial injury
(healthy blood donors, normal controls and atypical/anginal chest pain group).
Table 5A shows the sensitivities of cardiac markers for the diagnosis of patients with
non-Q wave MI during the first 24 hours after presentation. Heart-FABP was the
most sensitive early marker with almost 80% of patients showing elevated
concentrations at presentation. The sensitivity had increased to 93% at 2 hours, and
remained elevated at this level for the next 8-10 hours. The sensitivity had
decreased to 64% at 16-24 hours. Myoglobin was the second most sensitive early
marker with 71% of patients in the non-Q wave MI group showing elevated
concentrations (> 95 p.g/1) at presentation. The sensitivity increased to 93% at 2
hours, and then gradually dropped to 71% over 16-24 hours. The sensitivity of
myoglobin and H-FABP were similar between 2 and 4 hours (93%).
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The sensitivity of cTnl at presentation was 67%. However, cTnl reached 100%
sensitivity 2 hours later, and remained at this high level throughout the 16 - 24 hours
sampling period. Cardiac-TnT and CK-MB mass sensitivities were similar at
presentation (64%), but the maximum sensitivity for CK-MB mass (93%) and cTnT
(100%) were reached at 2 hours and 16-24 hours respectively (Table 5A). The
sensitivities of these markers for the diagnosis of myocardial injury in patients with
UA are shown in Table 5B. Cardiac-Tnl was the marker that showed the most
abnormal values. Fifty-five per cent of patients had elevated cTnl >0.18 jag/1.
Cardiac-TnT (> 0.1 pg/1) and H-FABP (>16 pg/1) detected myocardial injury in
40% of patients with UA. The sensitivity of CK-MB mass and myoglobin was 30%
and 25% respectively. The peak sensitivity of H-FABP for the diagnosis of UA was
achieved early at 2 hours, whereas the peak sensitivity of all other markers occurred
more than 4 hours after presentation (Table 5B).
Table 5C and 5D show the sensitivity using different cut-off concentrations that best
discriminate (based on ROC curve analysis) patients with UA from patients with
NSTEMI. These cut-off concentrations were, CK-MB mass > 8 pg/1 [sensitivity =
81%, specificity = 81.5%], cTnl > 0.6 pg/1 [sensitivity = 89.9%, specificity =
87.6%], cTnT > 0.4 pg/1 [sensitivity = 80%, specificity = 80%], myoglobin > 107.5
pg/1 [sensitivity = 80%, specificity = 80.4%], and H-FABP > 21.5 pg/1 [sensitivity =
72.5%, specificity = 70.7%]. The sensitivities of these markers for the diagnosis of
non-Q wave MI are shown in Table 5C. As shown in Table 5C and 5A, the overall
sensitivity pattern of myoglobin (> 107.5 pg/1) was not much different with respect
to these two different cut-off concentrations.
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The overall sensitivity of CK-MB mass (> 8 jug/1) and cTnl (> 0.6 jug/1) remained
unchanged compared with Table 5A. There was two hours delay in the maximum
sensitivities reached by CK-MB mass and cTnl (4 hours vs 2 hours) and a drop in
sensitivity towards 16-24 hours (86% and 93% respectively). There was some drop
in the overall sensitivity of cTnT for the diagnosis of non-Q wave MI with cut-off
concentration > 0.4 pg/1 (93% vs 100%). The sensitivity of H-FABP at presentation
and 8-10 hours was reduced with cut-off concentrations exceeding 21.5 pg/1 (71%
vs 79% and 64% vs 93%), but the early sensitivity at 2 hours was relatively
unchanged.
Table 5D, shows the percentages of patients with UA that would be misclassified as
non-Q wave MI (false positive rate), using these cut-off concentrations. Twenty-five
per cent (25%) of patients admitted with UA would fulfil the diagnostic criteria to be
classified as non-Q wave MI based on CK-MB mass and cTnl. Only a small number
of patients (10%) would be classified as non-Q wave MI using cTnT. There was little
change in the sensitivity of H-FABP in the range 16-21.5 pg/1 with forty per cent of
patients with UA having concentration > 21.5 pg/1 i.e. high number of 'false
positive' classification for non-Q wave MI. There was also little improvement on the
specificity of H-FABP from using concentrations more than three times the upper
limit of normal (36 pg/1). Based on ROC curve analysis, a discriminatory cut-off
concentrations of H-FABP > 21.5 pg/1 had a sensitivity of 72.5% and specificity of
70.7% only, for the diagnosis of non-Q wave MI. Selecting a higher cut-off
concentrations (e.g. 36 pg/1) decreased the sensitivity significantly (62.5%).
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The small numbers of patients in this group may have partly contributed to this
problem. Despite the small overlap, there was still a significant difference between
the concentrations of H-FABP in patients with UA and patients with non-ST
elevation MI and ST elevation MI, which reflects an increase in myocardial injury in
these conditions. The mean concentration (± SD) of H-FABP in patients with UA,
non-ST elevation MI and ST elevation MI was 28.27 ± 19.62 pg/1 [range 19-62
jj.g/1], 165.36 ± 128.74 pg/1 [range 17 - 431 pg/1], and 373.66 ± 244 pg/1 [range 20 -
1184 pg/1] respectively. Animal studies provide evidence to support large releases of
H-FABP with larger areas of myocardial ischaemia.39 As compared with H-FABP,
myoglobin (> 107.5 pg/1) was equally sensitive (71%) but more specific (20% false
positive rate) for the diagnosis of non-Q wave MI, but its sensitivity for the diagnosis
ofUA was less than H-FABP (25% vs 40%).
Table 5A. IV on-Q wave MI group
Marker(s) Ohr 2 hrs 4 hrs 8-10 hrs 16-24 hrs
CK-MB 64 93 93 93 93
CTnl 61 100 100 100 100
CTnT 64 79 79 86 100
Myoglobin 71 93 93 79 71
H-FABP 79 93 93 93 64
Table 5B. UA group
Marker(s) Ohr 2 hrs 4 hrs 8-10 hrs 16-24 hrs
CK-MB 20 25 30 25 20
CTnl 35 40 55 55 45
CTnT 15 20 35 40 30
Myoglobin 20 20 20 25 25
H-FABP 30 40 30 30 17
Table 5A and 5B. Shows the sensitivities of the various cardiac markers for
the diagnosis of non-Q wave MI and UA at 0, 2, 4, 8 - 10, and 16 - 24 hours after
presentation, using the following concentrations CK-MB mass > 5 pg/1, cTnl >
0.18 pg/1, cTnT > 0.1 pg/1, H-FABP > 16 pg/1, and myoglobin > 95 pg/1.
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Table 5C. IN on-Q wave MI group
Marker(s) Ohr 2 hrs 4 hrs 8-10 hrs 16-24 hrs
CK-MB 64 79 93 93 86
CTnl 64 86 100 100 93
CTnT 50 71 71 86 93
Myoglobin 71 93 86 79 71
H-FABP 71 93 79 64 57
Table 5D. UA group
Marker(s) Ohr 2 hrs 4 hrs 8-10 hrs 16-24 hrs
CK-MB 15 20 25 20 20
CTnl 10 15 25 20 15
CTnT 0 0 5 10 10
Myoglobin 20 20 20 20 20
H-FABP 25 40 30 30 10
Table 5C and 5D. Table 5C shows the sensitivities of the various cardiac
markers for the diagnosis non-Q wave MI, at 0, 2, 4, 8 - 10, and 16 - 24 hours
after presentation, using the following concentrations CK-MB mass > 8 jj.g/1,
cTnl > 0.60 jig/1, cTnT > 0.40 p.g/1, H-FABP >21.5 jixg/I, and myoglobin > 107.5
pg/1. Table 5D shows the number of patients with UA that would fulfil the
diagnostic criteria for non-Q wave MI (false positive results).
The value of serial cardiac markers testing for the diagnosis ofmyocardial infarction
in patients without the classical ST segment elevations on the ECG will be illustrated
by several examples. It will be made clear from these examples the importance that
rapid (within 15 minutes) cardiac markers testing availability will have on clarifying
the diagnosis and influencing appropriate decisions in the management of these
patients. These examples will concentrate on common situations in the A&E
department, where either the clinical history is atypical or the admission ECG shows
ST-T segment changes that are inconclusive or difficult to interpret.
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Non-diagnostic initial ECG
In one patient, a 61 years old lady with extensive cardiac history who presented with
atypical chest pain, the admission ECG showed 1.5 mm ST segment elevation in lead
III only, with ST depression in lead I and AVL. Initially she was admitted to CCU
and treated as a case ofAMI with streptokinase. Later, it was thought that she did not
sustain an AMI and instead this was a significant episode of UA and the treatment
was discontinued. Cardiac markers results suggested that this patient had suffered an
AMI [CK-MB mass - 27 pg/1, cTnl = 13.37 pg/1, cTnT = 1.05 pg/1, H-FABP = 40
gig/1 and myoglobin = 354 pg/1]. At 2 hours after presentation the concentration of
cTnl was 1.26 pg/1, H-FABP was 24 gig/1 and myoglobin was 137 pg/1, and at 4
hours cTnl had risen to 3.64 pg/1, H-FABP to 40 pg/1, myoglobin to 307 pg/1 and
CK-MB mass to 13 pg/1. This patient was kept in hospital for 7days.
This case highlights a relatively common situation and a diagnostic dilemma. That is
when significant ST segment elevation is present in one lead only. The significance
of this elevation is even more difficult to interpret when the patient presents for the
first time and had no prior ECGs recording. This ECG change could represent a large
AMI in evolution, a small MI involving limited territories, UA or an old finding. The
availability of rapid cardiac markers results would help resolve this confusion and
influence management decisions. The following ECG changes at admission were
also other examples from this study, where concomitant serial cardiac markers
testing have contributed significantly towards clarifying the early diagnosis ofMI in
these patients; (1) Transient ST segment elevation; (2) Mild ST segment elevation <
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1 mm; (3) Marked ST segment depression; (4) Deep T wave inversion; and (5) Poor
R wave progression.
Presentation prior to release ofdiagnostic levels ofcardiac markers
Another example of equivocal ST segment elevation was a 65 years old man with
multiple risk factors who presented with two weeks history of worsening chest pain.
The last episode of chest pain was one hour before presentation. The ECG revealed 1
mm ST segment elevation anteriorly, ST segment depression laterally, ECG voltage
criteria for left ventricular hypertrophy with strain pattern, and T wave inversion
inferiorly. He also had mild pulmonary oedema. The interpretation of the ECG was
difficult because of the changes due to left ventricular hypertrophy. The
interpretation of subtle ST elevation was also difficult. These ECG changes were
considered insufficient criteria for thrombolytic therapy and the patient was treated
with pharmacological agents without percutaneous coronary intervention.
He developed acute shortness of breath shortly after admission and proceeded to
coronary angiography. Coronary angiography showed occlusion of the left anterior
descending artery, with two further severe lesions in the right coronary artery and the
left circumflex artery. Cardiac markers concentrations in this patient on arrival were
almost normal. At 2 hours, cardiac markers concentrations had risen considerably
CK-MB mass = 50.7 pg/1, cTnl = 8.72 pg/1, cTnT = 0.82 pg/1, H-FABP (peak
concentration) = 431 jug/1 and myoglobin > 900 pg/1. Four hours later, CK-MB mass
increased to 80.2 pg/1, cTnl > 50 pg/1, cTnT = 1.9 pg/1, H-FABP = J,344 p.g/1 and
myoglobin = 1843 pg/1. The absence of abnormal concentrations at presentation is
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consistent with the very early presentation of this case (one hour). Heart-FABP
showed a significant early peak (within 3 hours) compared with other markers
including myoglobin. The ECG was unhelpful for the diagnosis myocardial
infarction in this patient because of the presence of confounding changes due to left
ventricular hypertrophy. Serial cardiac markers testing would have established the
diagnosis shortly after admission and permitted appropriate therapy to be
implemented within 3 hours after symptoms onset.
Patients with major conduction disorders on the ECG
One patient with acute chest pain had left bundle branch block that was not a new
finding and was present in old ECGs. He had poor left ventricular function and
severe three vessel disease with occluded left anterior descending artery and right
coronary artery that were considered unsuitable for any form of intervention. This
old conduction abnormality made interpretation of the admission ECG very difficult.
Cardiac markers were significantly increased at presentation [CK-MB mass =150
pg/1, cTnl > 50 pg/1, cTnT = 4.18 pg/i, H-FABP = 26 pg/l, and myoglobin = 527
pg/1]. The measurements of cardiac markers in this situation had clarified the
diagnosis. The cardiac markers concentrations profile at presentation (i.e. high cTnl
and low H-FABP) is consistent with a diagnosis of an earlier AMI event (>12 hours
old).
Previously documented coronary artery disease but uncertain recent events
This was a 63 years old man with extensive previous cardiac history (CABG, redo
CABG, PCI, three previous Mi's, and left ventricular failure) who presented with
212
typical history of ischaemic pain unresponsive to usual medications.
Electrocardiogram showed an old partial conduction abnormality. He was admitted
and treated for UA with pharmacologic agents. The ECG changes later evolved to
lateral T wave inversion. He experienced recurrent chest pains and proceeded to
coronary angiography, which showed re-stenosis of saphenous vein grafts to obtuse
marginal and left circumflex artery branches. He was treated with PCI. Routine CK
and cTnl were markedly elevated at 494 IU/L and 14.7 pg/1 respectively. The value
of serial cardiac markers testing in clarifying the significance of these ECG changes
can be demonstrated in this patient.
At presentation, cardiac markers concentrations in this patient were normal. At 2
hours myoglobin and H-FABP were significantly elevated at 285 pg/1 and 49 p.g/1
respectively but cTnl and cTnT were only slightly elevated at 0.33 pg/1 and 0.103
pg/1 respectively. At 4 hours, significant rises had occurred in CK-MB mass, H-
FABP, and myoglobin 26.2 pg/1, 99 p.g/1, and 587 jLxg/1 respectively, whereas cTnl
was 0.95 p.g/1 and cTnT was 0.169 ju.g/1. Eight hours after presentation, most cardiac
markers concentrations were significantly elevated (CK-MB mass = 81.7 p.g/1, cTnl
= 4.38 pg/1, H-FABP = 123 p.g/1 and myoglobin = 585 pg/1). At 19 hours after
presentation, there were even more significant increases in these markers [CK-MB
mass = 131.4 jtg/1, cTnl = 21.99 jug/1, cTnT = 2.22 ptg/1] and myoglobin and H-
FABP concentrations had decreased to 169 pg/1 and 24 ptg/1 respectively. This
example clearly illustrates the early release and clearance characteristics features of
H-FABP (and myoglobin) compared to other markers.
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Patients with posterior myocardial infarction
The accurate early diagnosis of posterior MI is sometime difficult to identify from
the 12-lead ECG. The changes may be subtle and sometimes more investigations are
needed to clarify this diagnosis e.g. V7 - V8 leads or echocardiogram. In the next
example an eighty-three years old lady was admitted with ischaemic chest pain but
the ECG changes on admission were thought to reflect UA and she was treated with
pharmacologic agents without PCI. The retrospective interpretation of these ECG
changes in light of routine cardiac markers results was considered as possible
posterior infarct (CK = 645 IU/L and cTnl = 20 pg/1). Serial cardiac marker
concentrations in this patient were significantly elevated at presentation (CK-MB
mass = 36.6 pg/1, cTnl = 20.84 pg/1, cTnT = 3.41 pg/1, H-FABP = 17 pg/1 and
myoglobin = 190 pg/1). It is worth noting that apart from cTnT that continued to
increase in subsequent samples (3.41—> 4.33 pg/1), the maximum value for the other
markers occurred at presentation. The low H-FABP concentrations and elevated cTnl
suggested delayed presentation or ongoing subclinical ischaemic events prior to
presentation. This case illustrates the difficulty of diagnosing possible posterior MI
and the additional diagnostic benefit of using serial cardiac marker testing in this
situation.
Detection ofre-infarction
This was a 75 years old man with extensive previous cardiac history who was
admitted with mild atypical chest pain and severe congestive cardiac failure (CCF).
He was treated with continuous positive airways pressure and inotropic support.
Initially, he made some clinical improvement, but he deteriorated a few days later,
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became acidotic and developed acute mesenteric infarction. He died 18 days after
admission. The cardiac markers concentration profiles in this patient were very
informative. Although he initially presented with chest pain as well as CCF, the chest
pain was only a minor complaint and was overshadowed by CCF, which was the
more dominant presenting feature. The ECG at presentation was normal. He was
treated as a case of severe CCF. As early as 2 hours after presentation, the cardiac
markers concentration profile in this patients were suggestive of MI with CK-MB
mass concentration of 27.7 pg/1 rising to > 150 pg/1, cTnl 3.25 pg/1 rising to 32.47
pg/1, cTnT 0.649 p.g/1 rising to 5.04 pg/1, H-FABP of 122 pg/1 rising to 441 pg/1, and
myoglobin 861 pg/1 rising to 1815 pg/1.
Further analysis of the time-concentration profile of cardiac markers H-FABP and
myoglobin suggests that this patient may have suffered re-infarction shortly after the
first infarct. This was reflected by a significant drop in concentrations in the third
sample following two initial successive increases and was followed by two further
increases. Such drop in concentration was not found with CK-MB mass and
troponins, which showed progressive increases in all samples. Congestive cardiac
failure may contribute some of the increases in cardiac markers concentrations.
However, with concentrations as high as this, it most probably indicates underlying
severe ischaemic damage, and the CCF may be a consequence of this initial
ischaemic insult.
All these cases highlight the importance of concomitant serial cardiac markers testing
for clarifying the diagnoses and influencing further management in situations where
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there is a high clinical suspicion of ACS in the presence of unhelpful ECG changes.
A preliminary cost effective analysis of serial cardiac markers testing in evaluating
patients with acute chest pain was performed. In this study, fifty-five patients were
admitted to hospital and in every patient five serial blood samples were collected
during the first 24 hours. In each sample five cardiac markers were analysed. The
total cost of analyses for the whole group (1375 tests) was approximately £4500.
This figure includes assays and all the quality controls and calibrator reagents
required to run these analyses. In clinical practice, the analysis can be reduced to two
markers at two intervals (or a maximum of three, depending on the duration between
symptoms onset and presentation) during the first 8 hours of presentation. This will
result in a further substantial reduction of the cost of these analyses by approximately
80%. Serial cardiac markers testing are reliable and will identify high-risk patients
with UA and non-Q wave MI and rule out myocardial damage within 8 hours after
presentation.
Based on informations obtained from the hospital financial department, the estimated
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consumable cost of hospital stay for the whole group was approximately £29,596.
This was only a conservative estimate, because it excludes the cost of specialised
investigations such as coronary angiography, thallium scan, computerised
tomography scan, ventilation - perfusion scan and also excludes specialised treatment
e.g. antiplatelet drugs and angioplasty procedures. Table 6 shows the average cost of
analyses in each group and the estimated cost reduction. Implementation of cardiac
markers testing will result in a reduced cost of in-hospital care by approximately
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34%. This reduction in cost is mostly due to a reduction in hospital stay, as a result of
early identification and management. The greatest reduction in cost (60%) is
expected in group 3 as a result of early rule out of ACS, reduction in the number of
investigations, and early discharge of low-risk patients [maximum hospital stay 1 - 2
day]. Early identification and better management may reduce the average hospital
stay for uncomplicated patients with UA [3-4 days]. Early diagnosis, treatment, and
implementation of post-MI care in patients with NSTEMI may also reduce hospital
stay. The cost reduction in the non-Q wave MI group was based on an average












Group 1 8.57 ±3.69 120 11,760 229 2156(18)
Group 2 5.21 ±2.95 102 9,996 327 3136(31)
Group 3 3.95 ±2.16 80 7,840 275 4753 (60)
Total ~ 302 29,596 831 10,045 (34)
Table 6. Shows the estimated cost reduction for the whole groups based on
serial cardiac markers analyses using an early marker and cardiac specific
marker.
6.4 DISCUSSION
As shown in this study, and depending on threshold concentration used, the
incorporation of serial cardiac markers testing, using H-FABP, myoglobin, CK-MB
mass or cTnl in patients who present with non-Q wave MI within 7 hours after
symptom onset, can diagnose 93 - 100% of patients (Table 5A), or 79 - 93% (Table
217
5C) within 2 hours of presentation. Heart-FABP was the most sensitive indicator of
myocardial injury and was increased in a substantial numbers of patients (79%) at
presentation. The maximum sensitivity achieved for myoglobin at presentation was
71%. However, the sensitivity of both markers at 2 hours was similar (93%). Heart-
FABP was either equally sensitive or superior to myoglobin for the early diagnosis of
non-Q wave MI (Table 5A and 5C).
The sensitivity of all other markers including cTnl, CK-MB mass, and cTnT at
presentation was low and ranged from 50 - 67%. Their value for the early rule in of
patients with non-Q wave MI was limited. Their sensitivity was considerably lower
than that of H-FABP. These differences are related to the early release characteristic
feature of H-FABP and the short time between symptom onset and presentation. The
sensitivity and the early release characteristics of cTnl were found in this study to be
superior to that of cTnT and CK-MB mass. Cardiac-Tnl was highly reliable [100%
sensitive] for the diagnosis of non-Q wave MI after four hours of presentation. These
variations may be due to the superior sensitivity of cTnl on Stratus CS, which allows
earlier detection of small amounts of this mass protein in serum following release
from the myocardial cells. This early release feature of cTnl supports the presence of
cytosolic pools for cTnl within myocardial cells.
The major influences found from using low diagnostic cut-off concentrations that
were based on normal controls groups (a common method used in many clinical
studies) to diagnose patients with non-Q wave MI, were an improvement in the early
and overall sensitivity (5A), on the expense of specificity. Some patients with UA
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will be misclassified as non-Q wave MI (5B). This problem was reduced
considerably by using two different threshold concentrations that best define
myocardial injury for UA and non-Q wave MI groups (5C and 5D).
Cardiac-Tnl and cTnT were the two most sensitive markers [55% and 40%
respectively] for the detection of myocardial injury in patients with UA. Heart-FABP
showed a high positive value in UA (40%) as well, and was low in normal coronary
patients having chest pain (10%). Its sensitivity was comparable to that of cTnT, but
was superior to CK-MB mass and myoglobin. There was however, some overlap
between the concentrations of H-FABP in non-Q wave MI and UA groups. It was
difficult to draw a clear distinctive cut-off concentration that will reliably
discriminate both conditions without severely affecting the sensitivity as well.
When early differentiation of non-Q wave MI from UA is required, concentrations of
H-FABP equivalent to five times the upper limit of normal (51.5 pg/1) can be used.
This high cut-off concentration was associated with more than 90% specificity, albeit
at a rather reduced sensitivity (57%) for the diagnosis of non-Q wave MI. The use of
this high threshold does not compromise the early value of H-FABP, because these
diagnostic concentrations were reached within 2 hours after presentations (8 hours
after symptom onset). Alternatively, H-FABP concentrations (> 16 p.g/1 - < 21.5
pg/1) and (> 21.5 p.g/1) may be combined with cardiac troponins to increase its
specificity for the diagnosis of UA or non-Q wave MI respectively. Concentrations
between 0.18 - 0.6 pg/1 for cTnl and 0.1 - 0.4 p.g/1 for cTnT are sensitive (> 80 -
85%) and specific (> 80 - 83%) for the diagnosis ofUA in these patients.
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The frequency of H-FABP elevations in patients presenting with UA and
atypical/anginal chest pain were similar to that reported by Tsuij et al (1993). They
reported that 56% and 17.8% of patients with UA and chest pain syndrome
respectively had elevated H-FABP concentrations. The concentration of H-FABP in
patients with UA was also lower than the concentration in patients with AMI.49 The
sensitivity of myoglobin for the early diagnosis of non-Q wave MI in this study
(93%) was similar to the sensitivity reported by Gornall et al (1996). They reported
the sensitivity and specificity of myoglobin within eight hours after symptom onset
for the diagnosis ofNSTEMI to be 93% and 100% respectively.52
Subtle changes of ischaemia on the admission ECG (such as minimal ST elevation <
1 mm, transient ST elevation, significant ST elevation in one lead only, suspected but
not evident changes of posterior MI, marked and deep T waves inversion, poor R
wave progression and conduction abnormalities e.g. left bundle branch block) were
common. The diagnostic power of the ECG alone in these circumstances was
limited. These ischaemic ECG changes may be considered non-specific and
insufficient to influence definitive diagnosis or treatment. However, when these ECG
changes are present in combination with positive cardiac markers concentrations
consistent with very early infarction, the evidence is shifted in favour ofMI and may
be towards an early implementation of reperfusion therapy in some of these patients.
It is worth noting that most of these patients were initially diagnosed and treated as
severe case of UA with non-thrombolytic pharmacological agents. The diagnosis of
non-Q wave MI in these patients was retrospective and was evident 12-24 hours
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after admission, from routine cardiac markers results. The hospital stay for this group
ofpatients was considerably long.
The reliance on clinical judgment and ECG changes alone is not sufficient to
diagnose MI in some groups of patients without the classical ST segment elevation
Mi.30,31 ;50;56 patients are put at risk from being misdiagnosed and subsequently
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given inappropriate treatment and care. There was no consistent relation between
the types of ST-T segment changes on the admission ECG and the degree of cardiac
markers elevations. This adds to the poor specificity of the ECG for predicting the
significance of myocardial damage. Serial testing of two cardiac markers at two
intervals within 8 hours of presentation can identify most patients with early
myocardial infarction, irrespective of the subtlety of ischaemic changes on the
admission ECG. The earliest evidence of myocardial damage that can be detected
using serial markers testing was present in 93 - 100% of patients within 2 hours after
presentation. This early identification of myocardial damage will have important
implications for the triage and management of these patients.
'Q wave MI' and 'non-Q wave MI' are considered old terminology. These two terms
are not thought to represent two distinct medical conditions.32"34 Phibbs et al (1999)
had recently reviewed nine major studies. They concluded that from a clinical,
pathological and electrocardiographic point of view, these two terms are meaningless
and should be an obsolete. They ascribed the continuous use of the term "non-Q
wave MI" as a separate clinical entity to improper study protocols and misdiagnosis
of Q wave equivalent.35 These protocols fail to differentiate between first and
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subsequent infarcts, because the frequency of new Q wave appearance decreases by
50% in subsequent infarcts. Also, the presence of Q wave equivalent on the ECG
(tall R waves in right precordial leads, poor R wave progression, low voltage QRS,
R/S pattern, QRS notching) is often ignored or missed, hence many patients in these
two groups will be classified as non-Q wave MI.35
These arguments may in turn call for a review of the current treatment strategy of
patients who are classified as non-Q wave MI. Unstable angina and non-Q wave MI
share similar pathophysiology with STEMI i.e. plaque rupture, fissure or erosion
with subsequent platelet aggregation and thrombus formation. With STEMI there is
more fibrin deposition leading to complete and prolonged coronary artery
occlusion.14 In UA and non-Q wave MI the disease process may be more dynamic,
with active thrombosis and fibrinolysis and the occlusion is either incomplete or less
severe or not prolonged, and platelet deposition is more of a component than fibrin
deposition.10 Patients with non-Q wave MI have a higher incidence of total coronary
artery occlusion (21%), and a higher incidence of a characteristic type II eccentric
lesion (65%) i.e. an eccentric stenosis with overhanging edges or irregular borders.3
Elevated cardiac markers were correlated with the presence of underlying complex
pathologies in these conditions.58
The routine use of thrombolytic therapy in NSTEMI (UA and non-Q wave MI)
within 24 hours of admission in the study by TIMI IIIB investigators, had not been
shown to be beneficial and was even associated with more adverse outcome e.g. AMI
and intracranial haemorrhage. This view is also supported by several small
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studies. 6"39 On the other hand, there are some studies that reported benefits of
thrombolytic therapy in refractory UA, especially when this treatment was used in
low doses and over a prolonged period of time in selected patients.40"42 Prolonged
administration of low dose recombinant tPA and heparin in patients with refractory
UA was associated with decreased rate of MI, need for revascularisation (PCI and
CABG), and a decrease in the number of episodes and total duration of ischaemia as
compared with heparin treatment only. These treatment benefits were evident over
14 ± 6 months of follow-up, with more patients in the treatment group pain-free, and
had a lower incidence of re-admissions.41
The adverse outcomes associated with the use of thrombolytic therapy in UA and
non-Q wave MI in earlier studies could be due to patient's selection bias attributed to
by several factors. First, the use of thrombolytic therapy in UA and non-Q wave MI
was guided more by ECG changes rather than by ECG changes and cardiac markers
concentrations at admission. As mentioned earlier, elevations of cardiac markers
concentrations were not consistently or directly related to the types of ECG changes
at admission. When most of these studies were conducted, the development of the
most sensitive and specific cardiac markers e.g. troponins, CK-MB mass and H-
FABP was still in its early stages and they were not part of the protocol used for
patients selection.39'41
Second, the greatest benefits of thrombolytic therapy in AMI were observed if this
treatment was given within the first 12 hours after the start of symptoms. Beyond this
interval generally the risks outweigh the benefits. The inclusion of patients in some
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of these studies was late and sometimes within 25 hours after symptom onset. '
The inclusion of patients beyond 12 hours may have offset the benefits that may be
gained from early enrolment and treatment within 12 hours after symptom onset.
Sometimes the failure of treatment was attributed to small sample size that does not
provide sufficient power to rule out treatment effect.
It is understandable that without the sensitive and specific cardiac markers that are
available today, proper early diagnosis and differentiation between patients with
minimal myocardial injury in UA and patients with non-Q wave MI was not possible
using ECG changes alone. The judicious use of thrombolytic therapy on
individualised bases, in selected high-risk patients with early positive cardiac
markers concentrations of infarction, and subtle ECG changes of infarction such as
'Q-wave equivalent', posterior MI, and non-classical ST elevations <1-2 mm, who
present within 12 hours after symptom onset has not yet been evaluated in clinical
trials. These are patients who fulfil the criteria for AMI based on clinical history and
positive cardiac markers concentrations but in the absence of the classical ST
segment elevations in the admission ECG. The potential benefits and risks of
thrombolytic therapy in patients without the classical ST segment elevations should
be examined and monitored closely in a pilot study. The result of such study will
determine whether further trials should be conducted.
The availability of point of care instruments that can offer simple, rapid (< 20
minutes), and reliable round the clock measurements of cardiac markers will help
with the management of high-risk patients with acute chest pain in several ways; (1)
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Clarifying atypical clinical history and equivocal or ambiguous ischaemic ECG
changes at presentation. The overall sensitivity of cardiac markers, clinical history
and ECGs for the diagnosis of non-Q wave MI was 100%, 93% and 86%
respectively; (2) Early stratification of high-risk patients; (3) Appropriate and speedy
triage ofhigh-risk patients to CCU or dependent units.
(4) Where appropriate, some of these high-risk patients with non-Q wave MI could
be considered for early with PCI. Alternatively, many of these high-risk patients can
be scheduled for early treatment with aspirin, LMWH, and glycoprotein GPIIb/IIIa
receptor inhibitor; (5) Early identifications will lead to proper instigation of post-MI
management and care e.g. aspirin, P-blockers and lipid lowering therapy; (6) Early
identifications of patients and prompt therapy may reduce complications and the time
of hospital stay. This may in turn reduce the consumable running cost; (7) Most
importantly early diagnosis will prevent inadvertent discharge of these high-risk
patients.
The development of new and more potent antiplatelet agents that act on different
platelet receptors had been a major advance in the treatment of patients with UA and
non-Q wave MI (Figure 1). Many studies had shown benefits of treatment in terms of
reducing the incidence of AMI and death when agents like tirofiban or clopidogrel
were used in the treatment of patients with ACS.21"23 The selection of the most
appropriate groups of patients for these treatments is an important issue, in terms of
maximising the benefits and minimising the cost and side effects. The ECG changes
do not necessarily reflect the significance of myocardial damage in vivo. As shown
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here and elsewhere, cardiac markers concentrations can be either normal or elevated
in similar ECG patterns.51 Nevertheless, the presence of significant ECG changes of
ischaemia e.g. ST segment depression are considered high-risk prognostic signs, and
are associated with the presence of three vessel disease, and a five-fold greater risk of
• • 407death and new myocardial infarction compared to those with normal ECG. '
The diagnostic and prognostic value of elevated cardiac troponins in patients with
ACS is supported by many studies.44"47'53"55 Patients with ACS and positive cTnl are
at increased risk of death and MI (13%) compared to patients with negative cTnl
(4.9%), [13.7% and 3.5% for cTnT positive and cTnT negative respectively].43
Stratifying patients by troponins concentrations at admission was associated with the
greatest reduction of death and MI in the groups treated with tirofiban medically and
for 48 hours before revascularisation.43 Furthermore, in a substudy by the fragmin in
unstable coronary artery disease investigators, long-term (five weeks) treatment with
dalteparin was most beneficial in reducing the risk of death and AMI compared to
placebo in patients with cTnT > 0.1 pg/1 [7.4% vs 14.2% at 40 days, p < 0.01]
compared to cTnT < 0.1 pg/1 [5.7% vs 4.7%].46 The combination of serial cardiac
markers testing at admission with ECG changes provide simple and reliable methods
that will help select patients most at risk of further ischaemic events. This group can
be considered for further treatment with LMWH, clopidogrel, and GP Ilb/IIIa
inhibitors, and other new antiplatelet compounds.
Coronary angiography was followed by angioplasty in a higher percentage of
patients with elevated cardiac markers at admission compared to those with normal
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cardiac markers (67% vs 20%). Stratifying patients by cardiac markers
concentrations at admission may help guide the application of this invasive
procedure. Patients who demonstrate significantly elevated cardiac markers
concentrations at admission are started on aspirin, LMWH and GP Ilb/IIIa and
allocated to early cardiac catheterisation ± angioplasty. Patients who are clinically
stable and with no significant elevations in cardiac markers are treated
conservatively. These patients can be investigated by angiography if they develop
further episodes of prolonged angina at rest, recurrent angina ± ST segment changes
on ECG, increased troponins, haemodynamic instability, or positive exercise
tolerance test or thallium scan. Patients with UA and no release of troponins have
less severe coronary artery disease and have excellent prognosis. It is suggested that
these patients may be managed more conservatively and without invasive evaluation
before discharge.38
6.4.1 Atypical/anginal chest pain group
Chest pain is a common complaint in the A&E department. Excluding patients
without serious cardiac chest pain is not possible by reliance on clinical history and
ECG alone. Sixty-two per cent (62%) of patients in this group had typical ischaemic
chest pain, and there were minor ECG changes of ischaemia in 28%. Most of these
patients end up in hospital for several days, and are usually treated in a similar
manner to patients with UA with pharmacologic agents, and some of them may have
invasive investigations. Serial cardiac markers testing at admission could help put the
clinical conditions in perspective, and avoid unnecessary prolonged hospitalisation
and invasive investigations in patients considered (based on their clinical condition,
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ECG, and cardiac markers concentrations) at low-risk of further acute ischaemic
events.47 Cardiac markers concentrations were all entirely normal in this group and
would have classified these patients into a low-risk group for whom admission to a
regular bed or early discharge would be appropriate.
It is possible that some of the patients classified in this group may well represent UA
patients with normal ECG and normal cardiac markers concentrations. However, the
fact that serial cardiac markers concentrations are normal is reassuring. Furthermore,
there are no major benefits of treatment with new antiplatelets or antithrombotic in
patients with normal ECG and troponins.43,46 Investigations in this group should be
proportionately scaled down especially the use of invasive investigations. The
duration of hospital stay should also be cut down to the minimum. If clinical doubt
exists and further risk stratifications were deemed necessary, these patients may be
subjected safely to an early exercise tolerance test before discharge.
Cardiac markers testing will optimise the triage and management of patients with
atypical/anginal pain from A&E department. Measurement of cardiac markers in
patients with chest pain can help with; (1) Proper identification of low-risk patients
with chest pain; (2) Triage of patients to less dependant units e.g. regular bed; (3)
Avoiding unnecessary invasive investigations; (4) Early discharge of low-risk
patients may reduce the consumable running cost substantially; and (5) In certain
cases where further risk assessment e.g. exercise tolerance test or stress
echocardiography is required, these patients may be subjected to this assessment
early before discharge or planned as an outpatients tests.
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6.4.2 Limitations of the study
(1) The cost effective analysis was only a preliminary study and was based mainly on
the cost reduction expected from early identification using biochemical markers and
subsequent management based on these results in patients with uncomplicated ACS.
Such as early discharge and avoiding invasive investigations and newer antiplatelet
treatment in low-risk patients; hence a reduction of overall cost and in-hospital stay.
This analysis was based primarily on the cost of occupying a hospital bed per day
and includes the cost of essential basic investigations and treatment. However, the
cost of specialised investigations [such as coronary angiography, thallium scan, and
computerised tomography scam] and specialised treatment [such as newer
antiplatelet and PCI] had been excluded from the analysis. It is therefore possible
that the savings made by doing an additional test may be offset by the increased cost
of identifying patients who need earlier treatment with more sophisticated and costly
intervention. The results of this preliminary study need to be verified with more
formal cost effective analysis.
(2) Although the sample size in the chest pain group has a high level of statistical
power (95%) to detect an early diagnostic benefit for H-FABP, the number of
patients in each subgroup (non-Q wave MI, UA, and atypical/anginal chest pain) was
small, to allow definitive recommendations to be made regarding the application of
these cut-off concentrations to clinical practice. (3) These cut-off concentrations are
also assay dependent, and in the absence of general standardisation of cardiac
markers assays, different cut-off concentrations that differentiate patients with UA
from patients with myocardial infarction will needs to be worked out for that
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particular assay used by each institution. This should be based on ROC curve
analysis in a larger number of patients in these three subgroups.
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THE ROLE OF HEART FATTY ACID BINDING PROTEIN IN THE EARLY
DIAGNOSIS OF ACUTE MYOCARDIAL INFARCTION AND THE
POTENTIAL INFLUENCE ON PATIENTS' MANAGEMENT
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7.1.1 Acute coronary syndromes
The new classification by the ESC/ACC identifies five main conditions that can be
classified as ACS.1 These five conditions are: (1) ST elevation Q wave MI; (2) ST
elevation Non-Q wave MI. These two conditions are referred to as ST elevation
ACS; (3) Non-ST elevation Q wave MI; (4) Non-ST elevation Non-Q wave AMI.
These two conditions are referred to as Non-ST elevation MI and are associated with
cardiac enzymes or proteins elevations diagnostic of AMI in the absence of the
classical ST segment elevation on the ECG. Most of the patients with NSTEMI have
prolonged ST segment depression and/or T wave inversion and a bout 20% of these
• 9 •
patients develop Q waves on subsequent ECGs; and (5) The last condition that is
classified as ACS is unstable angina. Patients with UA do not have classical ST
segment elevation, new Q waves on the admission ECG, or cardiac enzymes or
proteins elevation diagnostic of AMI. The last three conditions (3, 4, and 5) are
referred to as non-ST elevation ACS (Figure 1 page 16). Non-ST elevation ACS
(Unstable angina and NSTEMI) have been discussed in Chapter 6 and in this chapter
ST elevation ACS will be discussed.
From a first impression one might think that all these five conditions are separate
clinical entities and each one has its own presenting clinical features, ECG diagnostic
criteria, and specific treatments. The clinical reality is that all these conditions are
seen in a continuous spectrum with STEMI at one end and UA at the other end, and
NSTEMI in between without a clear-cut distinctive boundaries between them. The
only arbitrary distinction between these conditions exists in research protocols and
not in clinical practice. The only valid distinguishing criterion used to differentiate
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these conditions in clinical practice is the presence of significant ST segment
elevation in the ECG. The importance of ST segment elevation is to help decide
whether or not to administer thrombolytic therapy. The rest of the patients without
significant ST segment elevations are called non-ST elevation ACS and are usually
treated in a similar manner with pharmacologic agents including antiplatelets,
antithrombotic, and anti-ischaemic medications. The best treatment strategy for this
group is still controversial, not least because of the difficulty to differentiate the
various conditions that make up non-ST elevation ACS early after presentation.
In an attempt to provide some form of valid clinical distinction between conditions
referred to as non-ST elevation ACS, the ESC/ACC has established cardiac markers
concentrations above the 99th percentile of control group as the main distinguishing
factor between UA and the rest of conditions classified as non-ST elevation ACS.
According to this definition, myocardial infarction should be diagnosed in any
patient with cTnT or cTnl > the 99th percentile of control value on at least one
occasion or a maximum value of CK-MB mass exceeding the 99th percentile control
group on two successive samples or exceeding twice the upper limit of normal on
one occasion.1 Further classifications of these conditions by the presence or absence
of Q waves is probably academic since classifying patients into Q wave and non-Q
wave MI has no additional prognostic or therapeutic implications.3
7.1.2 Pathophysiology of acutemyocardial infarction
In more than 90% of affected patients atherosclerosis is the major underlying disease
process resulting from combinations of inflammation, smooth muscle cell
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proliferation, and fibrosis in response to vascular injury. " The 'response to injury
hypothesis' implicates endothelial dysfunction or injury as the fundamental step in
Q-1T • •• ••
the development of atherosclerosis. ' Many risk factors acting singly or in unison
(hyperlipidaemia, smoking, hypertension, and diabetes), along with local factors such
as (shear stress, endothelin, and abnormal vasomotion), contribute to the
• • 7* 10
development and progression of endothelial atherosclerotic lesions. ' The altered
endothelial barrier allows circulating monocytes and plasma lipids into the intima of
the vessel.6,11'12
Simultaneous aggregation and adherence of platelets to the endothelial cell causes
/,n
the release of platelet-derived growth factor and other mitogenic factors. ' These in
turn stimulate the migration and proliferation of vascular smooth muscle cells and
production of connective tissue matrix (e.g. collagen, elastin, protein, and
proteoglycan) and angiogenesis.14 Accumulated monocytes mature to macrophages
and ingest lipid products through scavenger receptors and become large cells loaded
with lipid products known as 'foam cells'.6'15 The ensuing inflammatory processes
involving cells like monocytes, macrophages, and lymphocytes, that result from low
density lipoprotein oxidation, cell necrosis, and the release of cytokines and
inflammatory mediators. In addition, episodes of plaque rupture and thrombosis
occur followed by healing and volume expansion, and the continuous production and
breakdown of the tissue matrix. All these processes lead to the formation of the
o
typical atherosclerotic plaque over several years or decades.
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Many cases of AMI and UA result from lesion fissure, rupture or erosion with
subsequent thrombosis and occlusion of the lumen.6'16"17 The process of plaque
rupture represent imbalance between matrix production and breakdown. Plaques that
rupture are of the advanced or raised fibro-lipid type. The core of the plaque consists
of extracellular lipid, inflammatory cells, foam cells, necrotic materials, and often
deposits of calcification separated from the lumen by thin fibrous tissue cap.6'18'19
The plaque characteristically ruptures at its margins the so-called 'shoulder area'.
This area is rich in macrophages.20 These macrophages are capable of releasing
inflammatory mediators and enzymes like matrix metalloproteinases (gelatinases,
collagenases, and stromelysin), which are capable of destroying virtually all the
structural components of the vascular matrix.21'22'23,24 The other factors that may also
contribute to plaque progression and destabilisation are infectious agents, and
mechanical stress on the weak plaque.41'25
Cardiac markers are important tools for the diagnosis of AMI. This topic had been
covered extensively in Chapter 2. So far this role had been mainly in the
retrospective confirmation of AMI within 12-24 hours after admission. The
utilisations of cardiac markers for the early diagnosis and treatment ofAMI (within 6
-12 hours) had not been possible before due to the lack of sensitive and specific
early markers of myocardial damage. Myoglobin is an early marker of myocardial
damage. However, the utilisation of myoglobin for the early diagnosis of AMI has
been hampered by poor specificity for myocardial tissues.26,27 Heart-FABP is a novel
marker that is released very early following myocardial tissue damage and had been
postulated as a marker with potential for the early diagnosis of AMI within 6 hours
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after symptoms onset.28 Its sensitivity for the diagnosis of AMI had been equated
with that ofmyoglobin. However, the specificity ofH-FABP for myocardial tissue is
significantly better than myoglobin because its concentration in serum of healthy
populations is about fifteen-fold lower than myoglobin.19 This early release feature
coupled with relative cardiac tissue specificity are considered superior advantages of
H-FABP that can be utilised for the early diagnosis of AMI. The ratio of myoglobin
and H-FABP has also been claimed to have superior sensitivity and specificity for
the diagnosis of myocardial injury compared to the measurement of either of these
markers alone. So far there had been few studies comparing the value of these two
markers for the early diagnosis of AMI. Also there had been no studies comparing
these two markers in a standardised setting with other cardiac markers such as CK-
MB mass, cTnl, and cTnT.
7.1.3 AIMS OF THE STUDY:
1. Compare and contrast the sensitivity, specificity, positive predictive value, and
negative predictive value of the new cardiac marker H-FABP for the early diagnosis
of AMI within 6 hours after onset of symptoms in patients who present with AMI,
with standard cardiac markers (CK-MB mass, cTnl, cTnT, and myoglobin) and
whether H-FABP has an advantage release characteristics.
2. To combine myoglobin and H-FABP in a ratio and to study the usefulness of this
ratio for the early differentiation between cardiac and non-cardiac injury in patients
who present with chest pain and the effect this ratio has on sensitivity and specificity
compared to the concentration of either marker alone.
241
3. Study the clinical benefits from the implementations of serial cardiac markers
testing in the early management of patients with AMI. Several examples from this
group will be used to illustrate this.
7.2 PATIENTS AND METHODS
7.2.1 Patients and treatment
The recruitment of patients with AMI, the inclusion and exclusion criteria, and the
diagnostic criteria for AMI are described in details in Chapter 4 materials and
methods pages 112 - 114. The methods used for analysis of cardiac markers and the
diagnostic cut-off concentrations for AMI are described under the methods section in
Chapter 4 pages 106 - 109, and Chapter 6 pages 189 - 190. Patients who had ST
segment elevations suggestive of AMI on the admission ECG and chest pain were
given intravenous thrombolytic therapy (if they have no contraindications) and fast-
tracked to CCU. The aim was a door to needle fast-track time less than 20 minutes.
Patients received intravenous streptokinase [1.5 million units for 60 minutes] or tPA
[a bolus of 15 mg, then 50mg (0.75 mg kg _1) during the first 30 minutes and 15 mg
(0.5 mg kg ~ ) over 60 minutes]. The latter regime used concomitant intravenous
heparin [a bolus of 5000 units followed by intravenous infusion 1000 units per hour]
adjusted to achieve activated partial thromboplastin time of 60 - 85 seconds. The
allocations of patients to either of these thrombolytic protocols were based on
standard local selection criteria such as age, type and severity of myocardial
infarction, and previous use of thrombolytic therapy. Patients received a
conventional treatment before CCU admission with sublingual administration of
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glyceryl trinitrate (GTN) ± intravenous diamorphine (2.5 - 5 mg) to relieve pain,
aspirin (300 mg initially to chow and swallow) and oxygen inhalation if necessary.
Additionally, all patients received routine coronary care and were treated with aspirin
(75 mg daily), nitrates, [3-blockers, angiotensin converting enzyme inhibitors and
anti-arrhythmic drugs as required.
7.2.2 Statistical analysis
Variables were expressed as mean ± SD. The sensitivity, specificity, PPV, and NPV
were measured for each marker at each time point after presentation and compared.
The changes in serum concentrations of cardiac markers cTnl, cTnT, CK-MB mass,
myoglobin, and H-FABP at 0, 2, 4, 8 - 10, and 16-24 hours were analysed with one
way analysis of variance for repeated measures (Greenhouse-Geisser correction) with
time as dependent factor. Post-hoc comparisons between times were performed with
the Bonferroni's test for multiple comparisons. Significant values were defined as P
value < 0.05. The best cut-off concentrations between patients with definite AMI and
those without AMI (UA, atypical/anginal chest pain, and normal controls) were
based on ROC analysis (Figure 2, A and B). The study used the following
concentrations to define the presence of AMI [CK-MB mass > 8 jug/1, cTnl > 0.6
pg/1. cTnT > 0.4 p.g/1, H-FABP > 16 p.g/1, and myoglobin > 107.5 pg/1].
7.3 RESULTS
The study group consisted of 45 patients (16 females and 29 males) who were
admitted with AMI within 6 hours after symptom onset. The mean age of the group
was 66.58 ± 11.74 years [range 38 - 82 years]. The demographic data of all patients
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in this group are shown in Table 1. The time from onset of symptoms to presentation
was 3.57 ± 2.33 hours (median 3 hours [range 1-6 hours]). Thirteen per cent of
patients in this group had previous history of angina and MI. Of interest was the high
number of patients who had no prior clinical history of ischaemic heart disease.
Thirty-three per cent (15 patients) had their first presentation with AMI without any
previous documentations of ischaemic heart disease. The commonest risk factor in
this group was hypercholestrolaemia (69%). The second most common risk factor
was smoking with 42% of patients are either current or ex-smokers. The prevalence
of other risk factors such as diabetes mellitus, hypertension, and family history of
ischaemic heart disease in this high-risk group was moderate (18 - 24%).
Table 2 shows the clinical details concerning the type of chest pain at admission,
types and leads distribution of ECG changes, and methods of reperfusion therapy
given at admission. Thirty-four patients (76%) presented with typical history of
ischaemic chest pain. In 11 patients (24%), the description of chest pain was not
typical of ischaemic heart disease. The admission ECG was immediately diagnostic
of AMI [significant ST segment elevations > 2 mm in more than two leads] in 37
patients (82%). Eighteen per cent (18%) had no thrombolytic eligible ECG changes
at admission. The implementation of reperfusion therapy and the subsequent
diagnosis of AMI in these patients were based on the evolution of new Q waves, the
development of further ST segment elevations on subsequent ECG's or the presence
of routine cardiac enzymes or proteins elevation consistent with the diagnosis of
AMI.
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Demographic data of patients with AMI
Demographic data Number(s)
Total number ofpatients 45 patients


















Smokers (ex-smokers = 8.7%)
Hypercholestrolaemia






Table 1. Shows the demographic data of patients with AMI. Continuous
variables are presented as mean ± SD and categorical variables are presented as
percentages. Abbreviations: PCI, percutaneous coronary intervention; SD,
standard deviation; AMI, acute myocardial infarction; IHD, ischaemic heart
disease.
The commonest ECG changes were ST segment elevation. Eighty-seven per cent of
patients who were admitted with chest pain evolved ST segment elevation at or
during admission. Six patients (13%) had other forms of ischaemia on the admission
ECG such as ST segment depression ± T wave inversion. In the latter group, new Q
waves were either present or cardiac markers were abnormally elevated. Overall 29%
evolved new Q waves during admission 'Q wave MI' and in 71% there were no new
Q waves seen on the ECG 'Non-Q wave MI'.
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Clinical data of patients with AMI
Clinical data Number(s)
Haemodynamic parameters at admission
Heart rate (BPM) 72.97 ± 17.14
Systolic blood pressure 136.4 ±25.93
Diastolic blood pressure 71.83 ± 16.86
Clinical history at presentation:
Typical history of ischaemic chest pain 34 (76)
Atypical history or equivocal history 11(24)
First ECG diagnostic ofAMI 37 (82)
First ECG not diagnostic ofAMI 8(18)
ECG changes ofischaemia:
ST elevation 39 (87)
ST depression (± T wave inversion) 6(13)
Q waves MI 13 (29)
Non-Q waves MI 32(71)
Leads distributions:
Anterior MI 17(38)
Inferior MI 23 (51)
Anterior lateral MI 1(2)
Inferior lateral MI 3(7)
Posterior MI 1(2)
Routine cardiac marker concentration:




Thrombolytic therapy + Rescue PCI 2 (4.5)
Table 2. Shows the clinical data of patients admitted with AMI. Continuous
variables are presented as mean ± SD and categorical variables are presented as
percentages. Abbreviations; BPM, beats per minute; ECG, electrocardiogram;
ST, Q are ST segment and Q wave of the ECG; CK, creatine kinase; SK,
streptokinase; tPA, tissue plasminogen activator; PCI, percutaneous coronary
intervention; AMI, acute myocardial infarction.
The distributions of ECG changes are also shown in Table 2. Seventeen patients
(38%) had anterior MI and 23 patients (51%) had inferior MI. In a very small
number of patients the ECG changes were in the anterior lateral, inferior lateral, and
posterior leads 2%, 7%, and 2% respectively. The mean concentration of the enzyme
CK in routine samples was significantly elevated in these patients 1310.3 ± 1008.9
IU/L. Most patients received standard treatment with streptokinase infusion (71%)
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and most of the remaining patients received tPA. Two patients had persistent chest
pain and failure of ST segment resolution after thrombolytic therapy and they were
treated by rescue angioplasty. Emergency coronary angiography followed by
angioplasty and stenting was undertaken in three more patients who developed
episodes of recurrent chest pain several days after admission.
The serial concentrations of cardiac markers (CK-MB mass, cTnl, cTnT, myoglobin,
and H-FABP) are shown in Table 3. There was a significant difference between
cardiac markers mean concentrations at each time point of sampling after admission
and the proceeding concentrations. The exception to this was cTnT concentration
between 8-10 and 16-24 hours; H-FABP and myoglobin mean concentrations
between 2 and 4 hours, where the mean concentration difference between these time
periods was not significant. The average concentrations of myoglobin, H-FABP, CK-
MB mass, and cTnl were above the diagnostic cut-off concentrations in all samples
taken after admission.
Figure 1 shows graphic representations of cardiac markers concentrations in Table 3.
Myoglobin and H-FABP were the earliest makers of myocardial injury. The peak
concentrations of myoglobin and H-FABP were reached in samples taken 2 hours
after presentation (8 hours after symptoms onset). The peak concentrations of CK-
MB mass and cTnl occurred at 8 - 10 hours after presentation (14 - 16 hours after the
onset of chest pain). The peak concentrations of cTnT could not be estimated
precisely because cTnT maximum concentration was present in the last sample taken
at 16-24 hours after presentation (24 - 30 hours after onset of symptoms). The
changes in cTnT concentration beyond this interval were not known because no
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further blood sampling was undertaken. Heart-FABP and myoglobin concentrations
had decreased significantly at 16 - 24 hours, whereas CK-MB mass, cTnl, and cTnT
were still present in high concentration. These two features, early concentration peak
following myocardial injury and rapid return to normal base line concentration ofH-
FABP and myoglobin demonstrate the superb qualities of these two proteins as
potential markers for early detection of myocardial injury and that they are also the
most suited markers for the detection of complications e.g. re-infarction in the
immediate post-MI period.
Marker(s) 0 hr 2 hrs 4 hrs 8-10 hrs 16-24 hrs P value
CK-MB 24.38 106.46 182.75 223.19 126.32
0.0005
SD 62.79 133.51 163.31 176.51 103.62
CTnl 6.53 33.48 83.44 111.11 66.33
0.038
SD 32.53 74.12 138.08 128.48 75.95
CTnT 0.19 0.94 2.72 5.16 5.84
0.004
SD 0.64 1.90 4.12 6.27 6.12
Myoglobin 331.82 1897.69 1379.62 597.07 253.36
0.0005
SD 411.57 2504.51 1463.81 713.16 300.78
H-FABP 56.89 251.23 235.64 103.98 45.68
0.0005
SD 72.05 218.8 186.23 95.86 51.06
Table 3. Shows the serial concentrations (mean ± SD) of cardiac markers CK-
MB mass, cTnl, cTnT, myoglobin, and H-FABP in patients with AMI at 0, 2, 4,
8-10, and 16-24 hours after presentation. The p value refers to the differences
between the mean concentration at each time and the proceeding mean
concentration.
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Figure 1. These graphs illustrate the release pattern (time-concentration
profile) of the different cardiac markers (CK-MB mass, cTnl, cTnT, myoglobin,
and H-FABP) at each time after presentation in patients with AMI.
The sensitivity of cardiac markers CK-MB mass, cTnl, cTnT, myoglobin, and H-
FABP for the diagnosis of AMI in patients who presented within 6 hours after
symptom onset is shown in Table 4. Heart-FABP was the most significant early
marker with 60% of patients with AMI correctly diagnosed at presentation. The
sensitivity had risen to 100% two hours after presentation and remained elevated for
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the next 2-8 hours after presentation (93 - 100%). The diagnostic window of H-
FABP was relatively prolonged up to 8 hours after presentation (14 hours after
symptom onset). The optimum sensitivity for the diagnosis of AMI was present
between 2-8 hours after presentation. Myoglobin was the second most sensitive
early marker shortly after presentation. At 2 hours after presentation, 93% of patients
with chest pain suggestive of AMI can be correctly identified using myoglobin
concentrations.
The optimum diagnostic sensitivity of myoglobin was present between 2-4 hours
after presentation. The sensitivity of myoglobin had decreased significantly at 16 - 24
hours after presentation. Cardiac-Tnl was the third best sensitive early marker of
AMI. Ninety-three per cent of patients had positive concentrations at 2 hours. The
sensitivity had risen to 100% in subsequent samples taken at 4, 8 - 10, and 16-24
hours.
The sensitivity of CK-MB mass was low at presentation (31%) and significantly
increased 2 hours after presentation (88.8%). Between 4-16 hours after presentation
most patients had positive CK-MB mass concentrations that were diagnostic ofAMI
(97.7 - 100%). The sensitivity of cTnT was very low at and shortly after presentation
(0 hour, 2 hours, and 4 hours) and it increased to a reasonable level (91%) only at 8 -
10 hours after presentation (Table 4), making cTnT a late marker that is unsuitable
for the early diagnosis ofAMI within the first 12 hours after symptoms onset.
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The effects of altering the diagnostic cut-off concentrations on cardiac markers
sensitivity for the early diagnosis of AMI are shown in Table 5. These selected
diagnostic cut-off concentrations were based on ROC curve analysis (Figure 2, C and
D) between this group of patients with definite AMI and in patients in whom
myocardial injury had been excluded (normal controls, UA patients excluded).
These cut-off concentrations were CK-MB mass > 5 pg/1 [AUC = 0.950, SE = 0.01,
P < 0.0005, 95% CI = 0.931 - 0.970, sensitivity = 86.3%, specificity = 99%], cTnl >
0.18 jig/1 [AUC = 0.993, SE = 0.003, p < 0.0005, 95% CI = 0.988 - 0.999, sensitivity
= 90.8%, specificity = 99%], cTnT > 0.1 pg/1 [AUC = 0.931, SE = 0.012, p < 0.0005,
95% CI = 0.907 - 0.955, sensitivity = 76.4%, specificity = 99%], H-FABP > 12.5
pg/1 [AUC = 0.932, SE = 0.019, p < 0.0005, 95% CI = 0.895 - 0.968, sensitivity =
91.4%, specificity = 86%], and myoglobin > 95 pg/1 [AUC = 0.945, SE = 0.012, p <
0.0005, 95% CI = 0.921 - 0.969, sensitivity = 81.2%, specificity = 99%]. Figure 2
shows the ROC curves that were used for the selection of these cut-off
concentrations.
There were different effects of these modifications on cardiac markers sensitivity. In
general, there was a noticeable improvement in the sensitivity of all markers (with
the exception of cTnT) for the diagnosis of AMI at presentation. The sensitivity at
presentation had increased to 51%, 60%, and 62% for cTnl, CK-MB mass, and
myoglobin respectively. The overall sensitivity of these three markers remained
relatively unchanged. There was a significant improvement in the overall sensitivity
of cTnT at 8 - 10 hours [100% vs 91%] (Table 5).
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Marker(s) Ohr 2 hrs 4 hrs 8-10 hrs 16-24 hrs
CK-MB mass 31 88.8 97.7 100 100
CTnl 26 93 100 100 100
CTnT 11 46.6 68.8 91 95.5
Myoglobin 57.7 93 93 88.8 66.6
H-FABP 60 100 100 93 77.7
Table 4. Shows the percentage sensitivity of cardiac markers CK-MB mass,
cTnl, cTnT, H-FABP, and myoglobin for the early diagnosis of AMI at 0, 2, 4, 8
- 10, and 16 - 24 hours after presentation in patients with AMI within 6 hours
after symptom onset. The cut-off concentrations were CK-MB mass > 8 pg/l,
myoglobin > 107.5 pg/l, cTnl > 0.6 pg/1, cTnT > 0.4 p.g/1, and H-FABP > 16 p.g/1.
1 - Specificity [ False Positive ] B
1 - Specificity [False Positive ]
1 - Specificity [ False Positive] D
1 - Specificity [ False Positive]
Figure 2. Shows four receiver operator characteristic curves that were used to
derive the cut-off concentrations of the various cardiac markers in this study. A
and C represent the improvement in cut-off concentration (sensitivity and
specificity) with respect to the two different cut-off concentrations used in Table
4 and 5 respectively. B and D show equivalent cut-off concentrations of H-
FABP. Blue, CK-MB mass concentrations; green, cTnl concentrations; red,
cTnT concentrations; black, myoglobin concentrations. See text for explanation.
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Figure 3 shows simple line chart representation of the sensitivity values in Table 5.
Heart-FABP was the most sensitive marker at presentations (75.5%), and it remained
elevated at 100% for the next 2-8 hours. Heart-FABP sensitivity was also superior
to other markers within the first two hours of presentation. Myoglobin and CK-MB
mass sensitivity were similar in the first 2 hours (93%). However, the peak
sensitivity of myoglobin (93%) and CK-MB mass (100%) were reached at 2 hours,
and 8-10 hours respectively. Cardiac-Tnl reached higher sensitivity (97.7%) earlier
(2 hours) than myoglobin, CK-MB mass, and cTnT. The sensitivity of cTnT
gradually increased from a low level at presentation (24%) to the highest level
(100%) at 8 - 10 hours after presentation. There was no evidence that cTnT had
reached peak concentrations during the sampling interval (Figure 3).
Marker(s) Ohr 2 hrs 4 hrs 8-10 hrs 16-24 hrs
CK-MB mass 60 93 97.7 100 100
CTnl 51 97.7 100 100 100
CTnT 24 68.8 86.6 100 100
Myoglobin 62 93 93 91 71
H-FABP 75.5 100 100 100 84.4
Table 5. Shows the percentage sensitivity of cardiac markers CK-MB mass,
cTnl, cTnT, and myoglobin for the early diagnosis ofAMI at 0, 2, 4, 8 - 10, and
16 - 24 hours after presentation in patients with AMI within 6 hours after
symptom onset. The cut-off concentrations were CK-MB mass > 5 p.g/1,
myoglobin > 95 p.g/1, cTnl > 0.18 pg/1, cTnT > 0.1 pg/1, and H-FABP > 12.5 pg/1.
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Figure 3. Shows a line chart representation of the sensitivity values in Table 5.
Each mark represents the percentage sensitivity of the cardiac marker at that
time point.
In a separate subgroup analysis a series of possible diagnostic cut-off concentrations
for H-FABP were evaluated to decide the best discriminate range of values. Table 6
shows the sensitivities of H-FABP for the early diagnosis of AMI based on a series
of increasing cut-off concentrations in the range 9 to 21.5 pg/1. There was a
significant but gradual reduction in the early sensitivity ofH-FABP at presentation (0
hour) as a result of increasing the diagnostic cut-off concentrations from 9 ju.g/1 to
21.5 pg/1. There was little effect from increasing the diagnostic threshold to values <
18 pg/1 on the sensitivity between 2 and 4 hours with 97.7 - 100% of patients
correctly diagnosed (i.e. within 8-10 hours after symptoms onset). The sensitivity
(early and late) had decreased significantly with concentration >21.5 pg/1. Cut-off
concentrations between 9 pg/1 and 12.5 pg/1 offered the best discriminate values,
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which included both, better early sensitivity at presentation combined with very high
sensitivity between 2-8 hours after presentation (Table 6).
— Increasing levels of diagnostic cut-off concentrations—*
Time
(hrs)
>9 pg/1 >10 fj.g/1 >12.5
ng/i
> 14 fo.g/1 >16 (j.g/1 >18 (ig/1 >21.5
ng/i
0 81.8 79.5 75.5 68.2 59.1 56.9 42
2 100 100 100 100 100 100 93.3
4 100 100 100 100 100 97.7 95.5
8-10 97.7 97.7 100 97.7 93.2 90.9 88.8
16-24 88.6 88.6 84.4 81.8 77.3 72.7 57.7
Table 6. Shows the various sensitivities of H-FABP at 0, 2, 4, 8 - 10, and 16 - 24
hours after presentation in patients admitted with AMI. The analysis was based
on a series of increasing cut-off concentrations ranging from 9 p.g/1 to 21.5 pg/1.
The overall sensitivity, specificity, PPV, and NPV of CK-MB mass, cTnl, cTnT,
myoglobin, and H-FABP for the diagnosis ofAMI was analysed in 100 patients who
were admitted to hospital with chest pain suggestive of ischaemia within 6-7 hours
after symptom onset. The total numbers of patients who had confirmed myocardial
infarction were 59 patients. Fourty-one patients had no MI (20 patients had UA and
21 patients had no myocardial damage). The cut-off concentrations used are shown
in Table 5 page 254. The study had chosen an overall decision threshold for
sensitivity, specificity, PPV, and NPV to be equal or greater than 90% to indicate the
required reliability of cardiac markers for the early rule in or rule out of patients with
AMI. Table 7 shows the percentages of these values for the different cardiac markers
at each time after presentation.
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Marker(s) Feature(s) Ohr 2 hrs 4 hrs 8-10 hrs 16-24 hrs
CK-MB Sensitivity 38.9 86.4 96.6 98.3 96.6
Specificity 92.7 90.2 87.8 90.2 90.2
PPV 88.5 92.7 91.9 93.5 93.4
NPV 51.4 82.2 94.7 97.4 94.8
CTnl Sensitivity 35.5 91.5 96.6 96.6 96.6
Specificity 95.1 92.7 87.8 90.2 92.7
PPV 93.1 94.7 91.9 93.4 95
NPV 50.6 88.4 94.7 94.8 95
CTnT Sensitivity 20.3 52.5 69.5 89.8 94.9
Specificity 100 100 97.6 95.1 95.1
PPV 100 100 97.6 96.4 96.6
NPV 46.6 59.4 83.3 86.7 92.8
H-FABP Sensitivity 65.5 98.3 96.6 89.6 75.8
Specificity 81.8 72.7 77.3 77.3 86.4
PPV 90.4 90.4 91.8 91.2 93.6
NPV 47.4 94 89.5 74 57.5
Myoglobin Sensitivity 61 93.2 91.5 86.4 67.8
Specificity 90.2 90.2 90.2 90.2 90.2
PPV 90 93.2 93.1 92.7 90.9
NPV 61.6 90.2 88.1 82.2 66.1
Table 7. This table shows the sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) of cardiac markers CK-MB mass,
cTnl, cTnT, H-FABP, and myoglobin for the early diagnosis of AMI within 6-7
hours after symptoms onset at each time (0, 2, 4, 8 - 10, and 16 - 24 hrs) after
presentation.
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Heart-FABP had the highest sensitivity at presentation (65.5%). Almost all patients
(98.3%) with MI were diagnosed within 2 hours after admission (8 hours after onset
of symptoms). The specificity ofH-FABP at 2 hours was only 72.7%. This is largely
because of the inclusion of patients with UA in the AMI negative group, who had H-
FABP concentration rise consistent with myocardial injury. These patients were
inaccurately referred to as 'false positive' results. Exclusion of these patients from
the analysis improves the specificity to 93.75%. As mentioned earlier in Chapter 6,
H-FABP detected a substantial numbers of patients with UA (40%). However, there
was some overlap between the concentrations ofH-FABP in patients with UA and in
those with NSTEMI and STEMI.
Myoglobin had the second highest sensitivity at 0 hour (61%) rising to 93.2% two
hours after presentation. The corresponding specificity, PPV, and NPV were 90.2%,
93.2%, and 90.2% respectively. There was a similar performance by CK-MB mass
and cTnl. The sensitivity and NPV of CK-MB mass and cTnl were both low at
presentation. Reliable sensitivity, specificity, PPV, and NPV were observed at 4 - 10
hours after presentation. There was a relatively low NPV (i.e. high false negative
rate) of CK-MB mass within the first 2 hours of presentation (82.2%). Using a
threshold above 0.1 pg/1, the sensitivity of cTnT at presentation was very low
(20.3%). However, the specificity was 100%. Reliable sensitivity (94.9%),
specificity (95.1%), PPV (96.6%), and NPV (92.8%) were evident at 16 - 24 hours
after presentation.
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The value of myoglobin to H-FABP ratio for the early differentiations between
cardiac injury and non-cardiac injury was assessed. It has been suggested that a
myoglobin to H-FABP ratio around 5 is highly specific for myocardial injury,
whereas a ratio >21 - 70 is consistent with non-cardiac injury.36 In this group of
patients with confirmed AMI, 7.7% had myoglobin to H-FABP ratio > 21. In the
remaining patients the ratio (mean ± SD) of myoglobin to H-FABP was 5.6 ± 4.0
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[range 0.6 - 14.7]. The overall sensitivity of myoglobin to H-FABP ratio for the
diagnosis of AMI during admission was 92.3%. The diagnostic sensitivity of this
combination ratio was lower than either H-FABP or myoglobin alone (Table 7). In
patients presenting with acute chest pain in whom AMI and skeletal muscle injury
had been excluded, 93% had myoglobin to H-FABP ratio similar to that seen in
patients with AMI [mean ± SD = 7.8 ± 4.64], Only 7% of patients in this group had
myoglobin to H-FABP >21.
The other potential values that serial cardiac marker testing could have in the
management of patients with acute myocardial infarction will be highlighted by
considering several clinical examples from this group.
Timing the onset ofacute myocardial infarction event
One patient who was later excluded from the study, presented 11 hours after
symptom onset with anterior MI. It was decided that this presentation was late and
contraindicated thrombolytic therapy. He was treated with LMWH and other
adjunctive pharmacological agents. Cardiac markers concentrations in this patient at
presentation were high [CK-MB mass = 389 pg/1, cTnl = 50 pg/1, cTnT = 4.23 pg/1,
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H-FABP = 209 fj.g/1, and myoglobin = 1623 fig/1]. The concentration of CK-MB
mass, cTnl, and cTnT continued to rise in the next two samples (at 2 and 4 hours),
before levelling off and declining. For myoglobin and H-FABP, after a peak
concentration rise at presentation, it continued to decline gradually towards normal.
At 16 - 24 hours after presentation the concentrations ofmyoglobin and H-FABP has
dropped to 212 p.g/1 and 6 pg/1 respectively.
The early release and peak concentration features of H-FABP as well as the rapid
return to normal base line concentration makes it an excellent marker to use to time
the approximate onset of AMI event. Raising concentration of H-FABP as well as
cTnl may suggest a recent onset of AMI within the last 12 hours. Declining
concentration of H-FABP and raising concentrations of other markers suggest
presentation more than 12 hours after symptom onset. Normal concentration of H-
FABP suggests delayed presentations more than 24 hours. This biochemical time-
concentration profile of H-FABP might help with decision-making on reperfusion
therapy in those patients with chest pain and ST elevation but with a presumed late
presentation or in whom the onset of symptom could not be determined precisely.
Detection ofreperfusion
This study was not designed to examine in detail the value of cardiac markers for the
detection of successful reperfusion after the initiation of intravenous thrombolytic
therapy. This section briefly presents analytical comparison between the usefulness
of cardiac markers ratios for the detection of successful reperfusion. These were
based on the ratios of cardiac markers obtained by dividing the concentrations at two
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hours by the basal concentration i.e. the concentration before thrombolysis. The
diagnosis of reperfusion in this group was based on clinical criteria alone such as
resolutions of chest pain and a significant decrease > 50% (or resolution) of ST
segment elevation. The diagnosis of reperfusion was not based on coronary
angiography. The ratios of cardiac markers at two hours following reperfusion were
CK-MB mass [range 0.95 - 257], cTnl [range 0.89 - 337], cTnT [range 0.23 - 352],
H-FABP [range 0.72 - 240], and myoglobin [range 0.6 - 151].
Based on ROC curve analysis between patients who received reperfusion treatment
(STEMI group) and those who were not thrombolysed (NSTEMI group), the
following were found to be the best cut-off ratios for the discrimination between
successful and failed reperfusion at two hours after the initiation of thrombolysis,
CK-MB mass > 2.6 [sensitivity = 72.7%, specificity = 75%], cTnl > 3.4 [sensitivity
= 63.6%, specificity = 75%], cTnT > 2.3 [sensitivity = 61.4%, specificity = 91.7%],
myoglobin > 2.2 [sensitivity = 75.5%, specificity = 83.3%], and H-FABP > 1.7
[sensitivity = 77.3%, specificity = 75%].
Detection ofre-infarction
A seventy-seven years old lady with previous history ofMI and angina was admitted
with AMI 6 hours after symptom onset. She had ST segment elevations in the
anterior and inferior leads of the admission ECG. She was treated with streptokinase
with good resolution of ECG changes. Four hours after presentation (10 hours after
the onset of chest pain), she had recurrent episodes of chest pain with further ST
segment elevation. The diagnosis of re-infarction was entertained and she was treated
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with another course of thrombolytic therapy (tissue plasminogen activator). She had
no further routine CK concentration rise. The temporal profiles of cardiac markers
concentrations in this patient are shown in Figure 4. Myoglobin was the most
significantly elevated cardiac marker at presentation. CK-MB mass, H-FABP, and
cTnl were also diagnostic of AMI at presentation. Re-infarction was reflected by a
prominent second peak rise in concentrations of myoglobin. Creatine kinase-MB
mass had a small second peak but it was not marked. Heart-FABP showed small
increases in concentrations after re-infarction (33, 35, and 38 pg/1). For cTnl and
cTnT, such peak rise was absent and their concentrations continued to rise slowly
after the first infarct (Figure 4).
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Figure 4. This graph shows the time-concentrations profile of cardiac markers
CK-MB mass, cTnl, cTnT, H-FABP, and myoglobin at 0, 2, 4, 8 - 10, and 16 - 24
hours, in a patient who had re-infarction ten hours after the first infarct. There
was a second peak rise in concentrations ofmyoglobin after re-infarction. There
was a small but less marked second peak for CK-MB mass. Heart-FABP had
small rises in concentrations, but there was no prominent peak during the
sampling interval. Cardiac-Tnl and cTnT concentrations continued to increase
steadily in serum.
262
A marker that can detect re-infarction must be released early and cleared rapidly
from the circulation i.e. has a short diagnostic window. In the event of re-infarction it
will show another peak rise in concentrations. There was some discrepancy between
H-FABP and myoglobin for the detection of re-infarction. Myoglobin was useful for
detecting re-infarction but H-FABP did not show a second prominent peak rise in
concentration in this patient who was a presumed case of re-infarction. However,
after an initial decline in concentration, H-FABP was staring to show a slight upward
trend in concentration in the last two samples taken after re-infarction. It might be
possible that the second peak occurred late outwith the sampling interval.
Value ofcardiac markers for detection ofinfarct extension
One patient was admitted with inferior MI and treated with streptokinase. The second
day of admission she developed episodes of chest pain with further elevations of ST
segment in the inferior leads. It was suspected that she was developing infarct
extension and was given another course of tPA. No serial testing of cardiac markers
were performed in this patient beyond 16-24 hours after presentation. However, it is
important to consider the changes in cardiac markers concentration in the last sample
taken at 16-24 hours and draw some assumptions on their possible usefulness for
the detection of infarct extension. The concentration of CK-MB mass continued to
rise from a normal concentration at presentation (2.4 ju.g/1) to a maximum
concentration (665.4 pg/1) at 16-24 hours. Similarly, cTnl also rose from 0.1 pg/1 to
a maximum concentration of 327 p.g/1 at 16 - 24 hours. Cardiac-TnT rose from
undetectable concentrations (0.01 pg/1) to a maximum concentration of 11.65 pg/1 at
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8-10 hours and then started to decrease reaching a concentration of 6.15 (j.g/1 at 16 -
24 hours.
The concentration of myoglobin was normal (63 pg/1) at presentation and increased
to a maximum concentration at 4 hours (1113 pg/1), and had decreased significantly
(110 jug/1) at 16-24 hours. Heart-FABP concentration increased from 11 pg/1 at
admission to a maximum concentration at 4 hours (280 pg/1), and had decreased
significantly (20 pg/1) at 16 - 24 hours. The diagnosis of infarct extension was made
several hours after the last sample was taken. It would be expected that myoglobin
and H-FABP concentrations would have decreased back to normal by this time. In
the event of significant myocardial extension there may be further rise in myoglobin
and H-FABP concentration. The other cardiac markers were still present in high
concentrations and they probably would not display a second prominent peak rise in
concentrations as a result of infarct extension.
Decisions with implementation ofthrombolytic therapy
This was a 75 years old man who was admitted with chest pain and tall R wave on
V2 and ST segment depression on the ECG. He also had congestive cardiac failure
with raised jugular venous pressure and pulmonary crepitation. The diagnosis was
assumed to be posterior myocardial infarction and he was admitted to CCU and
treated with tPA. During the course of treatment it was decided to stop tPA because
of insufficient ground for thrombolysis. Echocardiogram showed global and severe
impairment of left ventricular function. This patient's condition later deteriorated and
264
despite inotropic support he developed acute renal failure and died 5 days after
admission.
At presentation myoglobin and H-FABP where diagnostic of ischaemic event, the
other cardiac markers concentrations in this patient were normal or slightly raised
above the upper limit of normal, CK-MB mass = 7.4 pg/1, cTnl = 0.27 pg/1, cTnT =
0.01 p.g/1, H-FABP = 45 pg/1, and myoglobin = 580 p.g/1. The cardiac markers
concentrations in this patient were diagnostic of AMI at 2 hours after presentation,
CK-MB mass = 42 pg/1, cTnl = 24.47 p.g/1, myoglobin = 3120 pg/1, and H-FABP =
260 pg/1. There was a significant change in cardiac markers concentrations 2 hours
after presentation. This massive cardiac markers concentrations change most
probably reflects underlying posterior MI. These measurements were completed
before the onset of renal impairment (normal urea and creatinine). The availability of
this information sooner may have affected the decision on thrombolytic therapy.
The influence of several factors like infarct size, time to presentation, and
reperfusion on the rate of cardiac markers appearance in blood following the index
event and the effects that these might have on the sensitivity were studied. The peak
concentrations of cardiac markers were used as a qualitative measure of infarct size.
This peak concentration of cardiac markers in patients with STEMI was compared
with the peak concentration of cardiac markers in patients with NSTEMI (compare
Figure 1 pages 249 - 250 with Figure 2 pages 196 - 197). There were two to five-fold
increases in cardiac markers concentrations in patients with STEMI reflecting larger
myocardial tissue damage in this group compared to patients with NSTEMI. The
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sensitivity of cardiac markers for the diagnosis ofAMI was also higher in this group
compared to patients with NSTEMI (compare sensitivity in Table 5A page 208 with
sensitivity in Table 5 page 254). This would support that infarct size contributes to
the rate at which cardiac markers appear in blood and that large infracts are
associated with more significant release of these markers after the index event.
The duration between onset of symptoms and presentation was also an important
factor in determining the rate of appearance of these markers in blood. This was
demonstrated by the time-concentration profile of cardiac markers in the several
clinical examples quoted in these studies. The release of cardiac markers after AMI
was also affected by the administration of thrombolytic agents. There was a
significant increase in concentrations (and an improvement in sensitivity) of most
cardiac markers several hours after successful thrombolysis compared with
sensitivity at presentation or in the group of patients with NSTEMI who were not
thrombolysed.
7.4 DISCUSSION
This study investigated the role of H-FABP in the early diagnosis of AMI in 45
patients who were admitted to CCU with AMI within 6 hours after symptom onset
and before the administration of thrombolytic therapy. The diagnostic power of H-
FABP for the early detection ofAMI was compared with standard cardiac markers of
myocardial injury like CK-MB mass, cTnl, cTnT, and myoglobin. Heart-FABP
appeared in reliable concentrations 6 hours after symptom onset, peaked at 8 hours
and had decreased significantly towards normal concentrations by 16-24 hours after
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presentation. This early peak ofH-FABP is consistent with previous reports, which
suggested that H-FABP peak concentration occurs within 5-10 hours after symptom
onset.37
The sensitivity of H-FABP for the detection of AMI within the first 6 hours after
symptoms onset was 75.5%. Our results were in agreement with those published
previously. Glatz et al (1998) reported a sensitivity of 78% for H-FABP, 53% for
myoglobin in 83 patients with confirmed myocardial infarction who were admitted
less than 6 hours after symptom onset.19 Kleine et al (1992) using a threshold
concentration > 19 p.g/1, found in 18 out of 22 patients with established AMI, the H-
FABP concentration was increased above the threshold in blood samples taken at 3.5
hours after symptom onset of AMI. Only 40% of patients had elevated CK-MB
T 1 .
concentration. Ishii et al (1997) using cut-off concentrations > 12 p.g/1, the
sensitivity of H-FABP for the diagnosis of AMI within 6 hours after symptom onset
was 81.8%. The cut-off concentration in their study was based on ROC analysis
between patients with AMI and normal healthy volunteers (similar to the method
used to obtain the cut-off concentrations in Table 5). These investigators also
-50
reported superior sensitivity ofH-FABP over myoglobin.
The sensitivity of cardiac markers was mostly dependent on the threshold
concentrations. Overall, H-FABP was the most sensitive marker at presentation and
within the first two hours after presentation. It also demonstrated the highest NPV
(94%). The high sensitivity is essential for the early rule in of patients with AMI, and
the high NPV is very important to rule out AMI, since more than 90% of patients
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who present with acute chest pain to A&E department do not have AMI. Most of the
standard cardiac markers had limited diagnostic value at presentation. The sensitivity
of these markers for the early diagnosis of AMI was < 62%. This low sensitivity of
. • . • 'Xfx
cardiac markers at presentation is consistent with previously published data. Bakker
et al (1993) reported low sensitivity (< 64%) and low negative predictive value of
routine cardiac markers CK-MB mass, cTnT, myoglobin, CK-MB activity, and CK
TO
to allow early exclusion ofAMI.
This low early sensitivity may be attributed to; (1) the short time between symptoms
onset and presentations. As shown in Figure 1, cardiac markers need sufficient time
after onset of symptoms to accumulate in blood in reliable concentrations. The time
delay in cardiac markers appearance is different for each marker. At presentation, H-
FABP was the most sensitive early marker (75.5%), followed by myoglobin (62%),
CK-MB mass (60%) and cTnl (51%). From two hours onwards after presentation
most cardiac markers (except cTnT) were present in significant concentrations in
most patients with AMI; (2) the use of high diagnostic cut-off concentrations.
Myocardial injury in our study was defined as cTnl concentration >0.18 pg/1 (Table
5). This was very similar to the cut-off concentrations used by Heeschen et al (1999)
to define AMI in their group of patients. These investigators used Stratus CS and
based on ROC curve analysis, AMI was defined as cTnl >0.15 pg/1.46
The usefulness of myoglobin and H-FABP for the early diagnosis of AMI has been
supported by other studies. ' ' However, the performance ofH-FABP in this study
was significantly better than myoglobin (sensitivity at presentation, 75.5% vs 62%).
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Heart-FABP also had higher NPV (94%) for the early exclusion ofAMI compared to
myoglobin (90.2%). The superiority of H-FABP over myoglobin (both are cytosolic
protein and have similar molecular weight) has been suggested before.19,38 This
advantage of H-FABP may be attributable to more cardiac specificity and low base
line concentrations in normal patients. The distribution of H-FABP in the heart and
skeletal muscle is comparable to that of CK-MB and is inverse to the distribution of
myoglobin.48 These features allow the use of lower but discriminate cut-off
concentration thus improving the sensitivity.
The range of H-FABP in the control group ranged from 1 - 14.5 pg/1, median = 6.9
jLtg/1. The concentrations of H-FABP in normal healthy controls in previous studies
ranged from 1 - 11.4 pg/1, and 9-14 pg/1, which is consistent with the normal range
• "J1 .TO
in our group of controls. ' Based on the subgroup analysis, H-FABP in the
concentration range 9 - 12.5 pg/1 was the most appropriate threshold to define
myocardial injury, both in terms of early and late sensitivity. Haastrup et al (1999)
has found that H-FABP between 8-12 p.g/1 detected 90 - 95% with a specificity of
81 - 94%, and PPV 47 - 73% of patients with NSTEMI within 6 hours after symptom
onset. The low PPV was related to the low prevalence ofAMI in the study group.50
Some of the earlier studies have supported the additional beneficial role of
myoglobin to H-FABP ratio over and above the measurements of either myoglobin
or H-FABP alone (page 76).36 The value of myoglobin to H-FABP ratio as a
discriminator between cardiac and non-cardiac injury is not supported by the findings
of this study. This ratio was falsely negative (i.e. > 21) in a small number of patients
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with confirmed AMI and had a high false positive rate in normal patients with chest
pain, and does not offer any advantage over the measurement of H-FABP alone.
Furthermore, the measurement of both markers to obtain the ratio does not improve
the sensitivity and is not cost effective. Instead one of these markers (e.g. H-FABP)
should be combined with cTnl to allow risk stratification of patients with UA and
improve the specificity for definitive diagnosis ofAMI. Ishii et al (1997) reported no
clear advantage of myoglobin to H-FABP ratio over the measurements of H-FABP
o o
alone. The comparison of the area under the ROC curve for H-FABP (0.946), and
myoglobin (0.895) in patients with AMI was significantly greater than the area under
the ROC curve for myoglobin to H-FABP ratio (0.823). In addition, the myoglobin
to H-FABP ratio is not reliable following physical exercise, in the presence of renal
failure, and when there is a combined cardiac and skeletal muscle damage e.g.
. 36;43;44
coronary bypass surgery.
The maximum concentrations of cTnT in these studies was achieved very late (about
24 - 30 hours after symptom onset) compared to other markers e.g. cTnl.34 This late
peak may be due to genuine delay in the release of this marker from damaged
myocardial tissue, or could be related to matrix effects of cTnT and cTnl assays.
There is some supportive evidence for the existence of free cytosolic cTnl pool, as
well as cTnl attached to myofibril proteins. For cTnT, protein turnover studies do not
support the existence of such cytosolic pool for cTnT. ' The existence of cTnl
freely in the cytosol of myocardial cell, may explain the rapid release of cTnl
following myocardial tissue damage (within 8-10 hours after symptom onset) that
had been noticed consistently throughout these studies. This delay may also be
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related to different release kinetics as a result of differences in molecular weight
between CTnl (22.5 Kilodalton) and cTnT (37 Kilodalton). Cytosolic localisation or
matrix effect as opposed to molecular size of troponins (compare CK-MB mass [80
Kilodalton] and cTnT [37 Kilodalton]) is the most likely explanation for the rapid
appearance following myocardial injury. The continuous increase of cTnT
concentrations during the sampling interval will support the prolonged diagnostic
window (5 days), which had been observed for this marker following its release from
damaged myocardium.34
Cardiac markers can play an important role in the diagnosis and management of
patients with chest pain suggestive of AMI. Clarifications of non-diagnostic initial
ECG and the detection of posterior MI are just some of the useful aspects of
adjunctive serial cardiac markers testing in the diagnosis of AMI. As shown in this
study, about 20% of patients in this selected high-risk group had no diagnostic ECG
changes ofAMI at admission and a similar number had atypical history of chest pain.
Cardiac markers (cTnl and H-FABP) were diagnostic of AMI in 93 - 100% of
patients within the first 2 hours of admission. Early serial ECGs and serial cardiac
markers testing should both be an integral part of the investigation of patients with
suspected AMI in the presence of non-diagnostic ECG or when the clinical history is
atypical.
Other aspects where serial cardiac markers testing might be useful are in the
detection of re-infarctions and infarct extension. The frequency of re-infarction in the




thrombolytic therapy is about 17%. Clinical features of re-infarction or infarct
extension e.g. chest pain or new ECG changes may or may not accompany these
complications. The clinical suspicion of re-infarction or infarct extension may
necessitate the use of invasive investigations e.g. coronary angiography to ascertain
the diagnosis. These complications will also require further interventions to open the
occluded artery (thrombolytic agents or PCI). The availability of simple, safe and
reliable non-invasive alternative methods like cardiac markers for the detection of
early re-infarction or infarct extension will help with the management of some of
these patients. Most of the cardiac markers like CK-MB mass, cTnl, and cTnT take
longer time to return to the pre-infarction level, and thus are not reliable for the
detection of re-infarction if it occurs early.
The value of H-FABP and myoglobin for the detection of re-infarction has been
suggested by other studies.31-36 Due to the unpredictable time of occurrence of these
complications, it is suggested that serum should be collected at the same times when
other conventional samples are obtained and stored. The analysis is performed if in
retrospect there is a significant doubt regarding the diagnosis of re-infarction or
infarct extension. Further studies that include large numbers of patients with these
complications are needed to examine in much more details the value of myoglobin
and H-FABP for the detection of re-infarctions and infarct extension.
Thrombolytic therapy has become the standard therapeutic approach in patients with
AMI. The detection of successful reperfiision after the administration of thrombolytic
therapy is mandatory in the management of patients with AMI. Unsuccessful
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reperfusion is associated with a low ejection fraction and increased one year
mortality.42 it is estimated that between 15 - 50% of patients fail to achieve early
infarct artery patency following intravenous thrombolytic therapy49 and only 50% of
patients treated with thrombolytic therapy achieve TIMI grade 3 flow (unrestricted
flow) within 90 minutes of admission.51 The clinical markers of reperfusion e.g.
resolution of chest pain and ST segment elevation, and reperfusion arrhythmias have
70% sensitivity for the detection of reperfusion.43
The early assessment of reperfusion using cardiac markers ratios after the initiation
of treatment may be more sensitive than clinical markers. The reason for the low
sensitivity of these ratios in this study may be related to the difference between the
timing of post-thrombolytic samples. This study predicted the success of reperfusion
two hours after initiation of thrombolytic therapy, whereas most of the other studies
examined this effect within one hour. The sensitivity of these ratios may be inversely
related to the timing of post-thrombolytic samples and decreases with delayed
sampling after thrombolysis.
Abe et al (1991) has showed that a rise of H-FABP ratio > 1.5, 30 minutes after
thrombolysis was associated with 100% accuracy for the detection of reperfusion.
This sensitivity drops to 94% at 60 minutes after thrombolytic treatment. Creatine
kinase-MB ratio > 2 and myoglobin ratio > 2.4 were found to be associated with 95 -
100% sensitivity for the detection of reperfusion 60 minutes after the initiation of
thrombolysis.40'47 Measurement of cardiac markers ratios in addition to clinical
markers of reperfusion may offer a simple but efficient alternative to the use of
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coronary angiography for the detection of successful reperfusion, especially in
institutions that do not have access to coronary angiography facilities.
The administration of thrombolytic therapy in this group of patients may have
contributed to some extent towards the earlier release of cardiac markers in blood
samples taken beyond 0 hours, the so-called 'wash-out' phenomenon. This
'iatrogenic effect' may have influenced the sensitivity of some of the cardiac markers
in this study. This study did not include patients with STEMI who were admitted
within 6 hours but were not given thrombolytic agents for comparison. Hence, it is
difficult to draw firm conclusions regarding the size of contribution of successful
reperfusion towards sensitivity.
There are however, several arguments for the robustness of these results, and that
such improved sensitivity was not explained entirely by the effect of reperfusion; (1)
At 0 hour i.e. before the administration of thrombolytic therapy, the concentration of
H-FABP in the blood had significantly increased compared to other markers,
reflecting its genuine role as a sensitive early marker of AMI; (2) The sensitivity of
these markers over the first 24 hours was assessed in a group of patients with
NSTEMI, who were not given thrombolytic therapy. Although the proportion of
infarct size in this group of patients was less than in patients with STEMI.
Nevertheless, there were similar cardiac markers release characteristics patterns
between NSTEMI and STEMI (compare Figure 1 pages 249 - 250 with Figure 2
pages 196 - 197), and the peak concentrations of cardiac markers occurred at similar
times. Heart-FABP demonstrated superior sensitivity in this group of patients as
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well, compared with other markers over the first two hours of presentation; (3) The
effects of reperfusion on cardiac markers release were distributed across all markers,
thus excluding specific bias.
7.4.1 Summary
Overall 76% of patients in this group had typical history of ischaemic chest pain at
admission. The overall diagnostic power of the ECG in this highly selected group of
patients was 86%. Heart-FABP was the most sensitive marker of myocardial injury
with 75.5% and 100% of patients with AMI identified at presentation and 2 hours
after presentation. It also had the highest NPV (94%) for the early exclusion ofAMI.
The early diagnostic power of the other cardiac markers (CK-MB mass, cTnl, cTnT,
and myoglobin) at presentation was low (< 62%). However, within 4 hours of
presentation most cardiac markers (CK-MB mass, cTnl, and myoglobin) had 90 -
100% sensitivity, specificity, PPV, and NPV for the diagnosis and exclusion ofAMI.
The adjunctive value of serial cardiac markers testing using H-FABP in combination
with cTnl in AMI diagnosis and management in the presence of non-diagnostic ECG
is invaluable. Serial cardiac markers testing may also be helpful in timing the onset
ofMI event, detection of re-infarction, infarct extension, and reperfusion.
7.4.2 Limitations of the study
(1) Patients admitted to the CCU constitute a highly selected group of patients at
high-risk for myocardial injury compared for example to patients with chest pain
seen at the A&E department. This factor is a disadvantage and may have affected
positively the sensitivity and specificity of the different cardiac markers in the study.
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(2) The role ofH-FABP and other markers for the detection of complications such as
early re-infarction and infarct extension could not be assessed properly due to the
relative absence of these complications in the study group.
(3) This study had no control group (i.e. patients with STEMI who were not
thrombolysed) for comparison. Therefore the measurements of the ratios for
detecting successful reperfusion and the release pattern of the different cardiac
markers were compared with a group of patients with NSTEMI who were not
thrombolysed. The timing of the first post-thrombolytic sample at two hours had
limited our ability to examine the role of these markers for the detection of
successful reperfusion. In the future, such studies should be based on ratios obtained
from ROC curve analysis in patients with STEMI who were thrombolysed and
patients with STEMI who were not thrombolysed. These ratios should also be based
on samples obtained within one hour after intravenous thrombolytic therapy.
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CHAPTER 8
IMPLICATIONS OF STUDIES, LIMITATIONS, AND FUTURE HORIZONS
FOR IMPROVING THE EARLY IDENTIFICATIONS AND MANAGEMENT
OF PATIENTS WITH ACUTE CORONARY SYNDROMES USING HEART
FATTY ACID BINDING PROTEIN
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8.1 CARDIAC MARKERS AND PERCUTANEOUS CORONARY
INTERVENTION
Percutaneous coronary intervention is an invasive interventional procedure that is
becoming increasingly used in the treatment of a wide range of patients with ACS.
The introduction of PCI into interventional cardiology is relatively recent. However,
the remarkable successes in symptom relief and the feasibility of this intervention
have driven an expansion of its applications. The guidelines for its applications are
continuously changing to include many patients who may have been managed
medically or who were candidates for CABG. Currently PCI is mainly performed in
hospitals that have cardiothoracic surgical backup in case urgent CABG is required.
The development of coronary stents had been a revolutionary advance in terms of the
success and safety of PCI. The introduction of new and powerful regimes of
antiplatelets therapy has also reduced the complications associated with PCI. With
further improvement in experience, medical management (e.g. antiplatelets,
antithrombotic), and technological advancement (e.g. stents, catheters, and guide
wires), the complication rates associated with PCI could be further diminished. When
this is achieved, it may become feasible to perform PCI in hospitals that do not have
cardiothoracic surgery backup in site e.g. district general hospital.
This study has shown that elevated cardiac markers (CK-MB mass, H-FABP,
myoglobin, cTnl, and cTnT) concentrations were present in patients who had
undergone visually successful and uncomplicated PCI. These elevations in cardiac
markers concentrations may have prognostic implications, and were associated with
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significantly reduced event-free survival, and with the development of more
complications on long-term follow-up (Chapter 5). These complications included a
higher incidence of uncontrolled angina, and the need for revascularisation. Some of
the findings in this study are in agreement with previously published data. However,
there are new findings that can be specifically drawn from this study.
1. This study has found cTnl to be the most sensitive marker for the detection of
myocardial damage during and after PCI. It has shown the most frequent increase
after PCI compared to cTnT, CK-MB mass, H-FABP, and myoglobin, reflecting
superior sensitivity of cTnl assay used by Stratus CS. Cardiac-Tnl testing should be
the standard cardiac marker used for evaluation ofmyocardial injury following PCI.
2. Total cTnl elevation was associated with reported complications in 62% of
patients. Its specificity and positive predictive value for complications were 67% and
62% respectively. Therefore, elevated cardiac markers post-PCI may or may not be
associated with angiographically demonstrable complications during the procedure.
Measurement of cTnl is more sensitive for the detection of myocardial injury than
contrast angiography and should form part of the routine assessment of all patients
following PCI to exclude myocardial damage not detect or noticed during PCI.
3. Occurrence of complications (major dissections, side branch occlusion, transient
vessel closure, and bail out stent) during PCI was the variable that correlated most
with cardiac markers elevations. The significance of these complications was related
to the number of elevated cardiac markers, and the magnitude of elevation. The
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measurement of cTnl is a useful adjunct to PCI, and can help provide a quantitative
assessment ofmyocardial damage as a result of complications during PCI.
4. Measurements of cardiac markers post-PCI may be useful for the early detection
of evolving MI within the first 2 hours. In patients with chest pain post-PCI,
measurement of H-FABP before the procedure (stored serum) and after the onset of
chest pain may offer reliable detection of early evolving myocardial infarctions. The
combination testing of H-FABP and cTnl increased the specificity for the diagnosis
of AMI. This testing may allow the selection of high-risk patients for early re-
catheterisation to ascertain the diagnosis and re-establish early reperfusion of the
occluded artery.
5. Elevated cTnl > 0.18 jug/1 [cTnT >0.1 p.g/1] post-PCI may guide further
management. This elevation was associated with increased risk of complications.
Thirty-two per cent of patients with elevated cTnl post-PCI were not treated with
antiplatelets other than aspirin. These patients had more episodes of angina and more
revascularisation procedures on long-term follow-up (66.7%).
It is not clear at present whether further treatment of this group e.g. clopidogrel is
required or might have any impact on their outcome. Many studies have
convincingly demonstrated adverse prognostic outcome in patients with ACS and
elevated troponins.1 Even small increases of cTnl > 0.08 p.g/1 were associated with
appreciable risks (as suggested by this study as well). Further randomised trials are
needed to examine the benefits of long-term antiplatelet treatment in patients with
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elevated troponins post-PCI, in the absence of any demonstrable clinical and
angiographic complications.
6. The reporting of angiographic successes may be overestimated by reliance on
visual assessment alone. Even in the absence of complications at angiography,
significant numbers of patients had cTnl elevations. Contrast angiography is less
sensitive than coronary angioscopy for the detection of complex plaques and
thrombi.3 This may explain the low positive predictive value of cTnl. The correlation
and the predictive accuracy of cTnl for the detection of complications post-PCI
should be compared with the more sensitive coronary angioscopy.
7. Heart-FABP has been shown in this model of myocardial injury to be a truly an
early marker of myocardial damage, with concentration peaks occurring two hours
after PCI, and rapidly returns to normal concentration. This early release
characteristic of H-FABP is superior to myoglobin, CK-MB mass, and troponins.
Heart-FABP was also the most useful test for the very early detection of evolving
AMI, but is less sensitive than cTnl for the detection and quantification of other
complications post-PCI.
8. A significant numbers of patients (6 out of 7) had cTnl elevation following
investigations by intravascular ultrasound or pressure wire studies. It is not known
whether such investigations contribute to myocardial injury during PCI and if so by
what mechanism(s). This finding suggests that cTnl check should be performed in all
patients following these investigations to exclude myocardial damage.
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9. Percutaneous coronary intervention technology e.g. stents, balloons, and guide
wires is advancing rapidly. Recent years have also witnessed the introduction of
many investigative and therapeutic compounds for use with PCI. The exceptional
sensitivity of cTnl for the detection of subtle damages to the myocardium will
provide a reliable quantitative assessment of the direct impact and safety of all these
methods.
Cardiac markers testing post-PCI (using cTnl) should be part of the routine patients'
care and will help provide retrospective accurate validation of the success of the
procedure, verify suspicious complications during PCI, detect evolving myocardial
infarction early (using H-FABP), provide long-term prognostic risk and may guide
further antiplatelet treatment.
8.2 CARDIAC MARKERS AND NON-Q WAVE MYOCARDIAL
INFARCTION AND UNSTABLE ANGINA
In this study, H-FABP was shown to be superior or similar to myoglobin (that
depends on the threshold) for the detection ofmyocardial injury in patients with non-
Q wave MI within 7 hours after symptoms onset. Heart-FABP was increased in 79%
of patients at presentation; all the other markers including myoglobin were increased
in < 71%. Myocardial infarction can be confirmed using H-FABP, myoglobin, cTnl,
and CK-MB mass in 93%, 93%, 86%, and 79% respectively within the first 2 hours
of presentation. This suggests that H-FABP is the most sensitive marker for the very
early detection of non-Q wave MI. The sensitivity of cTnl was superior to that of
cTnT and CK-MB mass. These features of cTnl, combined with the slightly reported
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higher specificity over cTnT in patients with renal failure and skeletal muscle disease
in the literature, will support the preferential use of cTnl4
Cardiac-Tnl and cTnT were more sensitive (55% and 40% respectively) and specific
than CK-MB mass, myoglobin, and H-FABP for the diagnosis of UA. Heart-FABP
was increased in a fairly high numbers of patients with UA (40%), and showed an
earlier concentration peak (within two hours), and might be useful for the earlier
detection of these patients. However, H-FABP lacked specificity. There was some
overlap between the concentration of H-FABP in some patients with UA and those
with NSTEMI and STEMI. This overlap could limit the usefulness ofH-FABP as the
sole marker for the diagnosis of patients with UA. This problem could be overcome
by; using concentration of H-FABP more than five times the upper limit of normal
that is specific for the diagnosis of non-Q wave MI; or the combination of H-FABP
with cardiac troponins may improve the specificity for the early diagnosis ofUA.
Implementation of serial cardiac markers testing in patients presenting to A&E
department with acute chest pain is warranted. Point of care testing of two cardiac
markers, one that is totally specific e.g. cTnl, and one that is early and sensitive e.g.
H-FABP at two intervals within the first 8 hours after presentation is simple and may
be cost effective. This policy will reduce the pressure on the main hospital
laboratory, and speed up the decision process regarding many aspects of patients'
management such as diagnoses confirmation, triage policy (from A&E department
and within hospital), risk stratifications (high and low-risk groups), and treatment
(antiplatelets, antithrombotic, thrombolytic therapy, and PCI).
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Serial cardiac markers testing can clarify atypical chest pain, non-diagnostic ECG or
both. Patients may present with subtle changes of ischaemia on the admission ECG
such as; minimal ST elevation < 1 mm; transient ST elevation; significant ST
elevation in one lead only; suspected but not evident changes of posterior MI;
marked and deep T wave inversion; poor R wave progression; conduction
abnormality (paced rhythm and the presence of old left bundle branch block); 'Q
wave equivalent' changes; and ischaemic left ventricular failure. Concomitant serial
cardiac markers testing at admission or shortly afterwards, will help to clarify the
diagnoses of AMI in the majority of these patients very early. Patients with non-Q
wave MI have a higher rate of complex lesions and total coronary artery occlusion.?
Some patients may have missed posterior MI, missed Q wave equivalent or
confounding ECG changes that preclude the ECG diagnosis ofAMI, and may benefit
from early PCI.
Serial cardiac markers testing will also help with decisions regarding patients'
management such as; (1) Prevention of inadvertent discharge of patients with
myocardial damage from A&E departments; (2) Selection of high-risk patients for
admission to CCU and other dependent units; (3) Classification of patients into high-
risk group may guide early treatment with newer and more potent and expensive
antiplatelet regimes; (4) Target the use of invasive procedures such as PCI to the
most appropriate high-risk group.
In patients with chest pain but with no ECG changes of ischaemia, serial testing can
rule out serious myocardial damage early. This will impact on patients' management
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in several ways; (1) Early stratification of such patients into low-risk group. Low-risk
patients can be admitted to regular beds and if necessary subjected safely to early
exercise tolerance test to rule out ischaemic heart disease and discharged early.
Alternatively, low-risk patients can be safely discharged and further investigations
planned as outpatients. This will provide better and cost effective management of
resources; (2) Avoidance of unnecessary and expensive high-risk invasive
investigations in these low-risk patients; (3) There is little evidence to support cost
effective use of potent antiplatelets in low-risk patients, hence these treatments
should be reserved for high-risk groups.
8.3 CARDIAC MARKERS AND THE EARLY DIAGNOSIS OF ACUTE
MYOCARDIAL INFARCTION
In patients presenting with AMI within 6 hours after symptom onset, the peak
concentrations of H-FABP, myoglobin, cTnl, CK-MB mass, and cTnT were reached
at 2 hours, 2 hours, 8-10 hours, 8-10 hours, and 16 - 24 hours respectively after
presentation. Heart-FABP was the most sensitive marker for the very early diagnosis
of AMI (75.5%). In comparison, CK-MB mass, cTnT, cTnl and myoglobin had low
sensitivity (range 24% - 62%) at presentation. Heart-FABP achieved peak sensitivity
(100%) at 2 hours and remained elevated at 100% for the first 2-8 hours after
presentation. The optimum diagnostic window for myoglobin was between 2-8
hours after presentation (sensitivity 91 - 93%). The optimum diagnostic window for
CK-MB mass and cTnl was between 2-16 hours, but the sensitivity of cTnl (97.7 -
100%) during this interval was superior to CK-MB mass (93 - 100%). Cardiac-TnT
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was a late marker, and reliable sensitivity of cTnT was seen at 8 - 10 hours after
presentation (Table 5 page 254).
The following observations can be drawn from the results of this study; (1) Heart-
FABP was superior to myoglobin for the early diagnosis ofAMI within 6 hours after
symptom onset (75.5% vs 62%); (2) The diagnostic window of H-FABP was
relatively prolonged (up to 14 hours after symptom onset). This diagnostic window
will provide ample opportunity for the detection ofAMI within the most appropriate
time interval for thrombolytic therapy; (3) The sensitivity of cTnl used on Stratus CS
was superior to cTnT and CK-MB mass. This will support its use for the early
detection of patients with AMI; and (4) In patients who present within 6 hours after
symptom onset, serial combinations testing of H-FABP and cTnl at two intervals
during the first 8 hours, was sufficiently sensitive for the early diagnosis of all
patients with AMI.
This serial combination testing of cTnl and H-FABP may also be useful in the
following situations; (1) Timing the onset of AMI event. Heart-FABP concentration
has been shown repeatedly to peak between 5-10 hours after AMI (8 hours in this
study). The time-concentration changes of H-FABP and cTnl may help time the
onset ofMI event. Rising H-FABP and cTnl concentrations may suggest recent event
within the proceeding 12 hours. This information may in turn be a useful help with
decision on reperfusion therapy; (2) The early diagnosis of AMI in the presence of
ECG features that confound the detection of ischaemia such as left bundle branch
block and paced rhythm; (3) In patients with atypical chest pain or equivocal ECG
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changes ofAMI; (4) Detection of posterior MI; (5) Detection ofAMI in the presence
of skeletal muscle injury.
Serial cardiac markers testing may also be useful in the management of patients in
the early phase of MI; (1) Early estimation of infarct size within 24 hours can offer
important prognostic informations; (2) Detection of re-infarction if it occurs early;
(3) Detection of infarct extension; and (4) Detection of reperfusion. The value of
CK-MB mass, cTnT, and cTnl in these situations (with the exception of reperfusion)
is limited. Heart-FABP and myoglobin were the two markers with possible
diagnostic potential in these situations. Myoglobin was more sensitive than H-FABP
for detecting re-infarction in the patient who developed this complication. Both
markers may be useful for detecting infarct extension.
Heart-FABP and myoglobin were the only two markers that peaked at 8 hours. This
early peak suggests that these two markers may be more suitable than CK-MB mass,
cTnT and cTnl for detecting successful reperfusion. The sensitivity of myoglobin
and H-FABP ratios for detecting successful reperfusion at two hours was moderate
(75 - 77%). For better accuracy, this ratio may need to be calculated after one hour
following reperfusion. Heart-FABP and myoglobin may also be useful for the early
estimation of infarct size. However, this measurement can be obtained by other
means that are rapid, less invasive, and fairly reliable such as echocardiography.
When accurate early estimation of infarct size is required, serial H-FABP or
myoglobin testing can be used.
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The troponin proteins are more sensitive and specific than routine standard cardiac
markers like CK and CK-MB. The latter markers are cheap and may be used for the
confirmation ofMI in patients with unequivocal ECG changes ofAMI. However, for
better management of all other patients with acute chest pain and suspected MI, the
serial combinations of H-FABP and cTnl should be used. The results of serial
cardiac markers testing along with electrocardiographic finding, and the clinical
presentation, will allow satisfactory patients' care in most clinical settings.
8.4 IMPACT OF THE NEW DEFINITION OF ACUTE MYOCARDIAL
INFARCTION BY THE EUROPEAN SOCIETY OF CARDIOLOGY AND
THE AMERICAN COLLEGE OF CARDIOLOGY
This study examined the clinical impact of the new definition of AMI by the
ESC/ACC in the three groups of patients that constituted the study (for definition see
page 16). In PCI group, 57.5 per cent [46/80] of patients fulfilled the biochemical
criteria for the diagnosis of AMI (i.e. cTnl > 99th percentile of control group = 0.1
pg/1). The diagnosis of AMI in such a high numbers of patients (sometimes in
patients with no apparent complications) following this relatively safe procedure will
have many adverse repercussions in clinical practice.
This will raise concerns about the safety of the procedure. It will also have important
and widespread social, health and legal implications. Ultimately this may impact
negatively on the widespread and growing applications of this popular intervention,
and will call for drastic measures to reduce these complications. In patients with UA,
75 per cent had elevated cardiac markers concentrations consistent with AMI. This
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problem can be reduced significantly by using two different thresholds (based on
ROC curve analysis) that define patients with UA from those with myocardial
infarction.
The effects of the ESC/ACC definition on the AMI group were an improvement of
sensitivity and NPV and a decrease of specificity and PPV. Using the 99th percentile
of cTnl, 67% of patients will have evidence ofMI at presentation, but on the other
hand 50% of patients with UA will be misclassified as MI at presentation. The use of
this definition in isolation may lead to erroneous diagnosis of AMI. This definition
will be ideal in situations when there are cardiac markers that are 100% sensitive and
specific and when used in conjunction with unequivocal ECG changes of AMI.
Outside these specific situations, the applications and interpretation of these
recommendations may need to be exercised with caution.
8.5 LIMITATIONS OF HEART FATTY ACID BINDING PROTEIN
ASSAYS
Heart-FABP is potentially useful for the very early identifications of patients with
AMI. In combinations with cardiac specific markers (cTnl), H-FABP can offer very
early reliable warning of evolving AMI event. In addition, serial testing of H-FABP
can also assist in the triage and management of patients in many different ways as
detailed previously. There are however, some limitations that may interfere with the
applications ofH-FABP in clinical practice:
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(A) Reliability of the assay. The normal range quoted by the manufacturer for H-
FABP assay was < 5 pg/1. However, the range ofH-FABP in our control sample was
1 - 14.5 fj.g/1, and this may reflect insensitive assay. In addition, the coefficient of
variations of the current assay in the intermediate H-FABP concentration range 47.46
± 9.39 pg/1 was 19.8%. Further work is needed to develop and improve the
sensitivity and the precision of the assay across all concentration ranges to less than
the clinically accepted 10% level.
(B) Heart-FABP as a cardiac marker was designed to offer very early results. The
current turn around time of the assay is prolonged (60 minutes), and should be
reduced further to allow early results to be used immediately in the decision-making
process of patients' management. The ultimate goal would be to provide this assay in
the A&E department or CCU on a point of care instruments that can offer rapid and
reliable early result in less than 20 minutes.
(C) Most of the recent research work on H-FABP was mainly concerned with
developing sensitive and specific H-FABP assays, and their use in patients with
AMI. There have been few researches in certain key areas that are essential to
understanding the full potential of H-FABP for the early diagnosis of ACS. These
areas include:
1. The exact route(s) of excretion of H-FABP from the circulation. As suggested by
previous studies, the kidney is the major route of excretion of H-FABP from
circulation. The effects of disease states and in particular kidney disease on the renal
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handling of H-FABP has not yet been fully evaluated. The effects of renal
impairment on the level of H-FABP and cTnT concentration were studied in a small
group of 16 patients with renal failure [6 females, 10 males, aged between 30 - 70
years old], on haemodialysis or peritoneal dialysis. These patients had a range of
conditions that were commonly seen in the renal unit including chronic
glomerulonephritis, interstitial nephritis, adult dominant polycystic kidneys disease,
and hypertensive nephropathy. The average urea and creatinine concentration in this
group of patient was 19 ± 9.6 mmol/1 and 531.3 ± 231.2 mmol/1 respectively. Heart-
FABP was increased in all 16 patients (mean = 81 ± 53.3 pg/1 [range 24 - 173 pg/1]).
Cardiac-TnT was increased > 0.1 pg/1 in 50%, > 0.2 pg/1 in 31.3%, and > 0.3 p.g/1 in
6%. There were no correlations between the concentration of either urea or creatinine
and the concentration of H-FABP and cTnT. There was a positive correlation
between the concentrations of cTnT and H-FABP (r = 0.569, p < 0.02).
Gorski et al (1997) reported that H-FABP and myoglobin concentrations were both
significantly elevated in patients with renal failure. The concentrations of these
markers were not affected by dialysis. In addition, the myoglobin to H-FABP ratio in
this group was similar to the ratio found in patients with myocardial infarction.6
These two studies indicate that the power ofH-FABP, myoglobin, and myoglobin to
H-FABP ratio for the diagnosis of AMI in the presence of renal failure is limited.
The usefulness ofH-FABP or myoglobin for the detection of re-infarction, extension
of infarction, reperfusion, and estimation of infarct size may also be limited. The
presence of renal failure may also interfere greatly with the specificity of cTnT for
the detection myocardial injury.4 This interference should be borne in mind when
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interpreting the result of these markers in patients with ACS in the presence of renal
impairement.7
2- The effects of disease states in particular chronic liver disease on the normal
concentration of H-FABP was studied in a group of patients with a mixture of
chronic liver disorders [n = 10, mean age ± SD = 58.33 ±7.19 years (range 45 - 70
years), median = 59 years]. These patients had a range of conditions including
infective hepatitis and cirrhosis. The concentration of the following markers were
measured in each sample and compared, alanine aminotransferase [ALT], bilirubin,
and H-FABP. The normal concentrations of these markers in a normal reference
control group were H-FABP = 6.86 ± 2.21 pg/1, ALT =10-50 U/L, and bilirubin =
3-16 pmol/1. The concentration of these markers in patients with liver disease were
as follows; ALT [mean ± SD = 198.67 ± 122.89 U/L, range (73 - 500 U/L), median
= 114 U/L]; bilirubin [mean ± SD = 100.89 ± 87.85 pmol/1, range (17 - 337 pmol/1),
median = 66 pmol/1]; and H-FABP [mean ± SD = 6.44 ± 3.06 pg/1, range (2-11
pg/1), median = 7 pg/1].
These data illustrate clearly that there is no significant interference with the normal
concentration of H-FABP in the presence of liver disease, despite the significant
elevation of liver enzymes and proteins. These data are consistent with the reduced
cross reactivity (< 0.005) between H-FABP and other FABP including liver- FABP
[see page 69]. These data may support a useful role of H-FABP for the diagnosis of
myocardial injury in patients with liver disease.
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3. The metabolism of H-FABP and the effects of disease states and drugs on the
normal concentrations of H-FABP. In particular, the effect of inflammatory
conditions such as severe infections or autoimmune disease states. The base line H-
FABP was significantly elevated [52 jj.g/1] in a patient with active rheumatoid
arthritis, but without clinically proven myocardial damage. Cardiac-Tnl, cTnT,
myoglobin and CK-MB mass were within the normal range. The total white cell
count was significantly elevated (15.5). This patient was also on immunosuppressive
and anti-inflammatory drugs (methotrexate and prednisolone). The exact cause(s) of
elevated H-FABP in this patient is not clear. Elevated H-FABP in this patient may be
drug related or related to rheumatoid arthritis or to some other unknown factors.
4. Exploring the possibility of existence of isoforms ofH-FABP specific to the heart.
The abundance of this protein in myocardial cells, together with its proposed
multiple functions, raises the possibility of existence of H-FABP specific to the
myocardium. This possibility should be explored by further research work.
Clarification of all the physiological functions of H-FABP in the heart will help to
answer this question.
5. The true distribution ofH-FABP outside the heart using recent and more advanced
techniques like sensitive and specific H-FABP antibodies, cDNA and mRNA.
6. Direct comparison between H-FABP, myoglobin and CK-MB subforms.
Zimmerman et al (1999) showed in a large study (n = 955) that CK-MB subforms
[sensitivity = 91%, specificity = 89%], and myoglobin [sensitivity = 78%, specificity
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= 89%] were the two most sensitive and specific markers for the early diagnosis of
AMI within 6 hours after symptom onset. These were followed by CK-MB mass,
cTnl, and cTnT, which were more suitable for the late confirmation of AMI. The
authors concluded that combinations of CK-MB subforms and troponins reliably
triage patients with chest pain.8 So far there have been no studies comparing the
usefulness of these three early markers (myoglobin, CK-MB subforms, and H-
FABP) in patients with AMI. Such study is important especially to compare the
release kinetics and sensitivity of H-FABP and CK-MB subforms following
myocardial injury.
7. Urinary H-FABP testing. The possibility of detecting AMI from urinary H-FABP
testing is an interesting concept. The availability of test methods that can offer
reliable warning of ACS from analysis of urine samples might become useful for the
management of patients in the community. The early confirmation ofAMI (based on
qualitative tests using urine samples) may result in a rapid triage of patients to
hospital and this will shorten the time to thrombolytic therapy. Several urinary H-
Q 1 9 •
FABP assays are available. " However, the role of urinary H-FABP will depend on
the resolution of the above concerns and the development of sensitive assays that are
easy to use.
8.6 LIMITATIONS OF STUDIES
The aim of the current study was to investigate specifically the early release feature
of H-FABP in patients with ACS and compare it with the current cardiac markers of
myocardial injury. Therefore, it was necessary to control some outside factors and
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exclude some patients with conditions that could interfere with the normal
concentration of H-FABP. The relatively small numbers of patients and the selection
criteria in some of the groups have been limiting factors in the current study. Future
studies should be designed to eliminate these disadvantages by including a large
number of randomly selected groups of patients and employ rigorous validation
methods. Heart-FABP may be useful in ACS in different aspects of patients'
management [e.g. triage, diagnosis, and treatment]. Future studies should therefore
focus on specific areas only. Some ideas or proposal for future studies are discussed
below.
8.7 FUTURE STUDIES WITH HEART FATTY ACID BINDING
PROTEIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES
1. The usefulness of heart fatty acid binding protein to diagnose or rule out
acute myocardial infarction
An important study would be to evaluate the usefulness of H-FABP to diagnose or
rule out AMI in a large sample of patients enrolled consecutively, who present with
chest pain suggestive ofmyocardial ischaemia (e.g. chest pain at rest >30 minutes),
within 6-12 hours after the onset of symptoms to the A&E department. Two serial
blood samples for H-FABP analysis are obtained at presentation and 2 hours later.
Blood samples are also taken and analysed for CK-MB in the hospital main
laboratory using routine methods to verify or rule out the diagnosis ofAMI.
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The physician in the emergency department should be blind to the study. The triage
of patients from the A&E department [i.e. to coronary care unit, or to other medical
units, or discharged home], should be left to the discretion of the physician. The
diagnostic evaluation and care of all patients should be conducted by physicians who
are unaware of the results of H-FABP, and H-FABP should be analysed by a person
who is unaware of the clinical outcome of the patients and other clinical data,
including the results of routine assays ofCK-MB. The final clinical diagnosis should
be determined by consultant cardiologist or CCU team. For each patient, the results
of the assay for H-FABP and conventional assays [CK-MB] should be analysed
separately and independently by at least two of the investigators without knowledge
of the clinical findings. The diagnosis of myocardial infarction is confirmed or
excluded on the bases of abnormal or normal CK-MB respectively, according to a
valid cut-off criterion. The best cut-off concentration for H-FABP for the diagnosis
of AMI should be based on ROC curve analysis between patients with confirmed
AMI and without AMI.
The following ideas or proposals describe briefly other important areas of future
research for heart fatty acid binding. These studies should be designs with rigorous
validation methods similar to (1) above [with modifications where necessary].
2. Detection ofsuccessful coronary reperfusion following thrombolysis
In patients with unequivocal ECG diagnosis of AMI treated with thrombolytic
therapy, H-FABP can be used in these patients to detect successful reperfusion.
Heart-FABP concentration is measured immediately before thrombolysis and
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repeated again at 60 minutes following thrombolysis. The success or failure of
reperfusion should be confirmed immediately and independently with coronary
angiography. The best cut-off concentration ratio [i.e. post-thrombolytic
concentration divided by pre-thrombolysis concentration] selected to determine
successful reperfusion should be based on ROC curve analysis between patients with
successful and failed reperfusion. The sensitivity of H-FABP ratio for the detection
of successful reperfusion can be compared with other cardiac markers ratios or with
clinical markers of reperfusion e.g. decrease ST segment elevation.
3. Detection of early re-infarction or infarct extension following acute
myocardial infarction
In this study, patients with AMI should have extended observation. Patients who
develop chest pain suggestive of further ischaemia in the early phase ofAMI, should
have further blood samples taken for H-FABP measurement. This should be
compared with the previous H-FABP concentration [measured from stored routine
samples if no previous H-FABP result exist]. An increase in concentration compared
with the previous sample [i.e. double peak rise] indicates re-infarction.
The diagnosis of re-infarction or infarct extension should be confirmed
independently with coronary angiography [± echocardiography]. The best cut-off
concentration [or ratio] used to diagnose re-infarction or infarct extension should be
based on ROC curve analysis between patients with and without these complications.
The sensitivity of H-FABP for the detection of these complications should be
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compared with other cardiac markers ± ECG criteria ± echocardiographic features
measured at the same time.
4. Timing the approximate onset ofacute myocardial infarction event
In patients with unequivocal diagnosis of AMI e.g. significant ST segment elevation
but with uncertain time of onset of symptoms. Heart-FABP in combination with cTnl
may potentially be useful for estimating the approximate time of onset ofAMI within
the relevant time window for implementation of thrombolytic therapy [i.e. within 12
hours after symptoms onset], Heart-FABP [and cTnl] concentration changes between
presentation and 30 - 60 minutes later can be used to give an approximate time of
onset of AMI [see page 259 for details]. If concentration changes at 30 - 60 minutes
suggested a recent AMI event, these patients may be considered for thrombolytic
therapy [if they still have ongoing chest pain and no contraindication to thrombolytic
therapy] or to early intervention with PCI. The validity of this method, safety and
prognostic value of such interventions are then assessed in these patients.
5. Early detection of evolving myocardial infarction following percutaneous
coronary intervention
The usefulness of H-FABP for the early detection of high-risk patients with evolving
AMI following PCI should be investigated further using large numbers of patients
with recurrence of chest pain post-PCI. The confirmation or exclusion ofAMI should
be validated independently with repeat coronary angiography and with further blood
samples taken for CK-MB measurement in the main laboratory. Heart-FABP should
be measured in blood samples taken before PCI and after onset of chest pain and the
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increase in concentration examined. The best cut-off concentration in these patients
should again be based on ROC curve analysis between patients with and without
AMI. The value of H-FABP for the detection of AMI post-PCI should be compared
with other methods such as ECG criteria or other cardiac markers.
6. The significance of cardiac troponin I elevation following percutaneous
coronary intervention
The correlation between the frequency and magnitude of cTnl elevation post-PCI and
the types, frequency and severity of complications occurring during PCI should be
investigated with more sensitive methods other than contrast coronary angiography
e.g. intravascular ultrasound or coronary angioscopy. The results should be reported
by at least two independent observers. In addition, the measurement of cTnl on
Stratus CS should also be verified independently with extra measurements of cTnl on
dimension as well [both systems use cTnl assays with equal sensitivity].
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